<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005979.pub2" GROUP_ID="EPOC" ID="587704110311091944" MERGED_FROM="" MODIFIED="2014-10-09 09:14:30 +0100" MODIFIED_BY="Elizabeth Paulsen" REVIEW_NO="1" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2014-10-09 09:14:30 +0100" MODIFIED_BY="Elizabeth Paulsen">
<TITLE MODIFIED="2014-04-28 16:23:20 +0200" MODIFIED_BY="[Empty name]">Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies</TITLE>
<CONTACT MODIFIED="2014-10-09 09:14:30 +0100" MODIFIED_BY="Elizabeth Paulsen"><PERSON ID="38330998020910453246101013122633" ROLE="AUTHOR"><FIRST_NAME>Angela</FIRST_NAME><LAST_NAME>Acosta</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>angelap52@gmail.com</EMAIL_1><EMAIL_2>aacosta52@yahoo.es</EMAIL_2><MOBILE_PHONE>0057 1 3184018612</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Pharmacy</DEPARTMENT><ORGANISATION>Universidad Nacional de Colombia</ORGANISATION><ADDRESS_1>Avenida Carrera 30 # 45, Bogotá, Cundinamarca</ADDRESS_1><ADDRESS_2>Edificio Farmacia</ADDRESS_2><CITY>Bogota</CITY><ZIP>111321</ZIP><REGION>Bogota DC</REGION><COUNTRY CODE="CO">Colombia</COUNTRY><PHONE_1>0057 3184018612</PHONE_1><PHONE_2>0057 1 3165000 Ext.14623</PHONE_2><FAX_1>0057 1 3208320 Ext 14623</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-10-09 09:14:30 +0100" MODIFIED_BY="Elizabeth Paulsen"><PERSON ID="38330998020910453246101013122633" ROLE="AUTHOR"><FIRST_NAME>Angela</FIRST_NAME><LAST_NAME>Acosta</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>angelap52@gmail.com</EMAIL_1><EMAIL_2>aacosta52@yahoo.es</EMAIL_2><MOBILE_PHONE>0057 1 3184018612</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Pharmacy</DEPARTMENT><ORGANISATION>Universidad Nacional de Colombia</ORGANISATION><ADDRESS_1>Avenida Carrera 30 # 45, Bogotá, Cundinamarca</ADDRESS_1><ADDRESS_2>Edificio Farmacia</ADDRESS_2><CITY>Bogota</CITY><ZIP>111321</ZIP><REGION>Bogota DC</REGION><COUNTRY CODE="CO">Colombia</COUNTRY><PHONE_1>0057 3184018612</PHONE_1><PHONE_2>0057 1 3165000 Ext.14623</PHONE_2><FAX_1>0057 1 3208320 Ext 14623</FAX_1></ADDRESS></PERSON><PERSON ID="13819" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Agustín</FIRST_NAME><LAST_NAME>Ciapponi</LAST_NAME><POSITION>Coordinator - Faculty</POSITION><EMAIL_1>aciapponi@iecs.org.ar</EMAIL_1><EMAIL_2>aciapponi@gmail.com</EMAIL_2><URL>www.iecs.org.ar/cochrane</URL><ADDRESS><DEPARTMENT>Argentine Cochrane Centre IECS, Institute for Clinical Effectiveness and Health Policy - Hospital Italiano de Buenos Aires</DEPARTMENT><ORGANISATION>Southern American Branch of the Iberoamerican Cochrane Centre</ORGANISATION><ADDRESS_1>Dr. Emilio Ravignani 2024</ADDRESS_1><CITY>Buenos Aires</CITY><ZIP>C1414CPV  - C1181ACH</ZIP><REGION>Capital Federal</REGION><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>+5411 4777-8767</PHONE_1><PHONE_2>+5411 4777-8767</PHONE_2><FAX_1>+5411 4953 4058</FAX_1><FAX_2>+5411 4959 0381</FAX_2></ADDRESS></PERSON><PERSON ID="13414" ROLE="AUTHOR"><FIRST_NAME>Morten</FIRST_NAME><LAST_NAME>Aaserud</LAST_NAME><POSITION>Senior Adviser</POSITION><EMAIL_1>morten.aaserud@legemiddelverket.no</EMAIL_1><ADDRESS><DEPARTMENT>Statens legemiddelverk</DEPARTMENT><ORGANISATION>Norwegian Medicines Agency</ORGANISATION><ADDRESS_1>Sven Oftedals vei 8</ADDRESS_1><CITY>Oslo</CITY><ZIP>NO-0950</ZIP><COUNTRY CODE="NO">Norway</COUNTRY><PHONE_1>+ 47 22 89 77 46</PHONE_1><FAX_1>+ 47 22 89 77 99</FAX_1></ADDRESS></PERSON><PERSON ID="z1312041003272329979287192608894" ROLE="AUTHOR"><FIRST_NAME>Valeria</FIRST_NAME><LAST_NAME>Vietto</LAST_NAME><EMAIL_1>valeria.vietto@hospitalitaliano.org.ar</EMAIL_1><ADDRESS><DEPARTMENT>Division of Family and Community Medicine</DEPARTMENT><ORGANISATION>Hospital Italiano de Buenos Aires</ORGANISATION><CITY>Buenos Aires</CITY><COUNTRY CODE="AR">Argentina</COUNTRY></ADDRESS></PERSON><PERSON ID="B30F165F82E26AA200CD32E5AFE6E78B" ROLE="AUTHOR"><FIRST_NAME>Astrid</FIRST_NAME><LAST_NAME>Austvoll-Dahlgren</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>atd@nokc.no</EMAIL_1><ADDRESS><ORGANISATION>Norwegian Knowledge Centre for the Health Services</ORGANISATION><ADDRESS_1>Postboks 7004 St. Olavsplass</ADDRESS_1><CITY>Oslo</CITY><ZIP>0130</ZIP><COUNTRY CODE="NO">Norway</COUNTRY><PHONE_1>+47 -  46400406</PHONE_1></ADDRESS></PERSON><PERSON ID="B30F194D82E26AA200CD32E5A241F165" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jan Peter</FIRST_NAME><LAST_NAME>Kösters</LAST_NAME><EMAIL_1>japeko@gmail.com</EMAIL_1><EMAIL_2>japeko@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 3343</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK-2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON><PERSON ID="z1405131154230286558109449253544" ROLE="AUTHOR"><FIRST_NAME>Claudia</FIRST_NAME><LAST_NAME>Vacca</LAST_NAME><EMAIL_1>cpvacag@unal.edu.co</EMAIL_1><ADDRESS><DEPARTMENT>Grupo RAM</DEPARTMENT><ORGANISATION>Universidad Nacional de Colombia</ORGANISATION><CITY>Bogota</CITY><COUNTRY CODE="CO">Colombia</COUNTRY></ADDRESS></PERSON><PERSON ID="z1405131156251815755557691666446" ROLE="AUTHOR"><FIRST_NAME>Manuel</FIRST_NAME><LAST_NAME>Machado</LAST_NAME><EMAIL_1>mamachadob@unal.edu.co</EMAIL_1><ADDRESS><DEPARTMENT>Departamento de Farmacia</DEPARTMENT><ORGANISATION>Universidad Nacional de Colombia</ORGANISATION><CITY>Bogota</CITY><COUNTRY CODE="CO">Colombia</COUNTRY></ADDRESS></PERSON><PERSON ID="z1405131158230700119830188733771" ROLE="AUTHOR"><FIRST_NAME>Diana Hazbeydy</FIRST_NAME><LAST_NAME>Diaz Ayala</LAST_NAME><EMAIL_1>dhdiaza@unal.edu.co</EMAIL_1><ADDRESS><DEPARTMENT>Departamento de Farmacia</DEPARTMENT><ORGANISATION>Universidad Nacional de Colombia</ORGANISATION><CITY>Bogota</CITY><COUNTRY CODE="CO">Colombia</COUNTRY></ADDRESS></PERSON><PERSON ID="6765" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Andrew</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Oxman</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>oxman@online.no</EMAIL_1><ADDRESS><DEPARTMENT>Global Health Unit</DEPARTMENT><ORGANISATION>Norwegian Knowledge Centre for the Health Services</ORGANISATION><ADDRESS_1>P.O. Box 7004, St. Olavs plass</ADDRESS_1><CITY>Oslo</CITY><ZIP>N-0130</ZIP><COUNTRY CODE="NO">Norway</COUNTRY><PHONE_1>+47 48 25 49 24</PHONE_1><FAX_1>+47 23 25 50 40</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-08-19 11:22:09 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="6" MONTH="6" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="12" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-09-22 12:30:28 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-09-22 12:30:28 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="9" YEAR="2014"/>
<DESCRIPTION>
<P>The review team has changed since the previous update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-09-18 15:04:48 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="12" YEAR="2013"/>
<DESCRIPTION>
<P>We included seven more studies in this update and we excluded results from controlled studies with only one control site, which had been included in the previous review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-11-30 15:05:32 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-11-30 15:05:32 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>Papers from january 2012 search reviewed and data incorporated as appropiate. 3 new studies included (<LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>; <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>), and 1 added to studies awaiting assessment (Li 2008a), pending more information from the authors. Risk of bias tables generated. Text updated, no change in overall conclusions. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-11-30 12:56:26 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>Correction to typographical error.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-03-18 17:51:48 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="25" MONTH="1" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-10-16 18:48:20 +0200" MODIFIED_BY="Agustín Ciapponi">
<INTERNAL_SOURCES MODIFIED="2011-10-16 18:48:20 +0200" MODIFIED_BY="Agustín Ciapponi">
<SOURCE>
<NAME>Norwegian Knowledge Centre for the Health Services</NAME>
<COUNTRY CODE="NO">Norway</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Health Services Research Unit, University of Aberdeen</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-10-16 18:46:43 +0200" MODIFIED_BY="Agustín Ciapponi">
<NAME>Universidad Nacional de Colombia</NAME>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<DESCRIPTION>
<P>Proyecto Colciencias 2011</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2011-10-16 18:48:20 +0200" MODIFIED_BY="Agustín Ciapponi">
<NAME>Instituto de Efectividad Clínica y Sanitaria (IECS)</NAME>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<DESCRIPTION>
<P>Independent, non-profit organization, created by professionals from the medical and social sciences devoted to research, education and technical support with the main goal of improving efficiency, equity, and quality of health care systems and policies.</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-09-24 20:45:10 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-09-18 15:06:53 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-08-18 13:47:51 +0200" MODIFIED_BY="[Empty name]">The effect of pricing policies for pharmaceuticals</TITLE>
<SUMMARY_BODY MODIFIED="2014-09-18 15:06:53 +0200" MODIFIED_BY="[Empty name]">
<P>Researchers in The Cochrane Collaboration conducted a review of the effect of reference pricing and other pricing policies for pharmaceuticals. In 2012, they searched for all relevant studies and finally included 18 studies. Their findings are summarised below.</P>
<P>
<B>What are reference pricing and other pricing policies for pharmaceuticals?</B>
</P>
<P>Large amounts of healthcare funds are spent on medicines and these amounts are increasing. Spending more on medicines could mean less money for other healthcare or non-health care services. Health insurers are therefore looking for ways of controlling the costs of medicines while still ensuring that patients get the medicines they need.</P>
<P>One approach that health insurers can use is reference pricing. Here insurers group together medicines that have the same active ingredients or that are used for the same purpose and are just as effective and safe. They then set a 'reference price' that they are willing to pay. If the patient chooses the 'reference medicine', his expenses will be paid. If he chooses a more expensive medicine he will have to pay the difference.</P>
<P>Another approach is index pricing. Again, insurers group together similar medicines. They then set an 'index price' that they refund to pharmacies each time they dispense a medicine from this group. As the pharmacy is refunded the same amount for any of the medicines in this group it is in their interest to dispense a medicine that costs less than the index price.</P>
<P>A number of other pricing policies also exist that aim to control medicine costs. It is assumed that these types of policies can lead patients to switch to cheaper medicines and can encourage medicine producers to lower their prices.</P>
<P>
<B>What happens when new payment policies are introduced?</B>
</P>
<P>Most of the studies focused on the effect of reference pricing. These studies looked at the impact of reference pricing one year after it was introduced. They showed that this policy may lead to:</P>
<P>- an increase in 'reference medicine' prescriptions and a decrease in prescriptions for more expensive medicines (low certainty of evidence);</P>
<P>- a decrease in the amount of money insurers spend on medicines overall (low certainty of evidence).</P>
<P>None of these studies looked at the effect of reference pricing on people&#8217;s health, their use of healthcare services, or adverse effects.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-09-22 10:09:48 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-09-18 15:05:24 +0200" MODIFIED_BY="[Empty name]">
<P>Pharmaceuticals are important interventions that could improve people's health. Pharmaceutical pricing and purchasing policies are used as cost-containment measures to determine or affect the prices that are paid for drugs. Internal reference pricing establishes a benchmark or reference price within a country which is the maximum level of reimbursement for a group of drugs. Other policies include price controls, maximum prices, index pricing, price negotiations and volume-based pricing.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-04-19 15:44:43 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the effects of pharmaceutical pricing and purchasing policies on health outcomes, healthcare utilisation, drug expenditures and drug use.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-09-22 10:09:48 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), part of The Cochrane Library (including the Effective Practice and Organisation of Care Group Register) (searched 22/10/2012); MEDLINE In-Process &amp; Other Non-Indexed Citations and MEDLINE, Ovid (searched 22/10/2012); EconLit, ProQuest (searched 22/10/2012); PAIS International, ProQuest (searched 22/10/2012); World Wide Political Science Abstracts, ProQuest (searched 22/10/2012); INRUD Bibliography (searched 22/10/2012); Embase, Ovid (searched 14/12/2010); NHSEED, part of The Cochrane Library (searched 08/12/2010); LILACS, VHL (searched 14/12/2010); International Political Science Abstracts (IPSA), Ebsco (searched (17/12/2010); OpenSIGLE (searched 21/12/10); WHOLIS, WHO (searched 17/12/2010); World Bank (Documents and Reports) (searched 21/12/2010); Jolis (searched 09/10/2011); Global Jolis (searched 09/10/2011) ; OECD (searched 30/08/2005); OECD iLibrary (searched 30/08/2005); World Bank eLibrary (searched 21/12/2010); WHO - The Essential Drugs and Medicines web site (browsed 21/12/2010).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-09-18 15:05:46 +0200" MODIFIED_BY="[Empty name]">
<P>Policies in this review were defined as laws; rules; financial and administrative orders made by governments, non-government organisations or private insurers. To be included a study had to include an objective measure of at least one of the following outcomes: drug use, healthcare utilisation and health outcomes or costs (expenditures); the study had to be a randomised trial, non-randomised trial, interrupted time series (ITS), repeated measures (RM) study or a controlled before-after study of a pharmaceutical pricing or purchasing policy for a large jurisdiction or system of care.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-09-18 15:05:49 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data and assessed the risk of bias. Results were summarised in tables. There were too few comparisons with similar outcomes across studies to allow for meta-analysis or meaningful exploration of heterogeneity.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-09-18 15:06:15 +0200" MODIFIED_BY="[Empty name]">
<P>We included 18 studies (seven identified in the update): 17 of reference pricing, one of which also assessed maximum prices, and one of index pricing. None of the studies were trials. All included studies used ITS or RM analyses. The quality of the evidence was low or very low for all outcomes. Three reference pricing studies reported cumulative drug expenditures at one year after the transition period. Two studies reported the median relative insurer's cumulative expenditures, on both reference drugs and cost share drugs, of -18%, ranging from -36% to 3%. The third study reported relative insurer's cumulative expenditures on total market of -1.5%. Four reference pricing studies reported median relative insurer's expenditures on both reference drugs and cost share drugs of -10%, ranging from -53% to 4% at one year after the transition period. Four reference pricing studies reported a median relative change of 15% in reference drugs prescriptions at one year (range -14% to 166%). Three reference pricing studies reported a median relative change of -39% in cost share drugs prescriptions at one year (range -87% to -17%). One study of index pricing reported a relative change of 55% (95% CI 11% to 98%) in the use of generic drugs and -43% relative change (95% CI -67% to -18%) in brand drugs at six months after the transition period. The same study reported a price change of -5.3% and -1.1% for generic and brand drugs respectively six months after the start of the policy. One study of maximum prices reported a relative change in monthly sales volume of all statins of 21% (95% CI 19% to 24%) after one year of the introduction of this policy. Four studies reported effects on mortality and healthcare utilisation, however they were excluded because of study design limitations.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-09-18 15:06:20 +0200" MODIFIED_BY="[Empty name]">
<P>The majority of the studies of pricing and purchasing policies that met our inclusion criteria evaluated reference pricing. We found that internal reference pricing may reduce expenditures in the short term by shifting drug use from cost share drugs to reference drugs. Reference pricing may reduce related expenditures with effects on reference drugs but the effect on expenditures of cost share drugs is uncertain. Reference pricing may increase the use of reference drugs and may reduce the use of cost share drugs. The analysis and reporting of the effects on patients' drug expenditures were limited in the included studies and administration costs were not reported. Reference pricing effects on health are uncertain due to lack of evidence. The effects of other purchasing and pricing policies are until now uncertain due to sparse evidence. However, index pricing may reduce the use of brand drugs, increase the use of generic drugs, and may also slightly reduce the price of the generic drug when compared with no intervention.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-09-23 14:59:23 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-09-22 12:32:25 +0200" MODIFIED_BY="[Empty name]">
<P>See Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for a list of abbreviations used in this review.</P>
<CONDITION MODIFIED="2014-09-18 15:07:16 +0200" MODIFIED_BY="[Empty name]">
<P>Pharmaceuticals can be important for people's health. At the same time drugs are major components of healthcare costs. Organisation for Economic Co-operation and Development (OECD) countries spent USD 569 billion on pharmaceuticals (excluding pharmaceuticals for in-patients) in 2005; US pharmaceutical expenditure amounted to USD 235 billion, accounting for 41% of total expenditure on pharmaceuticals in OECD countries (<LINK REF="REF-OECD-2008" TYPE="REFERENCE">OECD 2008</LINK>). Pharmaceutical expenditure in Mexico represents 21% of total health spending, exceeding the average of OECD countries; and in 2003 88% of pharmaceutical expenditure in Mexico was out of pocket expenditure (<LINK REF="REF-Mo_x00ef_se-2008" TYPE="REFERENCE">Moïse 2008</LINK>).</P>
<P>Data on total pharmaceutical expenditure for 2006 confirm that pharmaceuticals account for an important share of all expenditure on health. This proportion varies considerably between high- and low-income countries; pharmaceutical spending as a share of total health expenditure ranges from a mean of 19.7% in the high-income countries to a mean of 30.4% in the low-income countries (<LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>). Per capita pharmaceutical expenditures in 2005 and 2006 ranged from USD 7.61 in low-income countries to USD 431.6 in high-income countries and, compared to 1995, the rate of increase is greater in middle- and low-income countries (<LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>). These increases put pressure on policy makers and insurers to control drug expenditure and to do this without causing adverse effects on health or increasing healthcare utilisation or other costs.</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-09-18 15:08:06 +0200" MODIFIED_BY="[Empty name]">
<P>Pharmaceutical pricing and purchasing policies intend to determine or affect the prices that are paid for drugs. They can be targeted at different components of drug prices, such as wholesale prices, retail prices, drug taxes and reimbursement prices. Examples are price controls, maximum prices, price negotiations, reference pricing, index pricing and volume-based pricing policies. Although this review also deals with purchasing policies, for simplicity we will use the term pricing policies (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>These policies can have an impact on drug expenditure in two main ways, directly through price changes, and indirectly through drug use changes related to the price changes. Furthermore, the split between third party and patient expenditure can be influenced. Since pharmaceutical pricing policies might affect drug use they could also have effects on health and utilisation of other healthcare services.<BR/>
</P>
<P>Pharmaceutical prices consist of different components reflecting who is receiving the payments: the manufacturers' prices, wholesalers' prices and retailers' prices. At each of these steps there are mark ups and possibly tax components. Pricing policies can be targeted at one or more of these specific components.<BR/>
</P>
<P>In most European Union countries pharmaceutical prices are controlled at the manufacturer level and by statutory pricing policy, where the authorities set the price on a regulatory basis. Most of the countries that are members of the Pharmaceutical Pricing and Reimbursement Information Project (PPRI) apply price control only to pharmaceuticals that are eligible for reimbursement (<LINK REF="REF-Vogler-2008" TYPE="REFERENCE">Vogler 2008</LINK>). This is not the case for recent pharmaceutical pricing policies applied in Latin American countries, such as Colombia (<LINK REF="REF-Vacca-2011" TYPE="REFERENCE">Vacca 2011</LINK>). Pharmacy margins are regulated in most European Union countries by regressive schemes in which pharmacy remuneration occurs via a fixed fee (<LINK REF="REF-Vogler-2008" TYPE="REFERENCE">Vogler 2008</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Reference drug pricing</HEADING>
<P>Reference prices can be established based on external prices (from other countries) or internal prices (within a country). Using the price(s) of a medicine in one or several countries to derive a benchmark or reference price for the purpose of setting or negotiating the price of medicines in a given country is described as external price referencing by the Worlg Health Organization (WHO) Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Glossary (<LINK REF="REF-PHIS-2011" TYPE="REFERENCE">PHIS 2011</LINK>). Using the price(s) of identical medicines (ATC 5 level) or similar medicines (ATC 4 level) or therapeutically equivalent treatments within a country to derive a benchmark or reference price for the purpose of setting or negotiating the price or reimbursement of medicines in a given country is described as <B>
<I>i</I>
</B>nternal price referencing by the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Glossary (<LINK REF="REF-PHIS-2011" TYPE="REFERENCE">PHIS 2011</LINK>). Different terms have been used for reference drug pricing policies, including reference pricing, reference-based pricing, maximum allowable costs, best available prices, and minimum pricing.</P>
<P>For reimbursement purposes the internal reference pricing makes patients aware of price differences by giving them the responsibility to pay for the difference. However, it does not restrict the drug producers', wholesalers' or retailers' freedom to set drug prices. The policy sets the reimbursement price and thus implicitly the payments by patients. This can lead patients to switch from more expensive to cheaper drugs, and thus decrease the sales for the producers of the more expensive drugs. The producers would then have incentives to reduce prices so that market shares would not be lost. Drugs that are assessed as therapeutically similar (here called a reference drug group) a reference drug (or a group of reference drugs) is chosen. The price of the reference drug is reimbursed (except for ordinary copayment). For drugs that are more expensive than the reference drug, the patient has to pay the expenses above the reference price. These are called cost share drugs. Policies that set reimbursement prices, like some reference pricing policies, are similar to copayment policies since both influence what the third party payer and patients pay for the drugs. The difference is that patients can choose to use the reference drug and thus not have to pay a reference premium, whereas with copayments patients have to pay a portion of the cost regardless of which drug they use within a drug group (<LINK REF="REF-Austvoll_x002d_Dahlgren-2008" TYPE="REFERENCE">Austvoll-Dahlgren 2008</LINK>).</P>
<P>Reference drug pricing can be applied to different levels of drug groups (<LINK REF="REF-Dickson-1998" TYPE="REFERENCE">Dickson 1998</LINK>; <LINK REF="REF-Galizzi-2011" TYPE="REFERENCE">Galizzi 2011</LINK>; <LINK REF="REF-Ioannides_x002d_Demos-2002" TYPE="REFERENCE">Ioannides-Demos 2002</LINK>; <LINK REF="REF-McLaughin-1997" TYPE="REFERENCE">McLaughin 1997</LINK>). At the highest level therapeutic groups are included, as all drugs used to treat a particular condition (for example all drugs for hypertension) or drugs included in the same Anatomical Therapeutic Chemical (ATC) classification system group (for example statins, angiotensin converting enzyme (ACE) inhibitors). At a more specific level competitors' drugs for International Nonproprietary Names (INN) are included, as used in Germany, Australia and US. These drugs could be considered as chemically equivalent drugs or multisource chemical entities, or could also be classified as brand name drugs and generic drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Index pricing</HEADING>
<P>An index price is the maximum refundable price to pharmacies for drugs within an index group (<LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>). An index group consists of therapeutically interchangeable drugs. The index price is updated quite frequently (for example every third month) and is based on the volume weighted average of prices in the index group. The price is refunded independently of which drug is dispensed. Since the pharmacy keeps the difference between the index price and the price of any drug in the index group, pharmacies have economic incentives to dispense a drug that is priced lower than the index price. Thus, the hypothesis is that the pharmacies will dispense more of the cheaper drugs, which will lead to a lower index price when that price is adjusted, which occurs frequently. A lower index price will then lead to lower reimbursements and thus reduced third party drug expenditures. An increase in the dispensing of cheaper drugs could also increase the producers' incentives to lower the drug prices so that their market shares will not decrease.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Maximum prices</HEADING>
<P>Maximum or ceiling price is a fixed price that attempts to secure pharmaceutical prices that are considered &#8216;reasonable&#8217; for a given health system. There are different approaches to set the maximum prices: negotiated prices, price-caps, cost-plus, price comparisons to other countries or to similar products within the same country, or price-volume trade-offs (<LINK REF="REF-Mossialos-2004" TYPE="REFERENCE">Mossialos 2004</LINK>). This is a cost-containment measure that fixes ex-ante the maximum price of medicines, for example taking into consideration inflation rates and production cost. Companies are allowed to choose any price below this threshold, described as price cap or price ceiling by the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Glossary (<LINK REF="REF-PHIS-2011" TYPE="REFERENCE">PHIS 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Profit regulation</HEADING>
<P>Rates of return on pharmaceutical companies' capital can be regulated by the government or negotiated between the government and the companies, as under the Pharmaceutical Price Regulation Scheme (PPRS) in the UK (<LINK REF="STD-Borrell-1999" TYPE="STUDY">Borrell 1999</LINK>). This can indirectly influence drug prices by setting profit limits. The PPRS is based on periodic negotiations between the Association of the British Pharmaceutical Industry and the Department of Health. It is reviewed every few years (<LINK REF="REF-PPRS-2009" TYPE="REFERENCE">PPRS 2009</LINK>). If profits exceed a certain level, the company must reduce profits by cutting prices, delaying or restricting previously agreed future price increases, or repaying the excess profit to the Department of Health.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Stepped price model</HEADING>
<P>Prices can be adjusted when patents expire (<LINK REF="REF-Norwegian-Pharmacy-Association-2008" TYPE="REFERENCE">Norwegian Pharmacy Association 2008</LINK>). For example, in Norway a stepped price model was introduced in January 2005. In this model a maximum reimbursement price is set for affected drugs (both branded and generics). The maximum price is automatically reduced in steps following generic competition after patent expiry. The size of the price cut steps depends on the sales volumes prior to establishment of generic competition and the time since competition was established (<LINK REF="REF-Festoy-2008" TYPE="REFERENCE">Festoy 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other pricing policies</HEADING>
<P>These include direct price controls, price negotiations, volume-based pricing, procurement and rebate policies. Direct price controls involve setting prices on a product by product basis. The prices can be set by the authorities or negotiated with the manufacturer. The price level can be fixed or a maximum price can be set, leaving the supplier free to set the price lower or equal to the maximum price. When setting or negotiating the price, several considerations can be taken into account: costs of products, prices in comparable countries, therapeutic value of the product, evidence of clinical effectiveness and safety, and price-volume arrangements (<LINK REF="REF-Productivity-2001" TYPE="REFERENCE">Productivity 2001</LINK>).</P>
<P>Under a price-volume arrangement the agreed drug price is based on a forecast volume of sales. If the actual volume exceeds the forecast, the drug price usually has to be lowered. Pricing regulation may apply to initial or posterior prices once products are marketed, and can be based on prices for the same product in other countries or on the costs of similar treatments for the same indication (<LINK REF="REF-Espin-2007" TYPE="REFERENCE">Espin 2007</LINK>).</P>
<P>Reimbursement decisions and pricing for new drugs can also be based on economic evaluations of the new treatment compared with existing options (<LINK REF="REF-Espin-2007" TYPE="REFERENCE">Espin 2007</LINK>).</P>
<P>Each of these interventions could generate important potential adverse effects or unintended effects that should be addressed.</P>
</SUBSECTION>
</INTERVENTION>
<IMPORTANCE MODIFIED="2014-09-22 12:32:25 +0200" MODIFIED_BY="[Empty name]">
<P>Recently <LINK REF="REF-Galizzi-2011" TYPE="REFERENCE">Galizzi 2011</LINK> provided an updated survey of original scientific studies on the effect of reference pricing policies in OECD countries, including results from searches of the PubMed database from 1966 to September 2009, EconLit and Web of Knowledge from 1979 to September 2009. This survey of the literature included theoretical and empirical studies.</P>
<P>There are recent reviews on some pricing policies, like reference pricing (<LINK REF="REF-Danzon-2008" TYPE="REFERENCE">Danzon 2008</LINK>; <LINK REF="REF-Puig_x002d_Junoy-2010" TYPE="REFERENCE">Puig-Junoy 2010</LINK>), and systematic reviews of pharmaceutical policies that include some pricing policies (<LINK REF="REF-Faden-2011" TYPE="REFERENCE">Faden 2011</LINK>; <LINK REF="REF-Puig_x002d_Junoy-2010a" TYPE="REFERENCE">Puig-Junoy 2010a</LINK>). Most of these reviews are limited in scope and identified poor quality studies with limited internal and external validity.</P>
<P>Complementary reviews on other pharmaceutical policies include Cochrane reviews of caps and copayments, financial incentives for prescribers, and restrictions on reimbursement (including prior authorisation policies) (<LINK REF="REF-Aaserud-2006a" TYPE="REFERENCE">Aaserud 2006a</LINK>; <LINK REF="REF-Austvoll_x002d_Dahlgren-2008" TYPE="REFERENCE">Austvoll-Dahlgren 2008</LINK>; <LINK REF="REF-Green-2010" TYPE="REFERENCE">Green 2010</LINK>; <LINK REF="REF-Sturm-2007" TYPE="REFERENCE">Sturm 2007</LINK>) and another systematic review of prior authorisation of pharmaceutical prescriptions (<LINK REF="REF-Puig_x002d_Junoy-2007" TYPE="REFERENCE">Puig-Junoy 2007</LINK>).</P>
<P>The cost of pharmaceuticals has a tremendous impact on health systems and hence on population health. This is true for high-income countries and is critical for low- and middle-income countries, where prioritisation of resources is even more essential. Most European countries have adopted reference pricing systems and some Latin American countries, such as Brazil (<LINK REF="REF-Espin-2011" TYPE="REFERENCE">Espin 2011</LINK>) and Colombia (<LINK REF="REF-Vacca-2011" TYPE="REFERENCE">Vacca 2011</LINK>), have pricing policies that use external price referencing.</P>
<P>To our knowledge other systematic reviews of pricing and purchasing policies have not been kept up to date. Our aim was to support informed decisions about pharmaceutical policies and to guide future evaluations by updating a comprehensive summary of what is known from well-designed research about the effects of alternative pricing and purchasing policies on drug use, healthcare utilisation, health outcomes and costs (expenditures).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-09-18 15:08:25 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the effects of pharmaceutical pricing and purchasing policies on health outcomes, healthcare utilisation, drug expenditures (costs) and drug use.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-09-23 14:59:23 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-09-18 15:08:48 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-09-18 15:08:31 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trials, non-randomised trials, interrupted time series (ITS) studies (with or without a control group), repeated measures (RM) studies (that is ITS studies where each individual contributed data to each point in time), controlled RM (CRM) and controlled before-after (CBA) studies.</P>
<P>We only included ITS and RM studies if they had a clearly defined time of intervention and at least three data points before and three data points after the intervention. If a natural transition period was not apparent from the description of the implementation of the intervention a common transition period of two months was used, understood as the period immediately after the intervention point.</P>
<P>For this update we only included CBA and CRM studies if there were at least two sites in each comparison group, due to the EPOC Group recommendation (<LINK REF="REF-EPOC-2013a" TYPE="REFERENCE">EPOC 2013a</LINK>): "We recommend only including cluster randomised trials, non-randomised cluster trials, and CBA studies with at least two intervention sites and two control sites".</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-09-18 15:08:36 +0200" MODIFIED_BY="[Empty name]">
<P>Healthcare consumers and providers within a large jurisdiction or system of care. Jurisdictions could be regional, national or international. Studies within organisations, such as health maintenance organisations, were included if the organisation had multiple sites and served a large population.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-09-18 15:08:40 +0200" MODIFIED_BY="[Empty name]">
<P>Policies on price and purchasing: policies that determine or are intended to affect the price that is paid for drugs. Included in this category are price control, maximum prices, price negotiations, rebates, reference pricing, index pricing, volume-based pricing, and procurement policies.</P>
<P>Policies in this review were defined as laws, rules, financial and administrative orders made by governments, non-government organisations or private insurers. Interventions applied at the level of a single facility were excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-09-18 15:08:48 +0200" MODIFIED_BY="[Empty name]">
<P>To be included a study had to include an objective measure of at least one of the following outcomes:</P>
<UL>
<LI>drug use (prescribed, dispensed or actually used);</LI>
<LI>healthcare utilisation;</LI>
<LI>health outcomes;</LI>
<LI>costs (expenditures), including drug costs and prices, other healthcare costs and policy administration costs.</LI>
</UL>
<P>Any important potential adverse effects of the intervention(s) were addressed.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-09-23 14:59:23 +0200" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-09-22 10:12:41 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the following databases:</P>
<P>· Cochrane Central Register of Controlled Trials (CENTRAL), 2012, Issue 10, part of <I>The Cochrane Library</I>. <A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A> (including the Effective Practice and Organisation of Care Group Register) (searched 22/10/2012)</P>
<P>· MEDLINE In-Process &amp; Other Non-Indexed Citations and MEDLINE 1946 to present, Ovid (searched 22/10/2012)</P>
<P>· EconLit 1969 - , ProQuest (searched 22/10/2012)</P>
<P>· PAIS International, Public Affairs Information Service 1914 - , ProQuest (searched 22/10/2012)</P>
<P>· Worldwide Political Science Abstracts 1975 - , ProQuest (searched 22/10/2012)</P>
<P>· INRUD Bibliography (searched 22/10/2012)</P>
<P>· Embase 1980 to 2010 Week 49, Ovid (searched 14/12/2010)</P>
<P>· NHS Economic Evaluation Database (NHSEED) 2010, Issue 4, part of <I>The Cochrane Library.</I> <A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A> (searched 08/12/2010)</P>
<P>· LILACS, VHL (searched 14/12/2010)</P>
<P>· International Political Science Abstracts (IPSA) 1951 - , Ebsco (searched (17/12/2010)</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-09-23 14:59:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Grey Literature</B>
</P>
<P>· OpenSIGLE (now called OpenGrey): <A HREF="http://www.opengrey.eu/">http://www.opengrey.eu/</A> (searched 21/12/2010)</P>
<P>· WHOLIS, WHO (the WHO library database): <A HREF="http://dosei.who.int/uhtbin/cgisirsi/Thu+Jul++5+16:26:22+MEST+2012/0/49">http://dosei.who.int/uhtbin/cgisirsi/Thu+Jul++5+16:26:22+MEST+2012/0/49</A> (searched 17/12/2010)</P>
<P>· World Bank (Documents and Reports): <A HREF="http://www.worldbank.org/">http://www.worldbank.org/</A> (searched 21/12/2010)</P>
<P>· Jolis Library Catalog (The Library Network serving the World Bank Group and IMF): <A HREF="http://external.worldbankimflib.org/external.htm">http://external.worldbankimflib.org/external.htm</A> (searched 09/10/2011)</P>
<P>· Global Jolis, online catalog for the World Bank Country Office PIC/Libraries (searched 09/10/2011)</P>
<P>· OECD: <A HREF="http://www.oecd.org/">http://www.oecd.org/</A> (searched 30/08/2005)</P>
<P>· OECD iLibrary (formerly SourceOECD): <A HREF="http://www.oecd-ilibrary.org/">http://www.oecd-ilibrary.org/</A> (searched 30/08/2005)</P>
<P>· World Bank eLibrary: <A HREF="http://elibrary.worldbank.org/">http://elibrary.worldbank.org/</A> (searched 21/12/2010)</P>
<P>· WHO - The Essential Drugs and Medicines web site: <A HREF="http://www.who.int/medicines/en/">http://www.who.int/medicines/en/</A> (browsed 21/12/2010)</P>
<P>
<B>Trial Registries</B>
</P>
<P>· International Clinical Trials Registry Platform (ICTRP), Word Health Organization (WHO) <A HREF="http://www.who.int/ictrp/en/">http://www.who.int/ictrp/en/</A> (searched 23/04/2013)</P>
<P>· ClinicalTrials.gov, US National Institutes of Health (NIH) <A HREF="http://clinicaltrials.gov/">http://clinicaltrials.gov/</A> (searched 23/04/2013)</P>
<P>
<B>We also </B>
</P>
<P>· We screened the reference lists of all of the relevant reports that we retrieved</P>
<P>· Conducted cited reference searches for all included studies in Science Citation Index and Social Sciences Citation Index 1975 - , ISI Web of Knowledge (searched 22/12/2012)</P>
<P>The search strategies for databases and websites are reported in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-09-18 15:11:07 +0200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-09-18 15:10:33 +0200" MODIFIED_BY="[Empty name]">
<P>For this update six authors (AA, AC, DD, MOA, MM, VV) independently reviewed all of the search results, abstracts and reference lists of relevant reports. The full texts of potentially relevant reports were retrieved (if one or both authors thought they were potentially relevant) and the same two authors independently assessed the relevance of those studies and the limitations of included studies. The lead author (AA) extracted data from new included studies in collaboration with one other author (CV). Disagreements were resolved by discussion and, when necessary, including another author (AC) in the discussion. The study selection was performed using Early Review Organizing Software (EROS), a web-based programme (<LINK REF="REF-Ciapponi-2011" TYPE="REFERENCE">Ciapponi 2011</LINK>; <LINK REF="REF-Glujovsky-2010" TYPE="REFERENCE">Glujovsky 2010</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-09-18 15:10:39 +0200" MODIFIED_BY="[Empty name]">
<P>Tables were prepared for each subcategory of interventions including the following information: study identification, characteristics of the intervention, drug use, healthcare utilisation, health outcomes, and costs. These tables formed the basis for the primary analyses. We described potential mechanisms through which the policies were intended to affect drug use and costs and postulated mechanisms for other effects, both intended and unintended. We also briefly listed and described important policy options for which no evaluations were found.</P>
<P>The following information, in addition to details for risk of bias assessment, was extracted from included studies using a standardised data extraction form.</P>
<UL>
<LI>Type of study (randomised trial, non-randomised trial, repeated measures study, ITS study, CBA study).</LI>
<LI>Study setting (country, key features of the healthcare system and concurrent pharmaceutical policies).</LI>
<LI>The sponsors of the study.</LI>
<LI>Characteristics of the participants (consumers, physicians, practices, hospitals, etc.).</LI>
<LI>Characteristics of the policies.</LI>
<LI>Main outcome measures and study duration.</LI>
<LI>The results for the main outcome measures.</LI>
</UL>
<P>If the study presented results for more than one outcome in each of the four outcome groups (drug use and costs), we chose what we considered the most important outcome in each group, either as specified by the authors or based on discussions among the review authors. We aimed to be parsimonious. However, in cases where additional outcomes might lead to different conclusions, we also included these. We did not otherwise decide which outcomes to include based on the direction or size of effect, or whether a finding was statistically significant.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-09-18 15:10:51 +0200" MODIFIED_BY="[Empty name]">
<P>Five review authors (AA, AC, AM, VC, VV) independently assessed the risk of bias for each new study that was included using the &#8216;risk of bias&#8217; tool described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and additional criteria developed by the Cochrane EPOC Group (<LINK REF="REF-EPOC-2013a" TYPE="REFERENCE">EPOC 2013a</LINK>).</P>
<P>The same two review authors updated the risk of bias assessments for studies included in the previous version of this review. Disagreements were resolved by discussion, involving a third review author (AC) if necessary.</P>
<P> For controlled ITS and controlled RM studies, the time series analyses were assessed independently from the controlled comparison, using the above criteria for ITS and CBA studies respectively. If the controlled comparison had a high risk of bias, it was not included and only the ITS analysis was used.</P>
<P>The risk of bias for each bias item and outcome was assessed using the approach described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<TABLE COLS="2" ROWS="4">
<TR>
<TD VALIGN="TOP">
<P>
<B>Risk of bias</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Interpretation</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Low risk of bias</P>
</TD>
<TD VALIGN="TOP">
<P>Plausible bias unlikely to seriously alter the results</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Unclear risk of bias</P>
</TD>
<TD VALIGN="TOP">
<P>Plausible bias that raises some doubt about the results</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>High risk of bias</P>
</TD>
<TD VALIGN="TOP">
<P>Plausible bias that seriously weakens confidence in the results</P>
</TD>
</TR>
</TABLE>
<P>Some setting dependent judgement (that is judgement dependent on knowledge of the setting in which a study was done) was used when assessing overall limitations. Where setting dependent judgement has been used, the explanations are provided in the <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK> (that is part of the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables).</P>
<P>We generated 'risk of bias' summary figures using <LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-09-18 15:10:56 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="6">ITS and RM studies</HEADING>
<P>The preferred analysis method for ITS and RM studies was either a regression analysis with time trends before and after the intervention, which adjusted for autocorrelation and any periodic changes, or ARIMA analysis. The results of these analyses include changes along two dimensions: change in level and change in slope. Change in level is the immediate effect of the policy and is measured as the difference between the fitted value for the first post-intervention data point (two months after the intervention) minus the predicted value one month after the intervention based on the pre-intervention slope only.</P>
<P>Change in slope is the change in the trend from pre- to post-intervention and reflects the 'long' term effect of the intervention. Since the interpretation of change in slope could be difficult, we chose to present the long term effects similarly to the way we calculated and presented the immediate effects. We presented the effects after half a year as the difference between the fitted value for the sixth month post-intervention data point (half a year after the intervention) minus the predicted outcome six months after the intervention based on the pre-intervention slope only. The effects after one year and two years were measured similarly. For drug expenditures, we also identified in some included studies cumulative expenditures outcomes (increase or decrease in measures) or if possible we calculated the cumulative savings after a half year, one year and two years as the area between the predicted expenditures curves and the actual expenditures.</P>
<P>Given that policy changes are often announced some months prior to official implementation, we defined a transition phase as the six months from the official announcement. If the included ITS and RM studies stated a different transition phase, we used two months of transition period. All results excluded the transition phase data.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-09-18 15:10:58 +0200" MODIFIED_BY="[Empty name]">
<P>Comparisons that allocate clusters (for example jurisdictions) but do not account for clustering in the analysis have a potential unit of analysis error, resulting in overly low P values and overly narrow confidence intervals. We planned to reanalyse this kind of comparison if we could extract the intra-cluster coefficient or obtain missing information from the investigators. However, none of the included studies had unit of analysis errors.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-12-31 10:57:38 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the original investigators to request missing data. If we could not obtain the missing data, we did not make any assumptions about missing data or attempt to impute the missing data.</P>
</MISSING_DATA>
<DATA_SYNTHESIS MODIFIED="2014-09-18 15:11:06 +0200" MODIFIED_BY="[Empty name]">
<P>If papers with ITS data did not provide an appropriate analysis or reporting of results but presented the data points in a scannable graph or in a table, we (JOJ) reanalysed the data using methods described in <LINK REF="REF-Ramsay-2003" TYPE="REFERENCE">Ramsay 2003</LINK> and <LINK REF="REF-EPOC-2013b" TYPE="REFERENCE">EPOC 2013b</LINK>. The following segmented time series regression model was specified: Y(t) = B0 + B1*Pre-slope + B2*Post-slope + B3*intervention + e(t), where Y(t) is the outcome in month t. Pre-slope is a continuous variable indicating time from the start of the study up to the last point in the pre-intervention phase and coded constant thereafter. Post-slope is coded 0 up to and including the first point post-intervention and coded sequentially from 1 thereafter. Intervention is coded 0 for pre-intervention time points and 1 for post-intervention time points. In this model, B1 estimates the slope of the pre-intervention data, B2 estimates the slope of the post-intervention data, and B3 estimates the change in level of outcome as the difference between the estimated first point post-intervention and the extrapolated first point post-intervention if the pre-intervention line was continued into the post-intervention phase. The difference in slope is calculated by B2 - B1. The error term e(t) was assumed to be first order autoregressive. Confidence intervals (95%) were calculated for all effect measures.</P>
<P>In a repeated measures design, the data are repeated outcome measures from many individual patients. If the study did not report appropriate results we did not reanalyse the data from the summary graphs because no estimate of within patient variability could be obtained from the summary graphs and any reanalysis would underestimate or overestimate the standard error of the effect sizes. Therefore, for RM studies we used the results reported in the original papers only.</P>
<P>We conducted a structured synthesis, as described in the EPOC resources for review authors (<LINK REF="REF-EPOC-2013c" TYPE="REFERENCE">EPOC 2013c</LINK>). We anticipated that the included studies would vary with respect to the characteristics of the interventions and the targeted drugs and did not plan on undertaking meta-analyses. The results of studies of similar interventions (reference pricing, index pricing and maximum prices) that reported similar outcomes were summarised in tables. For reference pricing, the only intervention for which we identified more than one study, we reported median effects and the range of effects. We prepared summary of findings tables using methods developed by the GRADE Working Group (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>), described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and recommended by EPOC (<LINK REF="REF-EPOC-2013d" TYPE="REFERENCE">EPOC 2013d</LINK>). We used the GRADE profiler software (<LINK REF="REF-GRADEpro-2008" TYPE="REFERENCE">GRADEpro 2008</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-09-18 15:11:07 +0200" MODIFIED_BY="[Empty name]">
<P>There was an insufficient number of comparisons for similar outcomes across studies to allow for meaningful exploration of heterogeneity. The following potential explanatory factors were considered: differences in the characteristics of the policies, differences in the settings, and differences in risk of bias (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>In addition, we attempted to identify important factors that might be taken into consideration by anyone contemplating implementing any of the policy alternatives, including: possible trade-offs (of the expected benefits versus harms and costs), short versus long term effects, indications and contraindications for when the polices might be used, limitations of the available evidence, and other important factors that might affect the translation of the available evidence into practice in specific settings.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-09-22 12:33:41 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-09-22 12:33:41 +0200" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2014-09-18 15:30:05 +0200" MODIFIED_BY="[Empty name]">
<P>The literature search for pharmaceutical pricing policies in databases and websites, including reference lists from relevant studies and reports, resulted in 26,797 references after removing duplicates(9265 of them identified through the new search). We identified and retrieved in full text a total of 380 papers (134 of them from the new search) that were potentially relevant; 362 (125 from the current update) of these papers were excluded, most of them because they did not meet the study design inclusion criterion. They were primarily reviews, editorials, modelling studies, cross-sectional studies, and before-after studies without a control group. Finally 18 studies were included (seven from the current update): <LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>; <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>; <LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>; <LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>; <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK> (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>Two studies (<LINK REF="STD-Huang-2012" TYPE="STUDY">Huang 2012</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>) were identified and judged to possibly meet the inclusion criteria. These studies are listed amongst studies awaiting assessment because responses following contacting the first author and additional information are still pending. These two references described multiple pricing policy interventions from Tawian (1997 to 2002): stepwise price adjustments, external reference pricing, and internal reference pricing for generic drugs groups. Because of the short period before and after each intervention the review authors required more information about interventions and the size and effects of outcomes.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-09-22 12:33:41 +0200" MODIFIED_BY="[Empty name]">
<P>Eighteen papers met the inclusion criteria (<LINK REF="STD-Aronsson-2001" TYPE="STUDY">Aronsson 2001</LINK>; <LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>; <LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>; <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>; <LINK REF="STD-McManus-2001" TYPE="STUDY">McManus 2001</LINK>; <LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>; <LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK>; <LINK REF="STD-Pavcnik-2002" TYPE="STUDY">Pavcnik 2002</LINK>; <LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>; <LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>; <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Study designs</HEADING>
<P>None of the studies were randomised or non-randomised trials. All 18 included studies used ITS or RM analyses. Some of the studies had more than one design, that is different designs for different outcomes.  Four studies included in the original review used a CRM or CBA studies design to assess the health outcome or healthcare utilisation outcomes (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>); these studies were excluded from summary of findings (SOF) tables and from the main report in this update according to an EPOC Group recommendation (August 2013): &#8220;We recommend only including cluster randomised trials, non-randomised cluster trials, and CBA studies with at least two control sites&#8221;. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Characteristics of settings and patients</HEADING>
<P>Seven of the reference pricing studies (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>; <LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>) were from Canada (British Columbia), two were from Germany (<LINK REF="STD-Pavcnik-2002" TYPE="STUDY">Pavcnik 2002</LINK>; <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>), and there was one study from each of the following countries: the USA (Maryland) (<LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK>), Australia (<LINK REF="STD-McManus-2001" TYPE="STUDY">McManus 2001</LINK>), Sweden (<LINK REF="STD-Aronsson-2001" TYPE="STUDY">Aronsson 2001</LINK>) and Spain (<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>). The index pricing study was from Norway (<LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>) and the maximum prices study was from Spain (<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>). The setting in all the Canadian studies was the British Columbia Ministry of Health's drug subsidy program, Pharmacare. The patients in all these studies were Pharmacare beneficiaries: senior citizens aged 65 years and older. The settings in the other studies were the national drug insurance plans, including all beneficiaries (Australia, Norway, Sweden), the Statutory Health Insurance (SHI) plan (Germany) and Medicaid (USA). The SHI plan in Germany covers about 88% of the population. It is compulsory for workers with incomes under a certain level, for unemployed and retired people, and for specific population groups such as farmers, artists and students. The state specific Medicaid programs in the USA provide medical benefits to low-income groups, medically needy groups, or special groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Setting</HEADING>
<P>Canada (eight studies: <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>; <LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>); German (two studies: <LINK REF="STD-Pavcnik-2002" TYPE="STUDY">Pavcnik 2002</LINK>; <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>); US (two studies: <LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>; <LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK>); Spain (two studies: <LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>; <LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>); Norway (two studies: <LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>; <LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>); Sweden (one study: <LINK REF="STD-Aronsson-2001" TYPE="STUDY">Aronsson 2001</LINK>); Australia (one study: <LINK REF="STD-McManus-2001" TYPE="STUDY">McManus 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Characteristics of interventions</HEADING>
<P>In 17 studies the effects of reference drug pricing were analysed (<LINK REF="STD-Aronsson-2001" TYPE="STUDY">Aronsson 2001</LINK>; <LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>; <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>; <LINK REF="STD-McManus-2001" TYPE="STUDY">McManus 2001</LINK>; <LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>; <LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK>; <LINK REF="STD-Pavcnik-2002" TYPE="STUDY">Pavcnik 2002</LINK>; <LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>; <LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>; <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>). One of these studies (<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>) analysed maximum prices policy. The one other study analysed effects of index pricing (<LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>). See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for more details.</P>
<P>Policies in the first included studies were mainly introduced in the 1990s, except for the Maximum Allowable Cost (MAC) policy in Maryland, USA (1970s). The years of introduction of policies of the new included studies were 1995 to 1997 for <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK> and <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; 2000 for <LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>; 2003 for <LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK> and <LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>; 2004 for <LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>; and 2005 for <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>.</P>
<P>The setting in all the Canadian studies was the British Columbia Ministry of Health&#8217;s drug subsidy program, Pharmacare. The patients in all these studies were the Pharmacare beneficiaries, senior citizens aged 65 years and older (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>; <LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>). The settings in the other studies were the National Public Insurance from Sweden and Norway (<LINK REF="STD-Aronsson-2001" TYPE="STUDY">Aronsson 2001</LINK>; <LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>; <LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>), the Pharmaceutical Benefits Scheme from Australia (<LINK REF="STD-McManus-2001" TYPE="STUDY">McManus 2001</LINK>). Germany has two types of settings: the Statutory Health Insurance (SHI) in Germany covers about 88% of the population that is compulsory for workers with income under a certain level, for unemployed and retired people, and for specific population groups such as farmers, artists and students (<LINK REF="STD-Pavcnik-2002" TYPE="STUDY">Pavcnik 2002</LINK>); and the Techniker Krakenkasse (TK), a sickness fund with more than 5.8 million insured members in 2005, which is 82% of German residents with public health insurance (<LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>). The state specific Medicaid programs in the USA provide medical benefits to low-income groups, medically needy groups, and special groups; one study setting was from the Maryland State (<LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK>), and other from Michigan State (<LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>). Spanish settings corresponded to the National Health System (<LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>; <LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>) and the Andalusian Public Health Service (<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>). See 'Additional table 2' for further details.</P>
<P>For all seven British Columbia studies RP policy interventions and outcomes were for large therapeutic groups of analogue drugs: angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), nitrates used for long term prophylaxis, histamine-2 receptor antagonists (H2RA), opiates, nonsteroidal anti-inflammatory drugs (NSAIDs) (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>; <LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>). Other studies were a German study for statins (<LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>), a German study for oral antidiabetics and antiulcer drugs (<LINK REF="STD-Pavcnik-2002" TYPE="STUDY">Pavcnik 2002</LINK>), and a US study for antihypertensive and antihyperlipidaemic drugs (<LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>). No information was given on the infrastructure around the policies, for example what kind, if any, of electronic systems for prescription claims. For all included drug classes there were special authority exemptions, which were valid indefinitely and given after the physician had applied and provided a valid reason for exemption, for example in British Columbia there were several exemptions in the reference price system.</P>
<P>Some studies described RP policies applied for international non-proprietary name drugs: one Australian study for ranitidine (<LINK REF="STD-McManus-2001" TYPE="STUDY">McManus 2001</LINK>); acetaminophen-codeine (<LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>); and atorvastatin (<LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>). Other studies reported intervention with a RP policy for generic grouping drugs: one Spain study (<LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>) and one Norwegian study (<LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>) for citalopram, omeprazole and cetirizine brand names and generic drugs. One US study described RP applied for dosage forms of multisource chemical entities (<LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK>). No information was provided for exemptions with this type of drug included in the analysis.<BR/>
</P>
<P>A Norwegian study (<LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>) included an index pricing policy for six groups of active substances: cetirizin (treatment of allergy), citalopram (antidepressant), enalapril (antihypertensive), lisinopril (antidepressant), loratadin (treatment of allergy) and omeprazol (treatment of gastro-intestinal disorders). An exemption to this intervention was the case when the prescribing physician proscribed substitution of a generic in the pharmacies. A Spanish study (<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>) reported maximum prices for 3-hydroxy-3-methylglutaryl- conenzyme A (HMG-CoA) reductase inhibitors and a group of six particular compounds (statins) sold primarily in oral dosage forms (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, and cerivastatin). No information was provided for exemptions with this type of drugs included in the analysis. See 'Additional table 2' for further details.</P>
<P>There was little information on specific incentives in the studies. The general incentives in reference pricing systems are described in the 'Background' section.</P>
<P>Few of the included studies reported the size of the difference between the reference price and other drugs in the relevant drug groups. Not much specific information was given in the studies on what incentives the physicians or pharmacists had to spend time on identifying and retrieving the reference drug, or whether this was facilitated in some way (for example through an automated system). However, in British Columbia the reference drug program was introduced at the same time as a province-wide online pharmacy network was established. The pharmacy network kept track of exempt patients, indicated the portion of the drug price that PharmaCare would cover, and relieved the patient of the responsibility of submitting claims to PharmaCare and of the need to understand complicated policies (<LINK REF="REF-Pharmanet-2003" TYPE="REFERENCE">Pharmanet 2003</LINK>; <LINK REF="REF-Pharmanet-2005" TYPE="REFERENCE">Pharmanet 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Characteristics of outcomes</HEADING>
<P>None of the studies presented data on all outcomes. The studies provided data on cumulative drug expenditures (six studies: <LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>; <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>; <LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>; <LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>); third party (insurance) drug expenditures (eight studies: <LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>; <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>; <LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>); drug use, that is either the number of dispensed doses or the number of dispensed prescriptions (10 studies: <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-McManus-2001" TYPE="STUDY">McManus 2001</LINK>; <LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>; <LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>; <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>); and drug prices (four studies: <LINK REF="STD-Aronsson-2001" TYPE="STUDY">Aronsson 2001</LINK>; <LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>; <LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>; <LINK REF="STD-Pavcnik-2002" TYPE="STUDY">Pavcnik 2002</LINK>). One study (<LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>) reported patient costs but no other study reported other costs (either intervention costs or costs in other parts of the health services sector) using one of the study designs specified in our inclusion criteria.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-09-18 15:32:41 +0200" MODIFIED_BY="[Empty name]">
<P>The excluded studies table provides the reasons for exclusion of 24 studies about which it was plausible to expect that a reader would question why the study was not included, that are well known but did not meet all of the inclusion criteria, or ITS studies that met all inclusion criteria except that there were too few data points. See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for more details.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-09-18 15:32:55 +0200" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<P>In August 2013 the EPOC Cochrane Group recommended only including cluster randomised trials, non-randomised cluster trials, and CBA studies with at least two intervention sites and two control sites to reduce the risk of bias. Due to this recommendation we excluded four originally included studies (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>) from the SOF tables and from the main report on outcomes for healthcare utilisation; and included only two of these studies for mortality (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>).</P>
<P>For the reference pricing the following studies presented high risk of bias in certain domains: <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK> (protection of secular changes, and shape of the curve not pre-specified); <LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK> (incomplete outcome data adequately addressed); <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK> (protection of secular changes); <LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK> (protection of secular changes, management of incomplete data, and reliable outcome measurement); <LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK> (protection against detection bias); and <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK> (similar baseline characteristics) (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>The included ITS study (<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>) for maximum pricing policy had limitations in assessing drug expenditures: the intervention could be not be protected from secular changes, the outcome could not be measured in a reliable way, and the use of overall volume of sales as a proxy for public expenditure data.</P>
<P>The included ITS study (<LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>) for index pricing had some limitations (the source of data collection changed during the study period).<BR/>
</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-09-18 15:34:12 +0200" MODIFIED_BY="[Empty name]">
<P>Detailed results for the included studies are provided in the 'Additional tables' (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>; <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>; <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>; <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>; <LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>). None included reference reported adverse effects caused by pricing policy interventions. There was no information in the included studies regarding the differential effects of the interventions on resource-disadvantaged populations.</P>
<P>For three outcomes, cumulative drug expenditure, drug expenditures and drug use, we included additional information about the expected effects in order to provide additional insight: effects on reference drugs, effects on cost share drugs, and effects on both reference drugs and cost share drugs. These are important factors for understanding the effects of the main outcomes.</P>
<P>
<B>Reference drugs</B>: drugs that determine the reference price level. There is no cost share by the patients for these drugs, which are fully reimbursed. The expectation is that reference pricing will lead to an increase in the use of these drugs.</P>
<P>
<B>Cost share drugs</B>: drugs in the same group as the reference drugs that cost more. Patients have to pay the difference between the reference price drugs and the price of these drugs. The expectation is that reference pricing will lead to a decrease in the use of these drugs.</P>
<P>
<B>Reference drugs + cost share drugs</B>: both the reference drugs and the cost share drugs. The expectation is that reference pricing will lead to little or no change in the overall use of these drugs.</P>
<SUBSECTION>
<HEADING LEVEL="5">Reference pricing ('Summary of findings' table 1)</HEADING>
<P>We included and assessed 17 studies (<LINK REF="STD-Aronsson-2001" TYPE="STUDY">Aronsson 2001</LINK>; <LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>; <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>; <LINK REF="STD-McManus-2001" TYPE="STUDY">McManus 2001</LINK>; <LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>; <LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK>; <LINK REF="STD-Pavcnik-2002" TYPE="STUDY">Pavcnik 2002</LINK>; <LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>; <LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>; <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>).</P>
<P>Some studies reported cumulative changes in drug expenditures while others reported absolute drug expenditures at specific time points. We have reported those results separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insurer's change in cumulative drug expenditures at specified time points</HEADING>
<P>See: Table 4.</P>
<P>Five studies (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>; <LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>; <LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>) assessed the change in cumulative drug expenditures. All of the studies were ITS studies.</P>
<P>Three reference pricing studies reported cumulative drug expenditures at one year after the transition period. Two studies (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>) reported median relative insurer's cumulative expenditures on both the reference drugs and cost share drugs of -18%, ranging from -36% to 3% at one year after the transition period. Two studies (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>) reported median relative insurer's cumulative expenditures on reference drugs of -16%, ranging from -37% to 4% at two years after the transition period.</P>
<P>
<LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK> reported relative insurer's cumulative expenditures on the total market of -1.5%.</P>
<P>
<LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK> reported absolute cumulative drug expenditures at one year after the transition period for four groups of drugs (both reference drugs and cost share drugs).</P>
<OL>
<LI>Antihypertensive drugs: USD 18,562 (95% CI -93 to 37,217).</LI>
<LI>Antihyperlipidemic drugs: USD 15,322 (95% CI -30,452 to 61,096).</LI>
<LI>Generic drugs: USD -35,448 (95% CI -50,470 to -20,425).</LI>
<LI>Brand-name drugs: USD 69,331 (95% CI 21,553 to 117,109).</LI>
</OL>
<P>
<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK> reported on mean monthly savings of total statin sales 10 months after the intervention and attributed to the RP revision applied to two reference drugs.</P>
<OL>
<LI>Simvastatin: Andalusia -29.7% (-26.8% to -32.6%) and rest of Spain -51.8% (-48.9% to -54.6%).</LI>
<LI>Lovastatin: Andalusia -11.5% (-3.5% to -19.5%) and rest of Spain -16.3% (-23.4 to -9.1).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Relative change in insurer's drug expenditures at specified time points</HEADING>
<P>See: <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>.</P>
<P>Six studies (<LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>; <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>; <LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK>) assessed the change in drug expenditures at specified time points.</P>
<P>Four reference pricing studies (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>) reported the median relative insurer's expenditures on both reference drugs and cost share drugs of -10%, ranging from -53% to 4% at one year after the transition period.</P>
<P>
<LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK> reported absolute change level at two time points.</P>
<P>Immediately after the transition period on cost share drugs:</P>
<UL>
<LI>generic copayment -12.92 (95% CI not applicable (NA));</LI>
<LI>brand-name copayment -6.37 (95% CI NA).</LI>
</UL>
<P>Two years after the transition period on cost share drugs:</P>
<UL>
<LI>generic copayment -12.76% (95% CI NA);</LI>
<LI>brand-name copayment -14.82% (95% CI NA).</LI>
</UL>
<P>
<LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK> reported the absolute and relative change levels on monthly Medicaid drug expenditures in Maryland for both reference drugs and cost share drugs:</P>
<UL>
<LI>absolute change immediate after transition period: USD 291,276 (95% CI -478,458 to -104,094);</LI>
<LI>relative change six months after transition period: USD -0.87 per month (95% CI NA).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Drug use</HEADING>
<P>See: <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>.</P>
<P>Ten studies about reference drugs (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-McManus-2001" TYPE="STUDY">McManus 2001</LINK>; <LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>; <LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>; <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>).</P>
<P>Four reference pricing studies (<LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>; <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>) reported a median relative change of 15% on <B>reference drugs</B> prescriptions at one year (range: -14% to 166%).</P>
<P>Three studies (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-McManus-2001" TYPE="STUDY">McManus 2001</LINK>; <LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK>) reported a relative change on <B>reference drugs</B> prescriptions six months after transition period of 131% (range: -35% to 251%).</P>
<P>
<LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK> reported that six months after transition period no significant difference in slope pre versus post intervention (P = 0.08)</P>
<P>
<LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK> reported a maximum increase of 60% on the number of median CCBs monthly doses dispensed per 10000 senior residents immediate after transition period.</P>
<P>Three reference pricing studies (<LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>) reported median relative change of -39% on <B>cost share drugs</B> prescriptions at one year (range: -87% to -17%).</P>
<P>Four reference pricing studies <LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>; <LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK> reported median relative change of -10.5% on <B>both reference drugs and cost share drugs</B> prescriptions at one year (range: -12% to -8%).</P>
<P>
<LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK> reported no change on prescription per capita from 1995 to 2006.</P>
<P>
<LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK> also reported for a Type 1 RP&#8212;only chemically equivalent drugs -3% days opiates dispensed per 1000 seniors. For Type 2 RP, all drugs from the same therapeutic class considered interchangeable 106% days opiates dispensed per 1000 seniors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Drug prices and patients' out of pocket payments</HEADING>
<P>See: <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>.</P>
<P>In three studies reference pricing appeared to reduce drug prices. In <LINK REF="STD-Pavcnik-2002" TYPE="STUDY">Pavcnik 2002</LINK> the estimate of price reductions for oral antibiotics was 18%. The prices of generics dropped by an average of 11% whereas the decline in brand prices was 26%. For anti-ulcer drugs the estimated reductions ranged from 12% to 26%. All the estimates were statistically significant at the 5% level. <LINK REF="STD-Aronsson-2001" TYPE="STUDY">Aronsson 2001</LINK> also found that brand prices were reduced, but did not report comparable data.</P>
<P>The absolute change observed in <LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK> for specific drug prices was:</P>
<OL>
<LI>antihypertensive drugs USD 0.06 (95% CI 0 to 0.12) per beneficiary;</LI>
<LI>antihyperlipidaemic drugs USD 0.37 (95% CI 0.09 to 0.64) per beneficiary;</LI>
<LI>generic drugs USD -0.13 (95% CI -0.20 to -0.06) per beneficiary;</LI>
<LI>brand-name drugs USD 0.17 (95% CI-0.03 to 0.38) per beneficiary.</LI>
</OL>
<P>
<LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK> assessed copayments for a group of generic and brand-name drugs two years after a reference pricing policy. In <LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK> copayments prices decreased 13% for generic drugs and 23% for brand-name drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Healthcare utilisation</HEADING>
<P>In the previous version of this review (<LINK REF="REF-Aaserud-2006b" TYPE="REFERENCE">Aaserud 2006b</LINK>), four analyses (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>) reported emergency room visits, four analyses (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>) reported hospital admissions, and four studies (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>) reported physician office visits and physician ambulatory consults. For all these outcomes the studies reported effects at different time points after the intervention, from one to 47 months.</P>
<P>All these analyses were excluded from this update because they were CBA studies with fewer than two intervention sites and two control sites.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>In the previous version of this review (<LINK REF="REF-Aaserud-2006b" TYPE="REFERENCE">Aaserud 2006b</LINK>), two CBA analyses (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>) assessed mortality. Because these analyses had only one intervention site, they were excluded from this update.</P>
<P>As happened with the healthcare utilisation outcome<B>, </B>these analyses were excluded from this update because they were CBA studies with fewer than two intervention sites and two control sites.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Index pricing</HEADING>
<P>See: <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>.</P>
<P>We identified one study of index pricing (<LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>), from Norway. It evaluated the effects of index pricing on drug use and drug prices for eight drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Drug use</HEADING>
<P>
<B>See: </B>
<LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>.</P>
<P>The effects on use of drugs in the index pricing groups were not analysed appropriately in the report. Based on graphs, we conducted an ITS analysis of the effect on the use of brand and generic citalopram only. The use of brand citalopram decreased relative to the use prior to index pricing, by 29 % (95% CI -11% to -48%) immediately afterwards and 43% (95% CI -18% to -67%) at six months after the transition period following the introduction of the index pricing system. The use of generic citalopram increased by 114% (95% CI 64% to 164%) immediately afterwards and 55% (95% CI 11% to 98%) at six months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Drug prices</HEADING>
<P>See: <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>.</P>
<P>Brand and generic drug prices were both reduced. The reduction in brand drug prices was not statistically significant. The generic drug prices were reduced by 4.0% (95% CI 2.9% to 5.1%) relative to the price prior to index pricing immediately afterwards and by 5.3% at six months after the transition period. The brand drug prices were reduced by 0.8% relative to the price prior to index pricing immediately afterwards and by 1.1% at six months after the transition period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Maximum prices</HEADING>
<P>See: 
<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>; <LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>.</P>
<P>We identified one study of maximum prices (<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>), from Andalusia in Spain. This study was designed as an ITS analysis with a comparison series of 46 months drug use and sales figures from January 2001 to October 2004 for each active ingredient. Three public reimbursement reforms were applied to the prescription of the six commercially available statins: a Spanish generic reference pricing system for lovastatin and simvastatin; and two competing policies introduced by the Andalusian Public Health Service for all statins, first a maximum consumer price (MCP) and then a so-called quality prescribing incentive (PI) for general practitioners (MCP plus PI), similar to a generic prescribing incentive.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Drug expenditures</HEADING>
<P>This study reported an increase in drug expenditures with a MCP one year after the transition period from when the policy was started of 21% (95% CI 19% to 24%) due to an increase in the volume of sales for all statins.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-09-22 12:34:18 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-09-22 12:34:18 +0200" MODIFIED_BY="[Empty name]">
<P>We included 18 studies (seven new studies in this update). Detailed results for the included studies are provided in the 'Additional tables' (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>; <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>; <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>; <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>; <LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>). None included reference reported adverse effects caused by the pricing policy interventions. There was no information in the included studies regarding the differential effects of the interventions on resource-disadvantaged populations.</P>
<P>We found no evidence of effects on heath and healthcare utilisation outcomes. The four studies included in the original review that used a CRM or CBA studies design to assess the health and healthcare utilisation outcomes (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>) were excluded from SOF tables and from the main report in this update according to EPOC Group recommendation (August 2013): &#8220;We recommend only including cluster randomised trials, non-randomised cluster trials, and CBA studies with at least two control sites&#8221;. All these analyses were excluded from this update because they were CBA studies with fewer than two intervention sites and two control sites.</P>
<P>The amount and quality of the evidence are larger for the effects on use and expenditures of reference drugs than for the effects on cost share drugs.</P>
<P>In the included studies the aggregate use of reference drugs increased, while the use of cost share drugs decreased. This was the intention of the policy. Thus, there seems to be an aggregate shift of drug use within each reference drug group. The total use of drugs did not change as much but there were some changes, which might be a little surprising. The idea of reference pricing is to shift the drug use within each reference group from expensive to cheaper but equally effective drugs, with no intended impact on the total use of drugs in the reference group.</P>
<SUBSECTION>
<HEADING LEVEL="5">Reference pricing</HEADING>
<P>We found that internal reference pricing may reduce third party drug expenditures immediately and for six months and one or two years. Although the immediate and six month results are very consistent, we prioritised reporting results at one or more years because they are less exposed to secular changes and to the effects of the transition period. The change in expenditures can be deconstructed to different effects, a) a shift in drug use from more expensive to less expensive drugs within the reference drug groups; b) patients or their private insurers paying a larger part of the expenditures; c) reduced prices; d) reduced total use of drugs in the reference drug groups. The studies provided little systematic information on which of these factors were the main factors behind the reduction in drug expenditures for third parties. The results indicate a shift in drug use from cost share drugs to less expensive reference drugs. However, it is not clear what proportion of the drug expenditure reduction can be accounted for by this shift.</P>
<P>Reference pricing may reduce expenditures related to effects on reference drugs, and the effect on expenditures of cost share drugs is uncertain. Reference pricing may increase the use of reference drugs and may reduce the use of cost share drugs. Two studies reported median relative insurer's cumulative expenditures on both reference drugs and cost share drugs of -18%, ranging from -36% to 3%. A third study reported relative insurer's cumulative expenditures on the total pharmaceutical market of -1.5%. Four reference pricing studies reported the median relative insurer's expenditures on reference drugs and cost share drugs of -10%, ranging from -53% to 4% at one year after the transition period. Four reference pricing studies reported a median relative change of 15% in reference drug prescriptions at one year (range -14% to 166%). Three reference pricing studies reported a median relative change of -39% in cost share drug prescriptions at one year (range -87% to -17%). The observed changes in expenditures outcomes are consistent with the observed drug use effects: reference pricing may increase the use of reference drugs and may reduce the use of cost share drugs. As is expected four reference pricing studies reported a median relative change of 15% in reference drug prescriptions at one year (range -14% to 166%). Three reference pricing studies reported a median relative change of -39% in cost share drug prescriptions at one year (range -87% to -17%).</P>
<P>The size of the savings varied across the different reference pricing policies. There are a number of potential explanations for this variation, such as how big the difference in cost is between the reference and price share drugs (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). The available data do not provide a reliable basis for assessing the extent to which such factors explain the observed variation in the effects of reference pricing.</P>
<P>The effects of reference pricing on drug use and expenditures beyond two years are uncertain. <LINK REF="REF-Ioannides_x002d_Demos-2002" TYPE="REFERENCE">Ioannides-Demos 2002</LINK>; <LINK REF="REF-Zammit_x002d_Lucia-1995" TYPE="REFERENCE">Zammit-Lucia 1995</LINK> and others have claimed that reference pricing does not reduce long term growth in drug expenditures since reference pricing mainly addresses only two of the drivers that increase drug expenditures (listed above): prices and shifts in drug use within the reference group of drugs. We found no data for long term growth effects that could support or refute this. However, even if the short term reductions in drug expenditures growth rates are not sustained, the absolute difference in drug expenditure could be sustained for many years.</P>
<P>The effects of reference pricing on drug prices and patients' out of pocket payments are also uncertain. In three studies reference pricing appeared to reduce drug prices, and in one study copayment prices decreased 13% for generic drugs and 23% for brand-name drugs.</P>
<P>An argument against reference drug pricing is that it could lead to disincentives to pharmaceutical innovation (<LINK REF="REF-Ioannides_x002d_Demos-2002" TYPE="REFERENCE">Ioannides-Demos 2002</LINK>). It is hard to document such effects of reference pricing empirically. We have not identified such documentation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other policies</HEADING>
<P>The evidence for other policies is much more limited than for reference pricing. <LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK> evaluated index pricing half a year after the policy started (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The effects on the prices of generic and brand drugs (though not statistically significant for the latter category) as well as on the use of generic and brand citalopram were all in the direction intended by the policy makers.</P>
<P>Index pricing may reduce the use of brand drugs and increase the use of generic drugs compared with no intervention. In addition, index pricing may slightly reduce the price of the generic drugs.</P>
<P>
<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK> evaluated maximum prices (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). One year after the policy was introduced, the volume of sales for total statins increased unexpectedly by 21.4% as a result of quantity increases for atorvastatin, an on-patent statin, possibly as a result of marketing efforts to shift drug use to higher-priced statins (<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>).</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-09-18 15:35:09 +0200" MODIFIED_BY="[Empty name]">
<P>This update is a complete review of the available evidence up to December 2012.</P>
<P>Several factors may limit the applicability of this evidence. These are that </P>
<P>all of the included studies were conducted in high-income countries; </P>
<P>the target populations were vulnerable groups covered by national insurance plans; </P>
<P>the studies were limited to specific groups of drugs.</P>
<P>Most of the included studies on reference pricing were for senior citizens in British Columbia, Canada. The applicability of these interventions to low- and middle-income country settings depends on several factors such as the</P>
<P>availability and access to drugs; t</P>
<P>he presence of significant price differences between the drugs in a reference group before the reference price system is introduced, with relatively high prices on the drugs most used; </P>
<P>the alignment of stakeholders' interests and the availability of adequate incentives for patients, physicians, pharmacists and pharmaceutical companies to comply with the reference price system; </P>
<P>provision of clinical and managerial information and support; and </P>
<P>quality control of generics drugs.</P>
<P>Other factors that might modify the effects of reference pricing include the equivalence of drugs in a reference group, exemptions and the availability of electronic information systems (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). We did not find evidence to support or refute the impact of these factors. Logically, the drugs in a reference drug group should be therapeutically similar. If they are not, the patients may have to pay more to get the most effective drug, or they may choose less effective drugs. There should be reasonable mechanisms for exemptions for patients that need such drugs for medical reasons. Too limited exemptions could lead to higher copayments for the most effective drug and to prescribing of less effective drugs by physicians. Too generous exemptions could reduce the savings by not shifting the drug use towards cheaper drugs. The administration costs, like time use for identifying, prescribing and dispensing the reference drugs and for handling exemption cases, should be as low as possible. An electronic processing system would be useful and potentially time saving. The lack of an electronic processing system might reduce the feasibility and increase the costs of reference pricing.</P>
<P>The existence of a regulatory framework that allows generic substitution or prescribing by international non-proprietary names could be important for pricing policy interventions.</P>
<P>None of the included studies provided a full analysis of cost-effectiveness or data on administration costs related to reference pricing. Such costs would be related to the logistic system and incentives for physicians, pharmacists and drug insurance administrators for handling prescriptions and exemptions. In a paper that did not meet our study design inclusion criteria, <LINK REF="STD-Schneeweiss-2004b" TYPE="STUDY">Schneeweiss 2004b</LINK> estimated the administrative spending due to the reference pricing for ACE inhibitors in British Columbia, Canada. The administrative expenditures related to the design, implementation, and ongoing support for the policy were estimated to approximately 7% (CAD 0.42 million to CAD 6.2 million) of the savings during the first year of the policy. In another paper excluded from our review, <LINK REF="STD-ECON-2000" TYPE="STUDY">ECON 2000</LINK> estimated the time costs for physicians and pharmacists related to a generic reference pricing system in Norway. The time costs were estimated to be approximately 60% of the public drug insurance savings.</P>
<P>We identified only one study of rate of return regulation, which did not meet our inclusion criteria (<LINK REF="STD-Borrell-1999" TYPE="STUDY">Borrell 1999</LINK>). The study indicated that the aggregate medicine price index in the UK changed (relatively) by 0.15% in relationship to a 1.00% change in the rate of return cap.</P>
<P>Four studies from low- and middle-income countries (Brazil) were identified in the LILACS database but they did not meet our inclusion criteria. Three of them (<LINK REF="STD-Barberato-2007" TYPE="STUDY">Barberato 2007</LINK>; <LINK REF="STD-Inocencio-2010" TYPE="STUDY">Inocencio 2010</LINK>; <LINK REF="STD-Vieira-2006" TYPE="STUDY">Vieira 2006</LINK>) evaluated use and expenditure outcomes after a generic drug policy was implemented in 1999. This policy promotes replacement of brand drugs with generics in national procurements.</P>
<P>All included studies were conducted in high-income countries: Canada (eight); German (two), USA (two), Spain (two), Norway (two), Sweden (one) and Australia (one). Taking into account the factors listed in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> we must be cautious to extrapolate the finding of our systematic review to low- and middle-income countries.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-09-18 15:35:13 +0200" MODIFIED_BY="[Empty name]">
<P>Five out of 17 studies of reference pricing were judged to have a high risk of bias in this update. The included ITS study of maximum prices policy also had a high risk of bias. It was unclear whether the intervention was independent of other changes in 11 out of 32 analyses and the intervention was not independent of other changes in another six analyses (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The quality of evidence was low for all of the outcomes reported in the included studies for reference pricing (except the insurer's cumulative drug expenditures one year after the transition period for the effect on reference drugs plus cost share drugs where it was very low) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). For index pricing policy the quality of the evidence was low (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>), and was very low for maximum prices policy (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-09-18 15:36:27 +0200" MODIFIED_BY="[Empty name]">
<P>Strengths of this update include a thorough search, systematic assessment of the risk of bias in the included studies, exclusion of CBA studies with only a single intervention site and a high risk of bias (<LINK REF="REF-EPOC-2013a" TYPE="REFERENCE">EPOC 2013a</LINK>), and appropriate analyses of all of the included ITS and RM studies (<LINK REF="REF-EPOC-2013b" TYPE="REFERENCE">EPOC 2013b</LINK>). It is unlikely that important published studies were not identified considering our highly sensitive search that yielded 26,797 references which were screened. However, it is possible that studies in the grey literature, such as working papers or internal government reports, have not been identified. It is uncertain whether there might be a publication bias. Although there may be unpublished studies that we did not identify, and those studies might have found systematically different results (smaller effects), we are unaware of any evidence to support this. The effects in the included studies varied, with some studies reporting little or no effect and some studies reporting findings in opposite directions.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-09-18 15:36:51 +0200" MODIFIED_BY="[Empty name]">
<P>The findings of this update are largely consistent with the findings of the previous version of this review (<LINK REF="REF-Aaserud-2006b" TYPE="REFERENCE">Aaserud 2006b</LINK>). Key differences are the following.</P>
<UL>
<LI>We included seven new studies of reference pricing and one of maximum prices.</LI>
<LI>We excluded four analyses (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>) that reported emergency room visits, four analyses (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>) that reported hospital admissions, four analyses (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>; <LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>) that reported physician office visits and physician ambulatory consults, and two analyses that reported mortality (<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>; <LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>). All of these analyses were excluded because they were CBA analyses with only one intervention site. Consequently, we did not report any evidence of the effects of reference pricing on healthcare utilisation or health outcomes in this update, whereas in the previous version of this review that evidence was reported as very low quality evidence.</LI>
<LI>We assessed the evidence of the effects of reference pricing on drug use as low quality in this update, whereas it was assessed as moderate quality in the previous version. This was because in the previous version we modified the GRADE approach and initially graded ITS and RM studies as moderate quality evidence. In this update we adhered to the GRADE guidance (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>) and initially graded ITS and RM studies as low quality.</LI>
</UL>
<P>
<LINK REF="REF-Galizzi-2011" TYPE="REFERENCE">Galizzi 2011</LINK> reviewed studies of the effects of reference pricing policies in OECD countries, including both theoretical and empirical studies. Some of the 30 empirical articles that were included agree with our included studies and showed that prices of drugs are likely to drop, and that more significant price decreases are observed in the submarkets in which drugs are already facing generic competition prior to reference pricing. Brand-named drugs originally priced above reference pricing values decreased their prices to a greater extent. The review also found that following the introduction of reference pricing, the generics market share significantly increased whenever the firms producing brand-name drugs did not adopt one of the following strategies: lowering prices to the reference pricing value, launching new dosages and formulations, or marketing substitute drugs still under patent protection. In the case of therapeutic clusters (level 3 reference pricing), although more evidence is needed the studies that were based on a large number of patient level observations showed no association between reference pricing and health losses for the patients.</P>
<P>Other recent reviews of pricing policies, including reference drug pricing (<LINK REF="REF-Puig_x002d_Junoy-2010" TYPE="REFERENCE">Puig-Junoy 2010</LINK>; <LINK REF="REF-Puig_x002d_Junoy-2010a" TYPE="REFERENCE">Puig-Junoy 2010a</LINK>) and systematic reviews of pharmaceutical policies that include some pricing policies (<LINK REF="REF-Danzon-2008" TYPE="REFERENCE">Danzon 2008</LINK>; <LINK REF="REF-Faden-2011" TYPE="REFERENCE">Faden 2011</LINK>; <LINK REF="REF-Puig_x002d_Junoy-2010a" TYPE="REFERENCE">Puig-Junoy 2010a</LINK>), also have findings that are consistent with the findings of this review.</P>
<P>
<LINK REF="REF-Puig_x002d_Junoy-2010" TYPE="REFERENCE">Puig-Junoy 2010</LINK> and <LINK REF="REF-Puig_x002d_Junoy-2010a" TYPE="REFERENCE">Puig-Junoy 2010a</LINK> included descriptive publications about generic competition and excluded theoretical models, comments or editorial letters. The 14 included studies published after 1999 provide a descriptive categorization of the main regulatory reforms in European countries. Direct price regulation or the generic reference pricing systems used to reduce generic drug prices were found to be successfully implemented in reforms by adopting measures that encourage consumer price competition in generic drug markets.</P>
<P>
<LINK REF="REF-Danzon-2008" TYPE="REFERENCE">Danzon 2008</LINK> compared pharmaceutical spending, availability, use and prices in 12 countries including the USA in 2005. They found that in recent years several European Union countries have changed their rules governing generics to expand pharmacists&#8217; authority and incentives to substitute cheaper generics. Comprehensive price indices show foreign prices to be 20% to 40% lower than US manufacturer prices but only 10% to 30% lower than US public prices.</P>
<P>
<LINK REF="REF-Faden-2011" TYPE="REFERENCE">Faden 2011</LINK> reviewed pharmaceutical management strategies to improve the cost-effectiveness of medicines in the context of health insurance systems in low- and middle-income countries. Even though the internal and external validity of the three identified references regarding generic reference pricing is questionable, this policy was found to decrease and stabilize medicine prices and to improve access.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-09-18 15:36:57 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-09-18 15:36:56 +0200" MODIFIED_BY="[Empty name]">
<P>Based on the evidence assessed in this review, internal reference pricing may decrease third party drug expenditures shifting drug use from cost share drugs to reference drugs in the short term. Reference pricing may reduce expenditures related to medicines under the reference pricing policy. Internal reference pricing shows the expected effect of the policy since it may increase the use of reference drugs and reduce the use of cost share drugs. The size of these effects varies and the effects beyond two years are uncertain. Effects on out of pocket patient expenditures, administration costs, healthcare utilisation and health outcomes are uncertain. The effects of other purchasing and pricing policies are until now uncertain due to sparse evidence. However, index pricing may also shift drug use towards less expensive generic drugs. Index pricing may reduce the use of brand drugs, increase the use of generic drugs and slightly reduce the price of the generic drugs but its effects on other outcomes are uncertain. None of the included studies reported on adverse effects caused by pricing policy interventions.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-09-18 15:36:57 +0200" MODIFIED_BY="[Empty name]">
<P>We found a number of well-designed evaluations of reference pricing and only two evaluations of other pharmaceutical pricing and purchasing policies. Although we performed an extensive literature search, there could be some more studies in the grey literature. Updates of this review will include further efforts to identify studies in the grey literature.</P>
<P>More than half of the reference drug pricing studies were from British Columbia, Canada. It is important to conduct evaluations in different settings, particularly in low- and middle-income countries. The study designs in our included studies were mostly interrupted time series designs for drug use and drug costs. Such observational designs have limitations, however they may be the most appropriate design for evaluating pharmaceutical policies when randomised trials are not feasible. This is likely to be the case for pricing and purchasing policies which typically must be implemented in a country or large jurisdiction.</P>
<P>Because pharmaceutical policies have uncertain effects and they might cause harms as well as benefits, it is important that they are properly evaluated. Evaluations should be planned ahead of introducing the policies and should be a routine part of the policy process.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-09-24 20:45:10 +0200" MODIFIED_BY="[Empty name]">
<P>We gratefully acknowledge the following.</P>
<P>For the previous version of this review:</P>
<P>- Sue Hill, Malcolm Maclure, Carolyn J Green and Kristin Kamilla Linnestad helped sift references and abstracts from the broad literature search for pharmaceutical policies and commented on drafts of the data collection form. Kristin Kamilla Linnestad also assessed one study (<LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>) together with MOA.<BR/>- Doris Tove Kristoffersen and Torbjørn Wisløff provided statistical advice.<BR/>- Curt D Furberg, Mark Gibson, Roberto Grilli, David A Henry, Bob Nakagawa, Dennis Ross-Degnan, Gail Shearer, Stephen B Soumerai, Luke Vale, Lisa Bero, Kirby Lee, Merrick Zwarenstein and Alain Mayhew provided helpful comments on drafts of the protocol or the review, or both.<BR/>- Morten Bjørklund, Matthew Oxman, Kjetil Olsen and the Library of the Norwegian Directorate for Health and Social Affairs helped retrieve, copy and register papers.</P>
<P>For this update:</P>
<P>- Marit Johansen and Daniel Comandé conducted the literature searches.<BR/>- Julián Lopez from Centro de Información de Medicamentos (CIMUN), Universidad Nacional de Colombia, supported the research project with Colcencias (Grant Code - 110151929152/2011)<I>
<BR/>
</I>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-09-18 15:37:07 +0200" MODIFIED_BY="[Empty name]">
<P>For the previous version of this review:</P>
<P>MOA has previously carried out short term pharmacoeconomic projects for the National Insurance Service and the Norwegian Medicines Agency. From 1997 to 1999 he worked for a private company, Brevreklame, doing market research for pharmaceutical firms in Norway.<BR/>HS is supported by the Dutch Health Care Insurance Board (CVZ).<BR/>JPK has previously worked for one year for each of the Danish Medicines Agency and Lundbeck A/S as part of a residency in clinical pharmacology and has been previously employed five hours a week at the Danish Medicines Agency (Licensing Division). Since March 2007 he has been working zero to five hours a week as an advisor for Nordic Biotech.</P>
<P>For this update:</P>
<P>AA has previously carried out short term pharmacoeconomic projects for the Commerce Ministry and other technical projects for the Ministry of Health and the local National regulatory authority (INVIMA) in Colombia.</P>
<P>AC has not carried out pharmacoeconomic projects before now.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-09-18 15:37:00 +0200" MODIFIED_BY="[Empty name]">
<P>For the previous version of this review:</P>
<P>MOA, ATD and ADO prepared the protocol. JPK and HS commented on protocol drafts. MOA, ATD, JPK and HS applied the inclusion criteria, assessed the quality and extracted the data for the included studies. CR further developed the quality criteria (based on the EPOC criteria) for interrupted time series (ITS) and repeated measures (RM) studies and conducted statistical reanalyses for the ITS studies. MOA prepared the first draft of the report. The others commented on and contributed to subsequent iterations.</P>
<P>For this update:</P>
<P>AA, AC, DD, MM, MOA and VV conducted the screening references phase. AA, AC, CV, MOA and VV extracted data and assessed the quality for the included references. JOJ conducted statistical reanalyses for the ITS studies and guided methodological assessment (based on the EPOC criteria). AA, AC and VV prepared the first draft of the report. The others commented on and contributed to subsequent iterations.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-09-18 15:37:09 +0200" MODIFIED_BY="[Empty name]">
<P>For this update we only included CBA and CRM studies if there were at least two sites in each comparison group, due to EPOC Group recommendations (<LINK REF="REF-EPOC-2013a" TYPE="REFERENCE">EPOC 2013a</LINK>): "We recommend only including cluster randomised trials, non-randomised cluster trials, and CBA studies with at least two intervention sites and two control sites".</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2011-10-16 18:28:25 +0200" MODIFIED_BY="Agustín Ciapponi"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-09-23 01:23:55 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-09-18 16:05:46 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-09-18 16:05:46 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aronsson-2001" MODIFIED="2014-08-19 11:13:41 +0200" MODIFIED_BY="[Empty name]" NAME="Aronsson 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-08-19 11:13:41 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;TilAndy080604&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2014-08-19 11:13:41 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aronsson T, Bergman MA, Rudholm N</AU>
<TI>The impact of generic drug competition on brand name market shares - evidence from micro data</TI>
<SO>Review of Industrial Organization</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>4</NO>
<PG>425-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11002"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brekke-2003" MODIFIED="2014-08-29 04:43:54 +0200" MODIFIED_BY="[Empty name]" NAME="Brekke 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-29 04:43:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Brekke K, Grasdal A, Holmås TH, Steen F, Sunnevåg K</AU>
<TI>Evaluation of the new pharmacy act and the index price system</TI>
<TO>Evaluering av ny apoteklov og indeksprissystemet</TO>
<SO>Bergen (Norway): Rokkansenteret; 2003; Rapport 17</SO>
<PB>Rokkansenteret</PB>
<CY>Beregen, Norway</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17406"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brekke-2011" MODIFIED="2014-08-29 03:58:42 +0200" MODIFIED_BY="[Empty name]" NAME="Brekke 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-29 03:58:42 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;225285&lt;/p&gt;" NOTES_MODIFIED="2014-08-29 03:58:42 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brekke KR, Holmas TH, Straume OR</AU>
<TI>Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment</TI>
<SO>Journal of Public Economics</SO>
<YR>2011</YR>
<VL>95</VL>
<PG>624-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grootendorst-2002" MODIFIED="2014-08-19 11:13:58 +0200" MODIFIED_BY="[Empty name]" NAME="Grootendorst 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Grootendorst P, Dolovich L, Holbrook A, Levy A, O'Brien B</AU>
<TI>The impact of reference pricing of cardiovascular drugs on health care costs and health outcomes: evidence from British Columbia. Volume 2: Technical Report. SEDAP research paper no. 71</TI>
<SO>Hamilton (ON): McMaster University QSEP Report Series No. 370; 2002</SO>
<EN>2</EN>
<PB>SEDAP</PB>
<CY>Hamilton, Ontario, Canada</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-19 11:13:58 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grootendorst PV, Dolovich LR, O'Brien BJ, Holbrook AM, Levy AR</AU>
<TI>Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2001</YR>
<VL>165</VL>
<NO>8</NO>
<PG>1011-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grootendorst-2005" MODIFIED="2014-08-29 04:00:21 +0200" MODIFIED_BY="[Empty name]" NAME="Grootendorst 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-29 04:00:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grootendorst PV, Marshall JK, Holbrook AM, Dolovich LR, O'Brien BJ, Levy AR</AU>
<TI>The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs</TI>
<SO>Health Services Research</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>5 Pt 1</NO>
<PG>1297-317</PG>
<IDENTIFIERS MODIFIED="2013-11-14 17:46:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16174135"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Grootendorst-2006" MODIFIED="2014-08-29 04:01:13 +0200" MODIFIED_BY="[Empty name]" NAME="Grootendorst 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-08-29 04:01:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grootendorst P, Stewart D</AU>
<TI>A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia</TI>
<SO>Health Economics</SO>
<YR>24 February 2006</YR>
<VL>15</VL>
<PG>735&#8211;42</PG>
<PB>Wiley InterScience</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-10-06 10:27:11 +0200" MODIFIED_BY="Angela Acosta">
<IDENTIFIER MODIFIED="2011-10-06 10:25:13 +0200" MODIFIED_BY="Angela Acosta" TYPE="DOI" VALUE="10.1002/hec.1103"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hazlet-2002" MODIFIED="2014-08-29 04:02:08 +0200" MODIFIED_BY="[Empty name]" NAME="Hazlet 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-08-29 04:02:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hazlet TK, Blough DK</AU>
<TI>Health services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly</TI>
<SO>Medical Care</SO>
<YR>2002</YR>
<VL>40</VL>
<NO>8</NO>
<PG>640-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kibicho-2012" MODIFIED="2014-09-18 16:05:46 +0200" MODIFIED_BY="[Empty name]" NAME="Kibicho 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-09-18 16:05:46 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;225290&lt;/p&gt;" NOTES_MODIFIED="2014-09-18 16:05:46 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kibicho J, Pinkerton SD</AU>
<TI>Multiple drug cost containment policies In Michigan's Medicaid program saved money overall, although some increased costs</TI>
<SO>Health Affairs</SO>
<YR>2012</YR>
<VL>31</VL>
<PG>816-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marshall-2002" MODIFIED="2014-08-29 04:04:18 +0200" MODIFIED_BY="[Empty name]" NAME="Marshall 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-08-29 04:04:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marshall JK, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR</AU>
<TI>Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2002</YR>
<VL>166</VL>
<NO>13</NO>
<PG>1655-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McManus-2001" MODIFIED="2014-08-29 04:06:47 +0200" MODIFIED_BY="[Empty name]" NAME="McManus 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-08-29 04:06:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McManus P, Birkett DJ, Dudley J, Stevens A</AU>
<TI>Impact of the minimum pricing policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia</TI>
<SO>Pharmacoepidemiology and Drug Safety</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>4</NO>
<PG>295-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moreno_x002d_Torres-2011" MODIFIED="2014-08-29 04:08:04 +0200" MODIFIED_BY="[Empty name]" NAME="Moreno-Torres 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-29 04:08:04 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;225288&lt;/p&gt;" NOTES_MODIFIED="2014-08-29 04:08:04 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moreno-Torres I, Puig-Junoy J, Raya JM</AU>
<TI>The impact of repeated cost containment policies on pharmaceutical expenditure: Experience in Spain</TI>
<SO>European Journal of Health Economics</SO>
<YR>2011</YR>
<VL>12</VL>
<PG>563-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Narine-2001" NAME="Narine 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Narine L, Senathirajah M, Smith T</AU>
<TI>An assessment of the impact of reference-based pricing policies on the H2 antagonist market in British Columbia, Canada</TI>
<SO>Journal of Research in Pharmaceutical Economics</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>1</NO>
<PG>63-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavcnik-2002" NAME="Pavcnik 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Pavcnik N</AU>
<TI>Do pharmaceutical prices respond to insurance?</TI>
<SO>Cambridge (MA): National Bureau of Economic Research; Working Paper 7865; 2000</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;0 (Drugs, Generic)&amp;#182;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pavcnik N</AU>
<TI>Do pharmaceutical prices respond to potential patient out-of-pocket expenses?</TI>
<SO>Rand Journal of Economics</SO>
<YR>2002</YR>
<VL>33</VL>
<NO>3</NO>
<PG>469-487</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3797"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Puig-2007" MODIFIED="2014-08-30 10:22:00 +0200" MODIFIED_BY="[Empty name]" NAME="Puig 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-30 10:22:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puig-Junoy J</AU>
<TI>The impact of generic reference pricing interventions in the statin market</TI>
<SO>Health Policy</SO>
<YR>2007</YR>
<VL>84</VL>
<NO>1</NO>
<PG>14&#8211;29</PG>
<PB>Elsevier</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-10-06 10:38:05 +0200" MODIFIED_BY="Angela Acosta">
<IDENTIFIER MODIFIED="2011-10-06 10:38:05 +0200" MODIFIED_BY="Angela Acosta" TYPE="DOI" VALUE="10.1016/j.healthpol.2007.02.010"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sawyer-1983" NAME="Sawyer 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sawyer DO</AU>
<TI>Pharmaceutical reimbursement and drug cost control: the MAC experience in Maryland</TI>
<SO>Inquiry</SO>
<YR>1983</YR>
<VL>20</VL>
<NO>1</NO>
<PG>76-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneeweiss-2002" MODIFIED="2014-08-29 04:24:11 +0200" MODIFIED_BY="[Empty name]" NAME="Schneeweiss 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-08-29 04:23:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneeweiss S, Maclure M, Soumerai SB</AU>
<TI>Prescription duration after drug copay changes in older people: methodological aspects</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2002</YR>
<VL>50</VL>
<NO>3</NO>
<PG>521-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-19 11:14:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM</AU>
<TI>Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2002</YR>
<VL>166</VL>
<NO>6</NO>
<PG>737-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-29 04:24:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB</AU>
<TI>Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>11</NO>
<PG>822-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneeweiss-2003" MODIFIED="2014-08-29 04:25:38 +0200" MODIFIED_BY="[Empty name]" NAME="Schneeweiss 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-29 04:25:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ</AU>
<TI>Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2003</YR>
<VL>74</VL>
<NO>4</NO>
<PG>388-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Stargardt-2010" MODIFIED="2014-08-29 04:26:22 +0200" MODIFIED_BY="[Empty name]" NAME="Stargardt 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-29 04:26:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stargardt T</AU>
<TI>The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany</TI>
<SO>European Journal of Health Economics</SO>
<YR>29 July 2010</YR>
<VL>2010</VL>
<NO>11</NO>
<PG>267&#8211;77</PG>
<EN>Springer-Verlag 2009</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-10-06 10:40:51 +0200" MODIFIED_BY="Angela Acosta">
<IDENTIFIER MODIFIED="2011-10-06 10:40:51 +0200" MODIFIED_BY="Angela Acosta" TYPE="DOI" VALUE="10.1007/s10198-009-0172-3"/>
</IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-08-30 10:32:09 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anis-1994" MODIFIED="2014-08-19 11:15:16 +0200" MODIFIED_BY="[Empty name]" NAME="Anis 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-08-19 11:15:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anis AH</AU>
<TI>Substitution laws, insurance coverage, and generic drug use</TI>
<SO>Medical Care</SO>
<YR>1994</YR>
<VL>32</VL>
<NO>3</NO>
<PG>240-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anis-2003" MODIFIED="2014-08-19 11:15:09 +0200" MODIFIED_BY="[Empty name]" NAME="Anis 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-19 11:15:09 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0 (Drugs, Generic)&lt;/p&gt;" NOTES_MODIFIED="2014-08-19 11:15:09 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anis AH, Guh DP, Woolcott J</AU>
<TI>Lowering generic drug prices: less regulation equals more competition</TI>
<SO>Medical Care</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>1</NO>
<PG>135-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3825"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atella-2000" NAME="Atella 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;10827308&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atella V</AU>
<TI>Drug cost containment policies in Italy: are they really effective in the long-run? The case of minimum reference price</TI>
<SO>Health Policy</SO>
<YR>2000</YR>
<VL>50</VL>
<NO>3</NO>
<PG>197-218</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5123"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barberato-2007" MODIFIED="2014-08-19 10:52:46 +0200" MODIFIED_BY="[Empty name]" NAME="Barberato 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-19 10:52:46 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9030&lt;/p&gt;" NOTES_MODIFIED="2014-08-19 10:52:46 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barberato FS, Lopes LC</AU>
<TI>The influence of the profit margin on the marketing of medicines. [Portuguese]</TI>
<SO>Revista de Ciencias Farmaceuticas Basica e Aplicada</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>1</NO>
<PG>99-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergman-1998" MODIFIED="2014-08-29 04:29:59 +0200" MODIFIED_BY="[Empty name]" NAME="Bergman 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-08-29 04:29:59 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;TilAndy080604&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2014-08-29 04:29:59 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergman M, Aronsson T, Rudholm N</AU>
<TI>Reduced drug costs with the reference cost system [Swedish]</TI>
<TO>Sankta lakemedelspriser med referensprissystemet</TO>
<SO>Lakartidningen</SO>
<YR>1998</YR>
<VL>95</VL>
<NO>23</NO>
<PG>2715-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17013"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergman-2003" MODIFIED="2014-08-29 04:30:17 +0200" MODIFIED_BY="[Empty name]" NAME="Bergman 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-29 04:30:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergman MA, Rudholm N</AU>
<TI>The relative importance of actual and potential competition: empirical evidence from the pharmaceuticals market</TI>
<SO>Journal of Industrial Economics</SO>
<YR>2003</YR>
<VL>51</VL>
<PG>455-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borrell-1999" NAME="Borrell 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;10537436&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borrell JR</AU>
<TI>Pharmaceutical price regulation. A study on the impact of the rate-of-return regulation in the UK</TI>
<SO>Pharmacoeconomics</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>3</NO>
<PG>291-303</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5400"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyce-1990" MODIFIED="2014-08-19 11:15:44 +0200" MODIFIED_BY="[Empty name]" NAME="Boyce 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-08-19 11:15:44 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Medicine prices in South Africa have increased significantly in recent years. Furthermore, a consideration of expenditure on medicines by medical schemes shows that this component of health care costs had grown to 26.1% in 1988, which is high by comparison with other Western economies. The use of generic medicines offers one possible solution to rising expenditure. For savings to be optimised, however, generics need to be used on a planned and structured basis. The maximum medical aid price (MMAP) system of the Pharmaceutical Society of South Africa provides such a programme. MMAP is a programme through which certain medical schemes elect to pay only a specified maximum price for off-patent products that have generic equivalents. Although MMAP does not require substitution by generic medicines, it does have the effect of encouraging their use. Two case studies measuring the savings that can be achieved through adoption of MMAP by medical schemes are reviewed. Although they differ in their respective methodologies, their results are consistent and show that savings of about 9.3% were possible in 1989. Medical schemes with higher proportions of older members tend to show greater savings. The studies also show that the potential for achieving savings through the use of MMAP increases with the passage of time Journal Article English&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2014-08-19 11:15:44 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyce D, Bartlett G</AU>
<TI>The maximum medical aid price programme. A review of the concept and of its ability to reduce expenditure on medicines</TI>
<SO>South African Medical Journal</SO>
<YR>1990</YR>
<VL>78</VL>
<PG>147-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="13952"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Danzon-1997" MODIFIED="2013-11-30 14:54:44 +0100" MODIFIED_BY="[Empty name]" NAME="Danzon 1997" YEAR="">
<REFERENCE MODIFIED="2013-11-30 14:54:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Danzon PM, Liu H</AU>
<TI>Reference pricing and physician drug budgets: The German experience in controlling pharmaceutical expenditures</TI>
<SO>Philadelphia (USA): Wharton School Working Paper; University of Philadelpha; 1997</SO>
<EN>Wharton School Working Paper; University of Philadelpha, 1997</EN>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16349"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duetz-2003" MODIFIED="2014-08-19 11:15:56 +0200" MODIFIED_BY="[Empty name]" NAME="Duetz 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-19 11:15:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duetz MS, Schneeweiss S, Maclure M, Abel T, Glynn RJ, Soumerai SB</AU>
<TI>Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia</TI>
<SO>Clinical Therapeutics</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>1</NO>
<PG>273-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ECON-2000" MODIFIED="2011-10-16 17:50:12 +0200" MODIFIED_BY="Agustín Ciapponi" NAME="ECON 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-10-16 17:50:12 +0200" MODIFIED_BY="Agustín Ciapponi" PRIMARY="NO" TYPE="OTHER">
<AU>ECON</AU>
<TI>Evaluation of the reference price system for pharmaceuticals [Norwegian]</TI>
<TO>Evaluering av referanseprissystemet for legemidler</TO>
<SO>Oslo (Norway): ECON; 2000</SO>
<VL>ECON-rapport 44/2000</VL>
<EN>ECON-rapport 44/2000; Oslo</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ekelund-2001" NAME="Ekelund 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Ekelund M</AU>
<TI>Generic entry before and after the introduction of reference prices</TI>
<SO>Competition and innovation in the Swedish pharmaceutical market</SO>
<YR>2001</YR>
<PG>Chapter 4</PG>
<ED>Ekelund M</ED>
<PB>Stockholm School of Economics</PB>
<CY>Stockholm</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16351"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giuliani-1998" NAME="Giuliani 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giuliani G, Selke G, Garattini L</AU>
<TI>The German experience in reference pricing</TI>
<SO>Health Policy</SO>
<YR>1998</YR>
<VL>44</VL>
<PG>73-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hsiao-2010" MODIFIED="2014-08-29 04:31:48 +0200" MODIFIED_BY="[Empty name]" NAME="Hsiao 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-29 04:31:48 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12000&lt;/p&gt;" NOTES_MODIFIED="2014-08-29 04:31:48 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsiao FY, Tsai YW, Huang WF</AU>
<TI>Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004</TI>
<SO>BMC Health Services Research</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>218</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inocencio-2010" MODIFIED="2014-08-30 10:32:09 +0200" MODIFIED_BY="[Empty name]" NAME="Inocencio 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-30 10:32:09 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;50817&lt;/p&gt;" NOTES_MODIFIED="2014-08-30 10:32:09 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcos I, Sanches Amorim MC, de Hoyos Guevara AJ, de Vivo B</AU>
<TI>Financial incentives for generic drugs: case study on a reimbursement program</TI>
<SO>Einstein (Säo Paulo)</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>2 Pt 1</NO>
<PG>154-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2011" MODIFIED="2014-08-19 10:53:13 +0200" MODIFIED_BY="[Empty name]" NAME="Johnson 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-19 10:53:13 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;225287&lt;/p&gt;" NOTES_MODIFIED="2014-08-19 10:53:13 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson JT, Neill KK, Davis DA</AU>
<TI>Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan</TI>
<SO>Journal of Managed Care Pharmacy</SO>
<YR>2011</YR>
<VL>17</VL>
<PG>200-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1983" NAME="Lee 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee AJ, Hefner D, Dobson A, Hardy RJ</AU>
<TI>Evaluation of the maximum allowable cost program</TI>
<SO>Health Care Financing Review</SO>
<YR>1983</YR>
<VL>4</VL>
<NO>3</NO>
<PG>71-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008" MODIFIED="2014-08-29 04:34:45 +0200" MODIFIED_BY="[Empty name]" NAME="Li 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-08-29 04:34:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li L, Chen Y, Yao L, Li Y</AU>
<TI>Evaluation of the effects of implementing the policy "Without Added Profit" to sale drug in community health service institutions of Chengdu. [Chinese]</TI>
<SO>Chinese Journal of New Drugs</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>21</NO>
<PG>1820-2,1842</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morton-1997" MODIFIED="2014-08-19 11:16:21 +0200" MODIFIED_BY="[Empty name]" NAME="Morton 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-08-19 11:16:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morton FMS</AU>
<TI>The interaction between a most-favored-customer clause and price dispersion: an empirical examination of the Medicaid rebate rules of 1990</TI>
<SO>Journal of Economics and Management Strategy</SO>
<YR>1997</YR>
<VL>6</VL>
<NO>1</NO>
<PG>151-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Narine-1997" MODIFIED="2013-11-30 14:54:57 +0100" MODIFIED_BY="[Empty name]" NAME="Narine 1997" YEAR="">
<REFERENCE MODIFIED="2013-11-30 14:54:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Narine L, Senathirajah M</AU>
<TI>Pharmaceutical cost containment policies: intended and unintended impacts</TI>
<SO>Toronto (ON): University of Toronto; 1997; Report prepared for the Pharmaceutical Manufacturers Association of Canada</SO>
<PB>Department of Health Administration, University of Toronto</PB>
<CY>Toronto</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Narine-1999" MODIFIED="2014-08-29 04:35:48 +0200" MODIFIED_BY="[Empty name]" NAME="Narine 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-08-29 04:35:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Narine L, Senathirajah M, Smith T</AU>
<TI>Evaluating reference-based pricing: initial findings and prospects</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1999</YR>
<VL>161</VL>
<NO>3</NO>
<PG>286-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rikstrygdeverket" MODIFIED="2011-10-16 18:00:27 +0200" MODIFIED_BY="Agustín Ciapponi" NAME="Rikstrygdeverket" YEAR="1999">
<REFERENCE MODIFIED="2011-10-16 18:00:27 +0200" MODIFIED_BY="Agustín Ciapponi" PRIMARY="NO" TYPE="OTHER">
<AU>Rikstrygdeverket</AU>
<TI>Economic consequences of the reference price scheme [Norwegian]</TI>
<TO>Økonomiske konsekvenser av referanseprisordningen</TO>
<SO>Oslo (Norway): Rikstrygdeverket; 1999; Rapport 4/99</SO>
<EN>4/99</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothberg-2004" MODIFIED="2014-08-29 04:36:42 +0200" MODIFIED_BY="[Empty name]" NAME="Rothberg 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-08-29 04:36:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rothberg AD, Blignault J, Serfontein CB, Valodia B, Eekhout S, Pels LM</AU>
<TI>Experience of a medicines reference-pricing model</TI>
<SO>South African Medical Journal</SO>
<YR>2004</YR>
<VL>94</VL>
<PG>183-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneeweiss-2004b" MODIFIED="2014-08-19 11:16:50 +0200" MODIFIED_BY="[Empty name]" NAME="Schneeweiss 2004b" YEAR="2004">
<REFERENCE MODIFIED="2014-08-19 11:16:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneeweiss S, Dormuth C, Grootendorst P, Soumerai S, Maclure M</AU>
<TI>Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents</TI>
<SO>Medical Care</SO>
<YR>2004</YR>
<VL>42</VL>
<NO>7</NO>
<PG>653-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steyn-2007" MODIFIED="2014-08-19 11:16:57 +0200" MODIFIED_BY="[Empty name]" NAME="Steyn 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-19 11:16:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steyn R, Burger JR, Serfontein JH, Lubbe MS</AU>
<TI>Influence of a new reference-based pricing system in South Africa on the prevalence and cost of antidiabetic medicine: a pilot study</TI>
<TO>Influence of a new reference-based pricing system in South Africa on the prevalence and cost of antidiabetic medicine: a pilot study</TO>
<SO>International Journal of Pharmacy Practice</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>4</NO>
<PG>307-11</PG>
<IDENTIFIERS MODIFIED="2012-01-05 13:13:48 +0100" MODIFIED_BY="Angela Acosta"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-1998" MODIFIED="2014-08-19 11:17:05 +0200" MODIFIED_BY="[Empty name]" NAME="Thomas 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-08-19 11:17:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas M, Mann J, Williams S</AU>
<TI>The impact of reference pricing on clinical lipid control</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1998</YR>
<VL>August</VL>
<PG>292-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tordoff-2008" MODIFIED="2014-08-29 04:38:05 +0200" MODIFIED_BY="[Empty name]" NAME="Tordoff 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-08-29 04:38:05 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;10675&lt;/p&gt;" NOTES_MODIFIED="2014-08-29 04:38:05 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tordoff JM, Norris PT, Reith DM</AU>
<TI>"Price management" and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals</TI>
<SO>Value in Health</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>7</NO>
<PG>1214-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ubeda-2007" MODIFIED="2014-08-29 04:39:46 +0200" MODIFIED_BY="[Empty name]" NAME="Ubeda 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-29 04:39:46 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9820&lt;/p&gt;" NOTES_MODIFIED="2014-08-29 04:39:46 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ubeda A, Cardo E, Selles N, Broseta R, Trillo JL, Fernandez-Llimos F</AU>
<TI>Antidepressant utilization in primary care in a Spanish region: impact of generic and reference-based pricing policy (2000-2004)</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>2007</YR>
<VL>42</VL>
<NO>3</NO>
<PG>181-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vieira-2006" MODIFIED="2014-08-29 04:41:20 +0200" MODIFIED_BY="[Empty name]" NAME="Vieira 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-08-29 04:41:20 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;8899&lt;/p&gt;" NOTES_MODIFIED="2014-08-29 04:41:20 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vieira FS, Zucchi P</AU>
<TI>[Price differences between generic and innovator medicines in Brazil]</TI>
<TO>Diferencas de precos entre medicamentos genericos e de referencia no Brasil</TO>
<SO>Revista de Saude Publica</SO>
<YR>2006</YR>
<VL>40</VL>
<NO>3</NO>
<PG>444-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-08-29 06:16:15 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2012" MODIFIED="2014-08-19 10:55:30 +0200" MODIFIED_BY="[Empty name]" NAME="Huang 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-19 10:55:30 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;225289&lt;/p&gt;" NOTES_MODIFIED="2014-08-19 10:55:30 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang SH, Hsu CN, Yu SH, Cham TM</AU>
<TI>Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan</TI>
<SO>BMC Public Health</SO>
<YR>2012</YR>
<VL>12</VL>
<PG>288</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lee-2006" MODIFIED="2014-08-29 06:16:15 +0200" MODIFIED_BY="[Empty name]" NAME="Lee 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-08-29 06:16:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee YC, Yang MC, Huang YT, Liu CH, Chen SB</AU>
<TI>Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996&#8211;2003</TI>
<SO>Pharmacoeconomics</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>9</NO>
<PG>891-902</PG>
<EN>&#63721; 2006 Adis Data Information BV. All rights reserved.</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1170-7690/06/0009-0891/$39.95/0"/>
</IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-09-23 01:23:55 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-09-23 01:23:55 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aaserud-2006a" MODIFIED="2014-08-29 06:16:51 +0200" MODIFIED_BY="[Empty name]" NAME="Aaserud 2006a" TYPE="COCHRANE_REVIEW">
<AU>Aaserud M, Austvoll-Dahlgren A, Sturm H, Kösters JP, Hill S, Furberg CD, et al</AU>
<TI>Pharmaceutical policies: effects on rational drug use (Protocol)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<PB>John Wiley and Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2008-11-07 17:13:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-07 17:13:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004397.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Austvoll_x002d_Dahlgren-2008" MODIFIED="2014-08-29 06:17:12 +0200" MODIFIED_BY="[Empty name]" NAME="Austvoll-Dahlgren 2008" TYPE="COCHRANE_REVIEW">
<AU>Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, et al</AU>
<TI>Pharmaceutical policies: effects of cap and co-payment on rational drug use</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<PG>CD007017</PG>
<IDENTIFIERS MODIFIED="2013-12-01 00:03:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-01 00:03:02 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="005979"/>
<IDENTIFIER MODIFIED="2013-12-01 00:01:56 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005979"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2014-08-29 06:17:56 +0200" MODIFIED_BY="[Empty name]" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ciapponi-2011" MODIFIED="2014-08-29 06:18:52 +0200" MODIFIED_BY="[Empty name]" NAME="Ciapponi 2011" TYPE="CONFERENCE_PROC">
<AU>Ciapponi A, Glujovsky D, Bardach A, García Martí S, Comande D</AU>
<TI>EROS: a new software for early stage of systematic reviews</TI>
<SO>ISPOR 3rd Latin America Conference</SO>
<YR>2011</YR>
<CY>Hilton Mexico City Reforma in Mexico City, Mexico</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Danzon-2008" MODIFIED="2014-08-29 06:19:48 +0200" MODIFIED_BY="[Empty name]" NAME="Danzon 2008" TYPE="JOURNAL_ARTICLE">
<AU>Danzon PM, Furukawa MF</AU>
<TI>International prices and availability of pharmaceuticals in 2005</TI>
<SO>Health Affairs (Millwood)</SO>
<YR>2008</YR>
<VL>1</VL>
<NO>1</NO>
<PG>221-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickson-1998" MODIFIED="2014-08-19 11:20:21 +0200" MODIFIED_BY="[Empty name]" NAME="Dickson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Dickson M, Redwood H</AU>
<TI>Pharmaceutical reference prices. How do they work in practice?</TI>
<SO>Pharmacoeconomics</SO>
<YR>1998</YR>
<VL>14(5)</VL>
<PG>471-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EPOC-2013a" MODIFIED="2014-08-29 06:20:28 +0200" MODIFIED_BY="[Empty name]" NAME="EPOC 2013a" TYPE="OTHER">
<AU>Effective Practice and Organisation of Care (EPOC)</AU>
<TI>Suggested risk of bias criteria for EPOC reviews</TI>
<SO>EPOC resources for review authors. Available at: http://epocoslo.cochrane.org/epoc-specific-resources-review-authors</SO>
<YR>2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EPOC-2013b" MODIFIED="2014-08-29 06:20:49 +0200" MODIFIED_BY="[Empty name]" NAME="EPOC 2013b" TYPE="OTHER">
<AU>Effective Practice and Organisation of Care (EPOC)</AU>
<TI>Interrupted time series (ITS) analyses</TI>
<SO>EPOC resources for review authors. Available at: http://epocoslo.cochrane.org/epoc-specific-resources-review-authors</SO>
<YR>2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EPOC-2013c" MODIFIED="2013-12-31 16:57:29 +0100" MODIFIED_BY="[Empty name]" NAME="EPOC 2013c" TYPE="OTHER">
<AU>Effective Practice and Organisation of Care (EPOC)</AU>
<TI>Synthesising results when it does not make sense to do a meta-analysis</TI>
<SO>EPOC Resources for review authors. Available at: http://epocoslo.cochrane.org/epoc-specific-resources-review-authors</SO>
<YR>2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EPOC-2013d" MODIFIED="2013-12-31 16:47:07 +0100" MODIFIED_BY="[Empty name]" NAME="EPOC 2013d" TYPE="OTHER">
<AU>Effective Practice and Organisation of Care (EPOC)</AU>
<TI>EPOC Worksheets for preparing a Summary of Findings (SoF) table using GRADE</TI>
<SO>EPOC Resources for review authors. Available at: http://epocoslo.cochrane.org/epoc-specific-resources-review-authors</SO>
<YR>2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Espin-2007" MODIFIED="2014-08-19 11:04:41 +0200" MODIFIED_BY="[Empty name]" NAME="Espin 2007" TYPE="OTHER">
<AU>Espin J, Rovira R</AU>
<TI>Analysis of differences and commonalities in pricing and reimbursement systems in Europe</TI>
<SO>European Commission</SO>
<YR>2007</YR>
<VL>http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/study_pricing_2007/andalusian_school_public_health_report_pricing_2007_en.pdf</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Espin-2011" MODIFIED="2014-08-30 10:36:25 +0200" MODIFIED_BY="[Empty name]" NAME="Espin 2011" TYPE="OTHER">
<AU>Espin J, Rovira J, Olry de Labry A</AU>
<TI>Review Series on Pharmaceutical Pricing Policies and Interventions Working Paper 1: External Reference Pricing</TI>
<SO>Review Series on Pharmaceutical Pricing Policies and Interventions. WHO/HAI Project on Medicine Prices and Availability</SO>
<YR>May 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Faden-2011" MODIFIED="2014-08-29 06:21:52 +0200" MODIFIED_BY="[Empty name]" NAME="Faden 2011" TYPE="JOURNAL_ARTICLE">
<AU>Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A</AU>
<TI>Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence</TI>
<SO>Health Policy (Amsterdam, Netherlands)</SO>
<YR>2011</YR>
<VL>100</VL>
<NO>2-3</NO>
<PG>134-43</PG>
<IDENTIFIERS MODIFIED="2013-12-01 17:03:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21185616"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Festoy-2008" MODIFIED="2014-09-18 16:07:14 +0200" MODIFIED_BY="[Empty name]" NAME="Festoy 2008" TYPE="OTHER">
<AU>Festöy H, Sveen K, Yu LM, Gjönnes L, Gregersen T</AU>
<TI>Pharmaceutical pricing and reimbursement information</TI>
<SO>Norwegian Medicines Agency</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galizzi-2011" MODIFIED="2014-08-19 11:06:13 +0200" MODIFIED_BY="[Empty name]" NAME="Galizzi 2011" TYPE="JOURNAL_ARTICLE">
<AU>Galizzi MM, Ghislandi S, Miraldo M</AU>
<TI>Effects of reference pricing in pharmaceutical markets: a review</TI>
<SO>PharmacoEconomics</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>1</NO>
<PG>17-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glujovsky-2010" MODIFIED="2014-08-29 06:25:19 +0200" MODIFIED_BY="[Empty name]" NAME="Glujovsky 2010" TYPE="CONFERENCE_PROC">
<AU>Glujovsky D, Bardach A, García Martí S, Comande D, Ciapponi A</AU>
<TI>New software for early stage of systematic reviews</TI>
<SO>XVIII Cochrane Colloquium. The Joint Colloquium of the Cochrane and Campbell Collaborations</SO>
<YR>2010</YR>
<CY>Keystone Resort, Colorado, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2008" MODIFIED="2014-08-29 06:26:29 +0200" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2008" TYPE="COMPUTER_PROGRAM">
<AU>Brozek J, Oxman A, Schünemann H</AU>
<TI>GRADEpro. [Computer program]. Version 3.2 for Windows</TI>
<YR>2008</YR>
<PB>the GRADE Working Group</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Green-2010" MODIFIED="2014-08-29 06:27:09 +0200" MODIFIED_BY="[Empty name]" NAME="Green 2010" TYPE="COCHRANE_REVIEW">
<AU>Green CJ, Maclure M, Fortin PM, Ramsay CR, Aaserud M, Bardal S</AU>
<TI>Pharmaceutical policies: effects of restrictions on reimbursement.</TI>
<TO>Pharmaceutical policies: effects of restrictions on reimbursement.</TO>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2013-12-01 00:13:27 +0100" MODIFIED_BY="Angela Acosta">
<IDENTIFIER MODIFIED="2011-10-25 10:52:12 +0200" MODIFIED_BY="Angela Acosta" TYPE="CENTRAL" VALUE="008654"/>
<IDENTIFIER MODIFIED="2013-12-01 00:13:27 +0100" MODIFIED_BY="Angela Acosta" TYPE="DOI" VALUE="10.1002/14651858.CD008654"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-08-19 11:06:24 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</SO>
<YR>2011</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannides_x002d_Demos-2002" MODIFIED="2014-08-29 06:29:49 +0200" MODIFIED_BY="[Empty name]" NAME="Ioannides-Demos 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ioannides-Demos LL, Ibrahim JE, McNeil JJ</AU>
<TI>Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes</TI>
<SO>PharmacoEconomics</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>9</NO>
<PG>577-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McLaughin-1997" MODIFIED="2014-08-29 06:32:23 +0200" MODIFIED_BY="[Empty name]" NAME="McLaughin 1997" TYPE="JOURNAL_ARTICLE">
<AU>McLaughin P</AU>
<TI>Reference-based pricing of prescription drugs</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>1997</YR>
<VL>13</VL>
<NO>1</NO>
<PG>31-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mossialos-2004" MODIFIED="2014-08-29 06:32:57 +0200" MODIFIED_BY="[Empty name]" NAME="Mossialos 2004" TYPE="BOOK">
<AU>Mossialos E, Mrazek M, Walley T</AU>
<SO>Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality</SO>
<YR>2004</YR>
<EN>First Edition</EN>
<PB>Open University Press, McGraw-Hill Education</PB>
<CY>Great Britain</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mo_x00ef_se-2008" MODIFIED="2014-09-18 16:12:30 +0200" MODIFIED_BY="[Empty name]" NAME="Moïse 2008" TYPE="JOURNAL_ARTICLE">
<AU>Moïse P, Docteur E</AU>
<TI>Pharmaceuticals pricing and reimbursement policies in Mexico, OECD, 2007</TI>
<TO>Las políticas de precios y reembolsos farmacéuticos en México, OCDE, 2007</TO>
<SO>OECD Health Working Papers</SO>
<YR>2008</YR>
<VL>No. 29</VL>
<PG>s504-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norwegian-Pharmacy-Association-2008" MODIFIED="2014-08-29 06:34:13 +0200" MODIFIED_BY="[Empty name]" NAME="Norwegian Pharmacy Association 2008" TYPE="OTHER">
<AU>The Norwegian Pharmacy Association</AU>
<TI>The medicines market in Norway - prices and regulations</TI>
<SO>www.apotek.no</SO>
<YR>August 2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-OECD-2008" MODIFIED="2011-10-15 19:35:07 +0200" MODIFIED_BY="Agustín Ciapponi" NAME="OECD 2008" TYPE="OTHER">
<TI>OECD Health Data 2008</TI>
<TO>Pharmaceutical Pricing Policies in a Global Market</TO>
<SO>Organisation for Economic Co-operation and Development</SO>
<YR>2008</YR>
<PB>ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pharmanet-2003" NAME="Pharmanet 2003" TYPE="OTHER">
<AU>British Columbia Medical Association</AU>
<TI>Physician access to Pharmanet</TI>
<SO>http://www.bcma.org/public/news_publications/publications/policy_backgrounders/PhysicianAccessPharmaNet.asp</SO>
<YR>(accessed 18 January 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pharmanet-2005" NAME="Pharmanet 2005" TYPE="OTHER">
<AU>Ministry of Health in British Columbia</AU>
<TI>Pharmanet</TI>
<SO>http://www.healthservices.gov.bc.ca/pharme/pharmanet/netindex.html</SO>
<YR>(accessed 18 January 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PHIS-2011" MODIFIED="2013-12-11 13:07:23 +0100" MODIFIED_BY="[Empty name]" NAME="PHIS 2011" TYPE="OTHER">
<AU>AIFA, Gesundheit Österreich GmbH</AU>
<TI>PHIS Glossary</TI>
<TO>Pharmaceutical Health Information System Glossary</TO>
<SO>http://whocc.goeg.at/Literaturliste/Dokumente/MethodologyTemplate/PHIS%20Glossary_UpdatedApril2011.pdf</SO>
<YR>2011</YR>
<PG>16, 25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PPRS-2009" MODIFIED="2014-08-29 06:35:41 +0200" MODIFIED_BY="[Empty name]" NAME="PPRS 2009" TYPE="OTHER">
<TI>Pharmaceutical Price Regulation Scheme, Tenth report Dec 2009</TI>
<SO>available at www.dh.gov.uk/publications [Accessed on 17th Oct 2011]</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Productivity-2001" NAME="Productivity 2001" TYPE="OTHER">
<AU>Productivity Commission 2001</AU>
<TI>International pharmaceutical price differences</TI>
<SO>Canberra (AU): Research report, Ausinfo</SO>
<CY>Canberra</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puig_x002d_Junoy-2007" MODIFIED="2014-08-29 06:37:08 +0200" MODIFIED_BY="[Empty name]" NAME="Puig-Junoy 2007" TYPE="JOURNAL_ARTICLE">
<AU>Puig-Junoy J, Moreno-Torres I</AU>
<TI>Impact of pharmaceutical prior authorisation policies: a systematic review of the literature</TI>
<SO>PharmacoEconomics</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>8</NO>
<PG>637-48</PG>
<IDENTIFIERS MODIFIED="2013-12-01 17:03:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17640106"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Puig_x002d_Junoy-2010" MODIFIED="2014-08-29 06:37:35 +0200" MODIFIED_BY="[Empty name]" NAME="Puig-Junoy 2010" TYPE="JOURNAL_ARTICLE">
<AU>Puig-Junoy J</AU>
<TI>Impact of European pharmaceutical price regulation on generic price competition: a review</TI>
<SO>PharmacoEconomics</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>8</NO>
<PG>649-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puig_x002d_Junoy-2010a" MODIFIED="2014-09-18 16:13:27 +0200" MODIFIED_BY="[Empty name]" NAME="Puig-Junoy 2010a" TYPE="JOURNAL_ARTICLE">
<AU>Puig-Junoy J</AU>
<TI>Policies encouraging price competition in the generic drug market: Lessons from the European experience</TI>
<TO>Polí&#769;ticas de fomento de la competencia en precios en el mercado de genéricos: lecciones de la experiencia europea</TO>
<SO>Gaceta Sanitaria</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>3</NO>
<PG>193-9</PG>
<IDENTIFIERS MODIFIED="2011-10-16 19:24:19 +0200" MODIFIED_BY="Agustín Ciapponi">
<IDENTIFIER TYPE="MEDLINE" VALUE="1343"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ramsay-2003" MODIFIED="2014-08-29 06:41:07 +0200" MODIFIED_BY="[Empty name]" NAME="Ramsay 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE</AU>
<TI>Interrupted time series design in health technology assessment: Lessons from two systematic reviews of behavior change strategies</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>612-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-10-16 10:41:28 +0200" MODIFIED_BY="Agustín Ciapponi" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sturm-2007" MODIFIED="2014-08-29 06:42:20 +0200" MODIFIED_BY="[Empty name]" NAME="Sturm 2007" TYPE="COCHRANE_REVIEW">
<AU>Sturm H, Austvoll-Dahlgren A, Aaserud M, Oxman AD, Ramsay C, Vernby A, Kösters JP</AU>
<TI>Pharmaceutical policies: effects of financial incentives for prescribers.</TI>
<TO>Pharmaceutical policies: effects of financial incentives for prescribers.</TO>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-11-30 23:59:58 +0100" MODIFIED_BY="Angela Acosta">
<IDENTIFIER MODIFIED="2013-11-30 23:57:45 +0100" MODIFIED_BY="Angela Acosta" TYPE="CENTRAL" VALUE="006731"/>
<IDENTIFIER MODIFIED="2013-11-30 23:59:58 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006731"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vacca-2011" MODIFIED="2014-08-29 06:43:03 +0200" MODIFIED_BY="[Empty name]" NAME="Vacca 2011" TYPE="JOURNAL_ARTICLE">
<AU>Vacca C, Acosta A, Rodriguez I</AU>
<TI>International reference prices and cost minimization analysis for pricing regulation in Colombia</TI>
<TO>Precios de Referencia Internacional y Análisis de Costo Minimización para la Regulación de Precios de Medicamentos en Colombia</TO>
<SO>Value in Health</SO>
<YR>July 2011</YR>
<VL>14</VL>
<NO>5</NO>
<PG>S16-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vogler-2008" MODIFIED="2014-08-29 06:43:28 +0200" MODIFIED_BY="[Empty name]" NAME="Vogler 2008" TYPE="OTHER">
<AU>Vogler S, Habl C, Leopold C, Rosian-Schikuta I, Joncheere K, Thomsen T, et al</AU>
<TI>The Pharmaceutical Pricing and Reimbursement Information project Report</TI>
<TO>PPRI Report</TO>
<SO>European Commission, Directorate-General Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth</SO>
<YR>June, 2008</YR>
<PG>XVI-XVIII</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2011" MODIFIED="2011-10-15 19:35:28 +0200" MODIFIED_BY="Agustín Ciapponi" NAME="WHO 2011" TYPE="OTHER">
<TI>The World Medicines Situation</TI>
<SO>WHO</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zammit_x002d_Lucia-1995" NAME="Zammit-Lucia 1995" TYPE="OTHER">
<AU>Zammit-Lucia J, Dasgupta R</AU>
<TI>Reference pricing: the European experience</TI>
<SO>Health Policy Review</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>1-31</PG>
<EN>10</EN>
<ED>Bosanquet N, Jarman B</ED>
<PB>St. Mary's Hospital Medical School</PB>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-12-30 12:04:19 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aaserud-2006b" MODIFIED="2013-12-30 12:04:19 +0100" MODIFIED_BY="[Empty name]" NAME="Aaserud 2006b" TYPE="COCHRANE_REVIEW">
<AU>Aaserud M, Austvoll-Dahlgren A, Kösters JP, Oxman AD, Ramsay C, Sturm H</AU>
<TI>Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-12-30 12:04:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-30 12:04:19 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005979"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-09-22 12:34:57 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-09-22 12:34:57 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Aronsson-2001">
<CHAR_METHODS>
<P>ITS<BR/>Some limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Sweden, national, public insurance</P>
<P>Physicians: No information provided</P>
<P>Patients: No information provided</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Reference pricing on 12 brand drugs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Drug prices</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Research grant from Swedish Competition Agency</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:37:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brekke-2003">
<CHAR_METHODS>
<P>ITS<BR/>Some limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Norway, national public drug insurance</P>
<P>Physicians: No information provided</P>
<P>Patients: No information provided</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Index pricing on six groups of active substances</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Drug use<BR/>Drug prices</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-18 15:37:12 +0200" MODIFIED_BY="[Empty name]">
<P>Commisioned by the Norwegian Pharmacist Association</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:37:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brekke-2011">
<CHAR_METHODS MODIFIED="2013-12-01 00:04:37 +0100" MODIFIED_BY="[Empty name]">
<P>ITS</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-29 10:36:45 +0200" MODIFIED_BY="[Empty name]">
<P>Setting: Norway, national public drug insurance</P>
<P>Physicians: No information provided</P>
<P>Patients: No information provided</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-18 15:37:25 +0200" MODIFIED_BY="[Empty name]">
<P>The reference pricing system, called 'index pricing', was introduced in March 2003 for a subsample of off-patent pharmaceuticals facing generic competition. Initially, the index price system covered six chemical substances: citalopram (depression), omeprazol (anti ulcer), cetirizin (allergy), loratadin (allergy), enalapril (high blood pressure) and lisinopril (high blood pressure). The system was later extended with two additional substances; simvastatin (high cholesterol) and amlodipine (high blood pressure)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-01 00:04:37 +0100" MODIFIED_BY="[Empty name]">
<P>Drug prices</P>
<P>Drug expenditures</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-01 00:04:37 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:37:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grootendorst-2002">
<CHAR_METHODS>
<P>ITS for drug expenditures<BR/>No serious limitations</P>
<P>CBA for health outcome<BR/>Limitations</P>
<P>CRM for Healthcare utilisation<BR/>Limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-18 15:37:27 +0200" MODIFIED_BY="[Empty name]">
<P>Setting: British Columbia, Canada, Ministry of Health's drug subsidy program Pharmacare</P>
<P>Physicians: No information provided</P>
<P>Patients: Senior citizens (65 yr and older)<BR/>ITS:<BR/>No information provided about number of patients<BR/>CBA and CRM:<BR/>Nitrates users: 11,155 patients in exposed group, 1760 in non-exposed group<BR/>ACE inhibitors users: 28,564 patients in exposed group, 7320 in non-exposed group<BR/>CCB users: 14,342 patients in exposed group, 20,086 in non-exposed group</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Reference pricing on nitrates, ACE inhibitors and CCBs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-14 20:22:49 +0100" MODIFIED_BY="[Empty name]">
<P>Health<BR/>Healthcare utilisation<BR/>Drug expenditures</P>
<P>Drug use<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Finanial support from the Health Transition Fund, Health Canada; Seed Grant award from the Father Sean O'Sullivan Research Centre, St. Joseph's Hospital; the Canadian Health Services Research Foundation; Brogan Inc.; the BC Ministry of Health; and the Drug Information Association</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:37:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grootendorst-2005">
<CHAR_METHODS MODIFIED="2013-11-14 17:51:00 +0100" MODIFIED_BY="[Empty name]">
<P>ITS</P>
<P>No serious limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-14 17:51:00 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: Ontario and British Columbia, Canada, Ministry of Health's drug subsidy program Pharmacare</P>
<P>Physicians: No information provided</P>
<P>Patients: Eligible senior beneficiary of the public drug plan operating in Ontario and senior citizens (65 yr and older) in British Columbia<BR/>ITS:<BR/>No information provided about number of patients<BR/>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-14 18:01:01 +0100" MODIFIED_BY="[Empty name]">
<P>Two types of reference pricing to nonsteroidal antiinflammatory drugs (NSAIDs) over the period February 1993<BR/>to June 2001.</P>
<P>Type 1: generic and brand versions of the same NSAID are considered interchangeable (in April 1994) </P>
<P>Type 2: different NSAIDs are considered interchangeable (in November 1995)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-14 18:28:01 +0100" MODIFIED_BY="[Empty name]">
<P>Drug Expenditure, Drug use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-18 15:37:28 +0200" MODIFIED_BY="[Empty name]">
<P>Results were reanalysed by reviewers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:37:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grootendorst-2006">
<CHAR_METHODS MODIFIED="2011-08-25 05:27:05 +0200" MODIFIED_BY="Angela Acosta">
<P>ITS</P>
<P>No serious limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-25 07:18:25 +0200" MODIFIED_BY="Angela Acosta">
<P>Setting: Ontario and British Columbia, Canada, Ministry of Health's drug subsidy program Pharmacare</P>
<P>Physicians: No information provided</P>
<P>Patients: Eligible senior beneficiary of the public drug plan operating in Ontario and senior citizens (65 yr and older) in British Columbia<BR/>ITS:<BR/>No information provided about number of patients<BR/>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-14 16:43:58 +0100" MODIFIED_BY="Angela Acosta">
<P>Reference pricing for reimbursement on ACE inhibitors and CCBs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-18 15:37:30 +0200" MODIFIED_BY="[Empty name]">
<P>Drug expenditure, drug use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-18 15:37:31 +0200" MODIFIED_BY="[Empty name]">
<P>Results were reanalysed by reviewers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:37:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hazlet-2002">
<CHAR_METHODS MODIFIED="2011-09-06 18:42:12 +0200" MODIFIED_BY="Angela Acosta">
<P>RM for drug use<BR/>Serious limitations</P>
<P>CRM for health and healthcare utilisation</P>
<P>Control part of the CRM<BR/>No serious limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-18 15:37:35 +0200" MODIFIED_BY="[Empty name]">
<P>Setting: British Columbia, Canada, Ministry of Health's drug subsidy program Pharmacare</P>
<P>Physicians: No information provided</P>
<P>Patients: Senior citizens (65 yr and older), random sample of 10,000 in intervention and 10,000 in control group</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Reference pricing on H2RAs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Drug use<BR/>Health<BR/>Healthcare utilisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Supported by the Research Royalty Fund, University of Washington and by Pharmacare, Ministry of Health (British Columbia)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-22 12:34:53 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kibicho-2012">
<CHAR_METHODS MODIFIED="2013-12-01 00:05:11 +0100" MODIFIED_BY="[Empty name]">
<P>ITS</P>
<P>Some limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-22 12:34:53 +0200" MODIFIED_BY="[Empty name]">
<P>Setting: Michigan State specific Medicaid Program (US)</P>
<P>Physicians: No information provided</P>
<P>Patients: Beneficiaries older than age sixty-five made up 20% of the Michigan Medicaid dual-eligible population</P>
<P>Prescriptions: Claims data for non-institutionalised dual eligibles age 65 yr and older covering fiscal years 2000&#8211;04 were drawn from Michigan&#8217;s Medicaid out-patient prescription drug fee-for-service program database</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-18 15:37:42 +0200" MODIFIED_BY="[Empty name]">
<P>The maximum allowable cost is a ceiling price set for generic and multisource brands that are chemically equivalent and have the same active ingredients (generic substitutes). Maximum allowable cost is similar to reference pricing used in Canada, which extends the concept of drug interchangeability to include chemically related active ingredients that are pharmacologically equivalent (therapeutic substitutes)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-01 00:05:11 +0100" MODIFIED_BY="[Empty name]">
<P>Drug prices</P>
<P>Drug expenditures</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-01 00:05:11 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:38:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marshall-2002">
<CHAR_METHODS>
<P>ITS<BR/>No serious limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: British Columbia, Canada, Ministry of Health's drug subsidy program Pharmacare</P>
<P>Physicians: No information provided</P>
<P>Patients: Senior citizens (65 yr and older)</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Reference pricing on H2RAs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-18 15:38:09 +0200" MODIFIED_BY="[Empty name]">
<P>Drug expenditure<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Financial support from the Health Transitions Fund of Health Canada</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:38:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McManus-2001">
<CHAR_METHODS>
<P>ITS<BR/>Limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Australia, Pharmaceutical Benefits Scheme <BR/>Physicians: No information provided</P>
<P>Patients: No information provided</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-18 15:38:12 +0200" MODIFIED_BY="[Empty name]">
<P>Reference pricing (minimum pricing policy) on ranitidine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Drug use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-18 15:38:13 +0200" MODIFIED_BY="[Empty name]">
<P>Financial support not stated. The author was employed at the government Department of Health and Aged Care in Australia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:38:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<CHAR_METHODS MODIFIED="2013-12-01 00:04:55 +0100" MODIFIED_BY="[Empty name]">
<P>ITS</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-01 00:04:55 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: Spain, national health system</P>
<P>Physicians: No information provided</P>
<P>Patients: No information provided</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-18 15:38:15 +0200" MODIFIED_BY="[Empty name]">
<P>A system of 'generic' reference pricing was introduced in December 2000 and remained in operation, with adjustments but without major changes, until December 2003. This system was applied to products with the same active ingredient, pharmaceutical form, dosage and number of units for which there was at least one generic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-01 00:04:55 +0100" MODIFIED_BY="[Empty name]">
<P>Drug prices</P>
<P>Drug expenditures</P>
<P>Drug use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-01 00:04:56 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:38:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Narine-2001">
<CHAR_METHODS MODIFIED="2014-09-18 15:38:18 +0200" MODIFIED_BY="[Empty name]">
<P>ITS<BR/>Serious limitations for outcome 'reference drug use'<BR/>Limitations for outcome 'cost share drug use'<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: British Columbia, Canada. Ministry of Health's drug subsidy program Pharmacare</P>
<P>Physicians: No information provided</P>
<P>Patients: No information provided</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Reference pricing on H2RAs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Drug use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-18 15:38:20 +0200" MODIFIED_BY="[Empty name]">
<P>Supported in part by an unrestricted research grant from Canada's Research-Based Pharmaceutical Companies</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pavcnik-2002">
<CHAR_METHODS>
<P>ITS<BR/>No serious limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: Germany, statutory health insurance</P>
<P>Physicians: No information provided</P>
<P>Patients: No information provided</P>
<P>Prescriptions: Retail pharmacy sales from IMS Health database<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Reference pricing on oral antidiabetics and antiulcerants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Drug prices</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Support from MacArthur Foundation Grant and the Centre for International Studies at Princeton University, USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:38:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Puig-2007">
<CHAR_METHODS MODIFIED="2011-10-06 22:44:35 +0200" MODIFIED_BY="Angela Acosta">
<P>ITS<BR/>Some limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 16:04:40 +0200" MODIFIED_BY="Angela Acosta">
<P>Setting: Andalucía, Spain</P>
<P>Physicians: No information provided</P>
<P>Patients: No information provided</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-31 16:47:36 +0100" MODIFIED_BY="Angela Acosta">
<P>Reference pricing and maximum consumer prices as a reimbursement policies for statins</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-24 16:08:10 +0200" MODIFIED_BY="Angela Acosta">
<P>Volume of sales</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-18 15:38:24 +0200" MODIFIED_BY="[Empty name]">
<P>Drug use data: Number of prescriptions dispensed per person for each of the six active ingredients in the therapeutic group of statins. Volume are measured as monthly sales and quantity ratios between the per capita value in each period and the per capita value of the initial period</P>
<P>Average cost per defined daily dose (DDD) for originator brand-name and lowest-priced generic statins dispensed in Spain</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:38:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sawyer-1983">
<CHAR_METHODS>
<P>ITS<BR/>Limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-18 15:38:28 +0200" MODIFIED_BY="[Empty name]">
<P>Setting: USA, Maryland State, Medicaid</P>
<P>Physicians: No information provided</P>
<P>Patients: No information provided</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-18 15:38:30 +0200" MODIFIED_BY="[Empty name]">
<P>Reference pricing (maximum allowable costs (MAC)) on 52 dosage forms of 25 multisource chemical entities</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Drug expenditures</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-18 15:38:30 +0200" MODIFIED_BY="[Empty name]">
<P>No sponsor. The study was carried out in the private capacity of the author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:38:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schneeweiss-2002">
<CHAR_METHODS MODIFIED="2014-09-18 15:38:33 +0200" MODIFIED_BY="[Empty name]">
<P>RM for drug expenditure and use<BR/>No serious limitations</P>
<P>CBA for healthcare utilisation<BR/>No serious limitations<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-16 20:03:14 +0200" MODIFIED_BY="Agustín Ciapponi">
<P>Setting: British Columbia, Canada, Ministry of Health's drug subsidy program Pharmacare</P>
<P>Physicians: No information provided</P>
<P>Patients: Senior citizens (65 yr and older), non-institutionalised, 119074 in study group</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Reference pricing on ACE inhibitors</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-18 15:38:33 +0200" MODIFIED_BY="[Empty name]">
<P>Drug use<BR/>Drug expenditures<BR/>Healthcare utilisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Supported by grants from the US Agency for Healthcare Research and Quality; the Drug Information Association (Fort Washington, Pa); Pharmacare, Ministry of Health (British Columbia); the Harvard Pilgrim Health Care Foundation; Deutsche Forschungsgemeinschaft; the Pharmacoepidemiology Teaching and Research Fund and the Takemi Associate Award of the Harvard School of Public Health</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:38:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schneeweiss-2003">
<CHAR_METHODS MODIFIED="2014-09-18 15:38:43 +0200" MODIFIED_BY="[Empty name]">
<P>RM for drug use and drug expenditures<BR/>No serious limitations</P>
<P>CBA for health and healthcare utilisation<BR/>Limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: British Columbia, Canada, Ministry of Health's drug subsidy program Pharmacare</P>
<P>Physicians: No information provided</P>
<P>Patients: Senior citizens (65 yr and older)<BR/>RM: 35886 CCB users<BR/>CBA: 1923 switchers, 15557 non-switchers </P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Reference pricing on CCBs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Drug use<BR/>Health outcomes<BR/>Healthcare utilisation<BR/>Drug expenditures<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-30 04:35:53 +0200" MODIFIED_BY="[Empty name]">
<P>Supported by grants from the US Agency for Healthcare Research and Quality; the Drug Information Association (Fort Washington, Pa); Pharmacare, Ministry of Health (British Columbia); the Harvard Pilgrim Health Care Foundation; Deutsche Forschungsgemeinschaft; the Pharmacoepidemiology Teaching and Research Fund and the Takemi Associate Award of the Harvard School of Public Health</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-18 15:38:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stargardt-2010">
<CHAR_METHODS MODIFIED="2011-10-05 20:03:05 +0200" MODIFIED_BY="Angela Acosta">
<P>ITS</P>
<P>No serious limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-18 15:38:45 +0200" MODIFIED_BY="[Empty name]">
<P>Setting: Germany</P>
<P>Physicians: No information provided</P>
<P>Patients: 237,762 patients prescribed statins in 2004; 42,021 patients treated with atorvastatin during the baseline period<BR/>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-24 16:14:28 +0200" MODIFIED_BY="Angela Acosta">
<P>Therapeutic reference pricing</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-11 16:30:38 +0100" MODIFIED_BY="Angela Acosta">
<P>
<BR/>Drug use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-18 15:38:45 +0200" MODIFIED_BY="[Empty name]">
<P>Results were reanalysed by reviewers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-09-18 15:38:51 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Anis-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only intermediate outcomes (market shares and prescription shares)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anis-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only intermediate outcomes (price ratios)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Atella-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Simulation model study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 15:38:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barberato-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 15:38:46 +0200" MODIFIED_BY="[Empty name]">
<P>Not met design inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bergman-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only intermediate outcomes (market shares and price ratios)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 15:38:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bergman-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 15:38:48 +0200" MODIFIED_BY="[Empty name]">
<P>The model considers a dummy variable taking the value one after the introduction of the Swedish reference price system</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 15:38:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borrell-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 15:38:48 +0200" MODIFIED_BY="[Empty name]">
<P>Time series study, but not with interrupted time series (ITS)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boyce-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Too few data points to be an ITS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-30 14:58:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Danzon-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-30 14:58:19 +0100" MODIFIED_BY="[Empty name]">
<P>This study could not be retrieved</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duetz-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Before and after study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-15 20:14:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ECON-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-15 20:14:33 +0100" MODIFIED_BY="[Empty name]">
<P>Survey without control group for assessing administration costs<BR/>Not scannable figures for prices<BR/>Do not take care of any historical trends in total reference group drug use, thus appropriate ITS study<BR/>Assume total drug use not affected by RP<BR/>Historical trends in composition of drug use not taken care of</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ekelund-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only intermediate outcome (generic entry)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giuliani-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Too few data points (post) to be an ITS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 15:38:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hsiao-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 15:38:49 +0200" MODIFIED_BY="[Empty name]">
<P>Less than three points before and after the intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 15:38:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inocencio-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 15:38:49 +0200" MODIFIED_BY="[Empty name]">
<P>Preintervention period was not assessed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-05 00:44:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-05 00:44:33 +0100" MODIFIED_BY="[Empty name]">
<P>Too few data points (pre) with two months of transition period as an ITS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Too few data points (post) to be an ITS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-30 15:26:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-30 15:26:31 +0100" MODIFIED_BY="[Empty name]">
<P>This study could not be retrieved</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 15:38:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morton-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 15:38:50 +0200" MODIFIED_BY="[Empty name]">
<P>Outcome outside inclusion criteria: Price dispersion<BR/>Cross-sectional study of impact on prices</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-30 14:58:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Narine-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-30 14:58:19 +0100" MODIFIED_BY="[Empty name]">
<P>This study could not be retrieved</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Narine-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Before and after study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rikstrygdeverket">
<CHAR_REASON_FOR_EXCLUSION>
<P>Do not use relevant historical data<BR/>Do not take care of any historical trends in total reference group drug use, thus not appropriate ITS study<BR/>Assume total drug use not affected by RP<BR/>Historical trends in composition of drug use not taken care of</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 15:38:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rothberg-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 15:38:50 +0200" MODIFIED_BY="[Empty name]">
<P>Too few data points, no clear point of intervention to be an ITS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schneeweiss-2004b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Time series data for drug use, but only post data for administration costs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-30 15:27:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steyn-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-30 15:27:05 +0100" MODIFIED_BY="[Empty name]">
<P>No information about primary data and no protection against secular changes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thomas-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Before and after study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 15:38:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tordoff-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 15:38:50 +0200" MODIFIED_BY="[Empty name]">
<P>Less than three points before the intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 15:38:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ubeda-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 15:38:50 +0200" MODIFIED_BY="[Empty name]">
<P>Time series. Unclear time point of the intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 15:38:51 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vieira-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 15:38:51 +0200" MODIFIED_BY="[Empty name]">
<P>Preintervention period was not assessed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-09-18 15:38:54 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-09-18 15:38:51 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2012">
<CHAR_METHODS MODIFIED="2013-11-30 12:49:15 +0100" MODIFIED_BY="[Empty name]">
<P>ITS</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-18 15:38:51 +0200" MODIFIED_BY="[Empty name]">
<P>Setting: Taiwan, National Health Insurance system. Pharmaceutical Benefit Scheme</P>
<P>Physicians: No information provided</P>
<P>Patients: No information provided</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-30 12:49:15 +0100" MODIFIED_BY="[Empty name]">
<P>Price adjustments</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-30 12:49:15 +0100" MODIFIED_BY="[Empty name]">
<P>Drug use, drug expenditures</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-18 15:38:51 +0200" MODIFIED_BY="[Empty name]">
<P>Authors were requested for more information about size and effect of outcomes and also pricing policies interventions description from Taiwan</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-09-18 15:38:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2006">
<CHAR_METHODS MODIFIED="2013-11-30 12:49:41 +0100" MODIFIED_BY="[Empty name]">
<P>ITS<BR/>Limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-30 12:49:41 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: Taiwan, National Health Insurance <BR/>Physicians: No information provided</P>
<P>Patients: No information provided</P>
<P>Prescriptions: No information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-18 15:38:54 +0200" MODIFIED_BY="[Empty name]">
<P>Reference pricing and generic grouping for ceiling prices</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-30 12:49:41 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmaceutical expenditure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-18 15:38:54 +0200" MODIFIED_BY="[Empty name]">
<P>Authors were requested for more information about size and effect of outcomes and also pricing policies interventions description from Taiwan</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-09-22 12:34:57 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:46 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>The intervention is independent of other changes. (Protection against secular changes)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.02" NO="2">
<NAME>Drug expenditures</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.03" NO="3">
<NAME>Drug use</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1">
<NAME>Drug prices</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.04" NO="4">
<NAME>Health Care Utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-09-18 15:37:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION>
<P>Comment: Probably not done. Quite long study period (1972-1996), specifically there are big chances of having secular changes in that period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-09-18 15:37:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION>
<P>Quote: Variables that affect prices (page 97) are adjusted for in the regression equation. In addition a control (the substances that were candidates for index pricing system but not included)</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2013-12-15 20:10:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-08-30 15:15:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>A control group did not show secular changes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2013-06-27 12:13:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>A control group did not show secular changes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" MODIFIED="2013-06-27 12:12:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" MODIFIED="2014-08-30 04:40:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2011-08-31 22:25:14 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2011-09-02 13:01:06 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Quote: Page 1012: Some CCBs (also anti-anginal drugs) became subject to reference pricing on Jan 1 1997. Page 1015: &#8220;No apparent concomitant changes in either pharmacological management of angina or Pharmacare reimbursement policy for these drugs over our study period&#8221;. Page 1015: &#8220;The presence of time-varying confounders could have affected our results.&#8221;</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" MODIFIED="2011-09-02 13:01:16 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Quote: Page 1012: Some CCBs (also anti-anginal drugs) became subject to reference pricing on Jan 1 1997. Page 1015: &#8220;No apparent concomitant changes in either pharmacological management of angina or Pharmacare reimbursement policy for these drugs over our study period&#8221;. Page 1015: &#8220;The presence of time-varying confounders could have affected our results.&#8221;</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" MODIFIED="2013-12-14 14:27:23 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-11-14 18:10:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2014-09-18 15:37:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Quote: Events like patent expiration, changes in prescribing patterns, and other unknown parameters are included in the regression model using ordinary least squares</P>
<P>Comment: Probably done, protection against secular changes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" MODIFIED="2014-09-18 15:37:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Quote: Events like patent expiration, changes in prescribing patterns, and other unknown parameters are included in the regression model using ordinary least squares</P>
<P>Comment: Probably done, protection against secular changes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" MODIFIED="2013-11-14 18:10:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-12-11 17:48:09 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2013-12-11 17:47:35 +0100" MODIFIED_BY="Angela Acosta" RESULT="NO" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Introduction of low-cost generic hypertensive drugs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" MODIFIED="2013-12-11 17:47:37 +0100" MODIFIED_BY="Angela Acosta" RESULT="NO" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Introduction of low-cost generic hypertensive drugs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" MODIFIED="2013-12-11 17:47:13 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" MODIFIED="2014-09-18 15:37:37 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably not done, simultaneous prior authorisation policy with the reference pricing on H2RAs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" MODIFIED="2013-12-14 15:02:14 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-09-18 15:37:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Long period series. Prescription drug use and spending data were aggregated on a monthly basis using the National Drug Code as the identifying variable (2000 to 2004)<BR/>
<BR/>To avoid this possible high risk we are going to select only one pricing policy, Period 2: joint purchasing arrangement (JPA)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2014-09-18 15:37:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Long period series. Fifty-seven months and covered five policy periods (one 26-month period before the policies were implemented and four policy periods of various durations (2000 to 2004)<BR/>
<BR/>To avoid this possible high risk we are going to select only one pricing policy, Period 2: joint purchasing arrangement (JPA) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" MODIFIED="2013-11-15 23:58:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" MODIFIED="2013-06-25 16:21:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2014-09-18 15:38:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION>
<P>Quote: Special authority policy introduced on PPIs simultaneously with the reference pricing on H2RAs. This would likely underestimate the drug cost savings, not overestimate them</P>
<P>Comment: Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" MODIFIED="2011-09-28 12:46:49 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" MODIFIED="2014-09-18 15:38:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McManus-2001">
<DESCRIPTION>
<P>Comment: Probably done. Compelling arguments are not mentioned and there might have been confounding historic events like new competitors on the market, new prices or marketing for competitor drugs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Long series (1995 to 2006)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Long series (1995 to 2006)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Long series (1995 to 2006)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" MODIFIED="2013-06-25 16:32:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2011-09-28 15:47:56 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" MODIFIED="2014-09-18 15:38:22 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Narine-2001">
<DESCRIPTION>
<P>Comment: Not written in this study, but from Hazlet and Marshall we know that Prior authorisation for PPIs were introduced simultaneously. The strict PPI policy most likely increase the use of H2RAs, both in total and with respect to the different H2RAs. Thus, where results show an increase in use, we do not know if the 'real result' is a decrease. Where the results show a decrease, the real result would be a (bigger) decrease</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-09-18 15:38:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION>
<P>Quote: The estimates that rely on the variation of prices before and after the reimbursement change to identify the impact of patient out-of-pocket expenses on pricing might be biased by intertemporal variation unrelated to changes in RP such as changes in technology, regulation, or demand. Thus, when data permit (as is the case for oral antidiabetics), I rely on differences in the intertemporal changes across products that vary in their exposure to reference prices.</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2011-09-29 00:15:02 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2014-09-18 15:38:25 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Puig-2007">
<DESCRIPTION>
<P>Quote: The coefficient estimates in Eq. (1) might be biased by intertemporal variation unrelated to insurer interventions, such as changes in technology or demand. Technology assumption</P>
<P>Inherent in all policy evaluations applied to a class of drugs is that results cannot be easily generalized to all drug categories or to other health systems or pharmaceutical markets<BR/>Some potential confounding factors such as marketing expenditure have not been considered because of lack of reliable data</P>
<P>Comment: Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-09-18 15:38:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION>
<P>Quote: Three concurrent events in the study period were mentioned by the author, and were controlled for in the analysis: 1) 50 cents copayment and elimination of OTC- coverage by Medicaid 2) drop in number of Medicaid recipients 3) effect of the MAC-EAC program on drug dispensing fees.</P>
<P>Comment: Probably done. There are other changes, but the author adjusts for these changes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2011-10-03 18:04:51 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2011-10-03 18:27:55 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2011-10-03 18:22:17 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably not done, not sure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" MODIFIED="2014-09-18 15:38:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably not done, not sure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" MODIFIED="2011-10-03 18:27:55 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2011-10-03 19:21:18 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" MODIFIED="2011-10-03 19:21:20 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-10-08 17:54:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2013-10-08 17:54:22 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.03" MODIFIED="2014-09-18 15:38:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P>Not described in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.04" MODIFIED="2013-12-11 16:41:17 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:34 +0200" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Data were analysed appropriately ?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-10.01" NO="1">
<NAME>Drug prices</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-10.02" NO="2">
<NAME>Drug expenditures</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-10.04" NO="4">
<NAME>Health Care Utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-10.03" NO="3">
<NAME>Drug use</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2014-09-18 15:37:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION>
<P>Comment: Probably done. Time series regression used, model specification not quite correct (did not let slopes vary between pre and post) but analysis is correct</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2014-09-18 15:37:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION>
<P>Quote: Page 95 - Autoregressive model with trend</P>
<P>Comment: Probably done. It seems that they have done it, but they are not explicit about it</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2014-08-29 10:38:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>The analysis relies on a comparison of the molecules affected by reference pricing (treatment group) to similar molecules under price cap regulation (control group). They compared inter-temporal variation in outcomes before and after the imposition of the reform. They estimated different versions of the following fixed effect regression model: Yit = X&#8242;it &#946; + ai + &#948;t + &#945;Dit + &#949;it</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2014-08-29 10:38:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>The analysis relies on a comparison of the molecules affected by reference pricing (treatment group) to similar molecules under price cap regulation (control group). They compared inter-temporal variation in outcomes before and after the imposition of the reform. They estimated different versions of the following fixed effect regression model: Yit = X&#8242;it &#946; + ai + &#948;t + &#945;Dit + &#949;it</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" MODIFIED="2013-06-27 12:13:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" MODIFIED="2013-06-27 12:12:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2011-08-31 17:51:12 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2011-08-31 18:00:34 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Quote: Log regression, enough time points but no trend calculations formally, Page 1013</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" MODIFIED="2011-08-31 18:00:36 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Quote: Log regression, enough time points but no trend calculations formally, Page 1013</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" MODIFIED="2013-12-14 14:27:38 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2013-11-14 18:10:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2014-09-18 15:37:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Quote: Assuming that RP did not affect quantity and using the same regression approach, we estimated the impact of the policies on Pharmacare on patients reimbursement price.</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" MODIFIED="2014-09-18 15:37:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Quote: Assuming that RP did not affect quantity and using the same regression approach, we estimated the impact of the policies on Pharmacare on patients reimbursement price.</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" MODIFIED="2013-11-14 18:10:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2013-12-11 17:48:09 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2013-12-11 17:48:09 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Data scanned and reanalysis done by reviewers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" MODIFIED="2013-12-11 17:48:18 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Data scanned and reanalysis done by reviewers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" MODIFIED="2013-12-11 17:48:09 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2011-09-06 18:50:44 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" MODIFIED="2011-10-16 19:56:35 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably not done, Poisson regression model</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" MODIFIED="2013-12-14 15:02:25 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2014-09-18 15:37:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>We used interrupted time series analysis to investigate the mix effect, the price effect, and the combined price and mix effect of the four cost containment policies on cardiovascular drugs used by Michigan&#8217;s dually eligible beneficiaries</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2014-09-18 15:37:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>We used interrupted time series analysis to investigate the mix effect, the price effect, and the combined price and mix effect of the four cost containment policies on cardiovascular drugs used by Michigan&#8217;s dually eligible beneficiaries </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" MODIFIED="2013-11-15 23:58:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" MODIFIED="2013-06-25 16:21:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2011-09-28 12:48:27 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2011-09-28 12:48:32 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" MODIFIED="2014-09-18 15:38:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McManus-2001">
<DESCRIPTION>
<P>Comment: Probably done after reanalysis, few post-period observations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>They applied ARIMA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>They applied ARIMA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>They applied ARIMA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" MODIFIED="2013-06-25 16:30:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" MODIFIED="2011-09-28 15:49:03 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Narine-2001">
<DESCRIPTION>
<P>Comment: Probably done by reanalysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2014-09-18 15:38:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION>
<P>Comment: Probably done, time series regression models</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2014-09-18 15:38:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Puig-2007">
<DESCRIPTION>
<P>Comment: Probably done, time series regression model</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2014-09-18 15:38:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2011-10-03 18:27:55 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2014-09-18 15:38:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" MODIFIED="2014-09-18 15:38:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" MODIFIED="2011-10-03 18:27:55 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2011-10-03 19:21:31 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" MODIFIED="2011-10-03 19:21:33 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2013-10-08 17:54:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2013-10-08 17:54:06 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.03" MODIFIED="2013-10-08 17:54:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P>Data scanned and reanalysis done by reviewers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.04" MODIFIED="2013-12-11 16:40:15 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-21" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:43 +0200" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Were baseline outcome measurements similar?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-21.01" NO="1">
<NAME>Health care utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" MODIFIED="2013-06-27 12:13:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" MODIFIED="2014-09-18 15:37:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably not done, reporting only combined figures as results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" MODIFIED="2013-11-14 18:10:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" MODIFIED="2013-12-11 17:48:09 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" MODIFIED="2014-09-18 15:37:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Quote: Table 1. lower part</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" MODIFIED="2013-06-25 16:21:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" MODIFIED="2013-06-25 16:32:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" MODIFIED="2014-09-18 15:38:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Quote: Table 1. Small baseline differences</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" MODIFIED="2014-09-18 15:38:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably not done. Baseline not reported for switchers versus non-switchers. But RRs adjusted for potential confounders (see table 4 in the paper)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-21.01" MODIFIED="2013-10-08 17:54:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-22" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:44 +0200" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Were baseline characteristics similar?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-22.01" NO="1">
<NAME>Health care utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" MODIFIED="2013-06-27 12:13:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" MODIFIED="2011-09-02 16:34:57 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Quote: Page 63 and appendix 2</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" MODIFIED="2013-11-14 18:10:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" MODIFIED="2013-12-11 17:48:09 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" MODIFIED="2014-09-18 15:37:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Quote: Table 1. upper part</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" MODIFIED="2013-06-25 16:21:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" MODIFIED="2013-06-25 16:32:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" MODIFIED="2014-09-18 15:38:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Quote: Table 1. Small baseline differences</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" MODIFIED="2014-09-18 15:38:44 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably not done. Baseline not reported for switchers versus non-switchers. But RRs adjusted for potential confounders (see table 4 in the paper)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-22.01" MODIFIED="2013-10-08 17:54:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:35 +0200" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Reason for the number and spacing of data points given</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-11.04" NO="4">
<NAME>Health Care Utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-11.02" NO="2">
<NAME>Drug expenditures</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-11.03" NO="3">
<NAME>Drug use</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-11.01" NO="1">
<NAME>Drug prices</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2011-08-30 20:49:25 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION>
<P>Comment: Probably done, they have used the highest level (years) available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-09-18 15:37:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION>
<P>Comment: Probably not done. Only 7 observations for post-intervention period, but no more observations were available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-09-18 15:37:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Registering system provide monthly data. Enough data points before and after the interventions were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" MODIFIED="2014-09-18 15:37:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Registering system provide monthly data. Enough data points before and after the interventions were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2013-06-27 12:14:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" MODIFIED="2013-06-27 12:12:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2011-08-31 17:51:12 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" MODIFIED="2011-08-31 18:02:37 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2011-08-31 18:02:40 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" MODIFIED="2013-12-14 14:27:56 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2013-11-14 18:10:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" MODIFIED="2013-11-14 18:14:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done, data on dispensing volumes and cost for the number of eligible senior beneficiaries by province and month from April 1994 to November 1997</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2013-11-14 20:25:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done, data on dispensing volumes and cost for the number of eligible senior beneficiaries by province and month from April 1994 to November 1997</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" MODIFIED="2013-11-14 18:10:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2013-12-11 17:48:09 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" MODIFIED="2013-12-11 17:49:08 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Monthly data are normal and plausible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2013-12-11 17:49:14 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Monthly data are normal and plausible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" MODIFIED="2013-12-11 17:48:10 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2011-09-06 19:10:39 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" MODIFIED="2013-12-14 15:02:36 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-09-18 15:37:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Prescription drug use and spending data were aggregated on a monthly basis using the National Drug Code as the identifying variable<BR/>
<BR/>Joint purchasing arrangement:<BR/>Pre-period: Jan 2000 - Feb 2003 Post-period: Feb. 2003 - May 2004</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" MODIFIED="2014-09-18 15:37:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Prescription drug use and spending data were aggregated on a monthly basis using the National Drug Code as the identifying variable<BR/>
<BR/>Joint purchasing arrangement:<BR/>Pre-period: Jan 2000 - Feb 2003 Post-period: Feb. 2003 - May 2004</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2013-11-16 00:00:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" MODIFIED="2013-06-25 16:21:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" MODIFIED="2011-09-28 13:35:54 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2011-09-28 14:30:32 +0200" MODIFIED_BY="Angela Acosta" RESULT="NO" STUDY_ID="STD-McManus-2001">
<DESCRIPTION>
<P>Comment: Probably not done, few data points</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-09-18 15:38:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Registering system provide monthly data. Enough data points before and after the interventions were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" MODIFIED="2014-09-18 15:38:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Registering system provide monthly data. Enough data points before and after the interventions were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2014-09-18 15:38:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Registering system provide monthly data. Enough data points before and after the interventions were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" MODIFIED="2013-06-25 16:30:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2011-09-28 15:49:43 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Narine-2001">
<DESCRIPTION>
<P>Comment: Probably done by reanalysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2011-09-29 00:20:26 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION>
<P>Comment: Probably done for the abstracted variables </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" MODIFIED="2014-09-18 15:38:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Puig-2007">
<DESCRIPTION>
<P>Comment: Probably done, series of 46 monthly drug use and sales figures from January 2001 to October 2004 for each active ingredient</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" MODIFIED="2014-09-18 15:38:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2011-10-03 18:27:55 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" MODIFIED="2014-09-18 15:38:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2014-09-18 15:38:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" MODIFIED="2011-10-03 18:27:55 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" MODIFIED="2011-10-03 19:24:04 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2011-10-03 19:24:10 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2013-10-08 17:54:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.02" MODIFIED="2013-10-08 18:00:41 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.03" MODIFIED="2013-10-08 17:54:35 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P>Monthly data are normal and plausible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.04" MODIFIED="2013-12-11 16:40:53 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-23" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:35 +0200" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Follow- up of professionals (protection against attrition/ exclusion bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-23.01" NO="1">
<NAME>Health care utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" MODIFIED="2013-06-27 12:14:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" MODIFIED="2011-09-02 16:40:48 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" MODIFIED="2013-11-14 18:10:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" MODIFIED="2013-12-11 17:48:10 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" MODIFIED="2011-09-06 18:55:40 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" MODIFIED="2013-06-25 16:21:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" MODIFIED="2013-06-25 16:33:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" MODIFIED="2014-09-18 15:38:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" MODIFIED="2011-10-03 19:24:19 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-23.01" MODIFIED="2013-10-08 17:54:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-24" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:38 +0200" MODIFIED_BY="[Empty name]" NO="24">
<NAME>Follow- up of patients (protection against attrition/ exclusion bias).</NAME>
<DESCRIPTION>
<P>Scored &#8220;DONE&#8221; if outcome measures were obtained for 80-100% of subjects allocated.</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-24.01" NO="1">
<NAME>Health Care Utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" MODIFIED="2013-06-27 12:14:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" MODIFIED="2013-11-14 18:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" MODIFIED="2013-12-11 17:48:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" MODIFIED="2013-11-16 00:00:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" MODIFIED="2013-06-25 16:33:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" MODIFIED="2014-09-18 15:38:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" MODIFIED="2011-10-03 19:24:22 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-24.01" MODIFIED="2013-10-08 17:54:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:39 +0200" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Shape of the intervention effect was pre-specified ?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-12.03" NO="3">
<NAME>Drug use</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-12.01" NO="1">
<NAME>Drug prices</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-12.02" NO="2">
<NAME>Drug expenditures</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-12.04" NO="4">
<NAME>Health Care Utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2011-08-30 20:52:12 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION>
<P>Comment: Probably done since they put a phase term in the model at the point of intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-09-18 15:37:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION>
<P>Quote: Dummy variable for the index price system (OBS: page 92: index price system announced fall 2002, several months ahead of implementation</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2013-06-27 12:14:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Explanations were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" MODIFIED="2013-06-27 12:14:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Explanations were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" MODIFIED="2013-06-27 12:14:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" MODIFIED="2013-06-27 12:12:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2011-08-31 17:51:12 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" MODIFIED="2011-08-31 18:06:20 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" MODIFIED="2011-08-31 18:06:22 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" MODIFIED="2011-08-31 22:31:26 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2013-11-14 18:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" MODIFIED="2013-11-14 18:15:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" MODIFIED="2013-11-14 20:26:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" MODIFIED="2013-11-14 18:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2013-12-11 17:48:10 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" MODIFIED="2014-09-18 15:37:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Pre-specified in the reanalysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" MODIFIED="2014-09-18 15:37:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Pre-specified in the reanalysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" MODIFIED="2013-12-11 17:48:10 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" MODIFIED="2011-10-16 19:58:05 +0200" MODIFIED_BY="Angela Acosta" RESULT="NO" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably not done, transition period of one month in data analysis not explained</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" MODIFIED="2013-12-14 15:02:45 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2013-11-16 00:00:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" MODIFIED="2013-12-19 21:57:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Rational explanation for the shape of intervention effect was given by the author</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" MODIFIED="2013-12-19 21:57:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Rational explanation for the shape of intervention effect was given by the author</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" MODIFIED="2013-11-16 00:00:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" MODIFIED="2011-09-28 13:37:41 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" MODIFIED="2013-12-15 20:14:03 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-McManus-2001">
<DESCRIPTION>
<P>Comment: Probably done after reanalysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Explanations were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Explanations were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Explanations were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" MODIFIED="2013-06-25 16:30:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" MODIFIED="2011-09-28 23:39:11 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Narine-2001">
<DESCRIPTION>
<P>Comment: Probably done by reanalysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2011-09-29 00:21:19 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" MODIFIED="2011-09-29 01:57:04 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Puig-2007">
<DESCRIPTION>
<P>Quote: A notable change in this generic RP system was introduced in January 2004, models take into account baseline trends.</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" MODIFIED="2014-09-18 15:38:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2011-10-03 18:27:56 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" MODIFIED="2014-09-18 15:38:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done. The number of pre-and post-data points seem justified with respect to the intervention, but no specific reasons given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" MODIFIED="2014-09-18 15:38:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done. The number of pre-and post-data points seem justified with respect to the intervention, but no specific reasons given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" MODIFIED="2011-10-03 18:27:56 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" MODIFIED="2011-10-03 19:24:38 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" MODIFIED="2011-10-03 19:24:43 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2013-10-08 17:54:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.02" MODIFIED="2013-10-08 18:00:22 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.03" MODIFIED="2013-10-08 17:54:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P>Prespecified in the reanalysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.04" MODIFIED="2013-10-08 17:59:57 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-10-03 19:14:41 +0200" MODIFIED_BY="Angela Acosta" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-10-03 19:14:41 +0200" MODIFIED_BY="Angela Acosta" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:39 +0200" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Intervention unlikely to affect data collection. (Protection against detection bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-13.01" NO="1">
<NAME>Drug prices</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-13.02" NO="2">
<NAME>Drug expenditures</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-13.03" NO="3">
<NAME>Drug use</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-13.04" NO="4">
<NAME>Health Care Utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2011-08-30 20:56:15 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-09-18 15:37:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION>
<P>Quote: Source of data collection changed in the study period (from sales survey to NAF statistics)</P>
<P>Comment: Probably not done. The reason for making use of two different data sources is that the authors wanted observations of prices both before the index price</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2013-06-27 12:14:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>A control group used the same data collection methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2013-06-27 12:14:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>A control group used the same data collection methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" MODIFIED="2013-06-27 12:14:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" MODIFIED="2013-06-27 12:12:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2011-08-31 17:51:12 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2011-08-31 18:07:50 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" MODIFIED="2011-08-31 18:07:52 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" MODIFIED="2013-12-14 14:28:08 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2013-11-14 18:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2013-11-14 18:15:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done, sources and methods of data collection were the same before and after the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" MODIFIED="2013-11-14 20:26:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done, sources and methods of data collection were the same before and after the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" MODIFIED="2013-11-14 18:10:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2013-12-11 17:48:14 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-09-18 15:37:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Reference pricing not likely to affect drug expenditure registries</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" MODIFIED="2014-09-18 15:37:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Reference pricing not likely to affect drug expenditure registries</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" MODIFIED="2013-12-11 17:48:15 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2011-09-06 18:58:40 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" MODIFIED="2011-09-06 19:11:09 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" MODIFIED="2013-12-14 15:03:01 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-09-18 15:37:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Sources and methods of data collection were the same before and after the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2013-12-19 21:58:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Sources and methods of data collection were the same before and after the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" MODIFIED="2013-11-16 00:02:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" MODIFIED="2013-06-25 16:21:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2011-09-28 13:38:05 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" MODIFIED="2011-09-28 14:32:59 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-McManus-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>The intervention did not affect data collection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>The intervention did not affect data collection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>The intervention did not affect data collection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" MODIFIED="2013-06-25 16:30:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" MODIFIED="2011-09-28 23:40:59 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Narine-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2011-09-29 00:21:40 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-09-18 15:38:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Puig-2007">
<DESCRIPTION>
<P>Comment: Probably done. IMS Spain</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-09-18 15:38:32 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION>
<P>Quote: An automatic claims processing system was implemented the same day the intervention started</P>
<P>Comment: Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2011-10-03 18:27:56 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-09-18 15:38:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" MODIFIED="2014-09-18 15:38:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" MODIFIED="2011-10-03 18:28:09 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2011-10-03 19:24:52 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" MODIFIED="2011-10-03 19:24:56 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2013-10-08 17:54:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2013-10-08 17:59:55 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.03" MODIFIED="2013-10-08 17:55:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P>Price policy changes not likely to affect drug expenditures registries</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.04" MODIFIED="2013-12-11 16:41:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:46 +0200" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Was knowledge of the allocated interventions adequately prevented during the study?</NAME>
<DESCRIPTION>
<P>Score &#8220;Yes&#8221; if the authors state explicitly that the primary outcome variables were assessed blindly, or the outcomes are objective, e.g. length of hospital stay.</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-14.02" NO="2">
<NAME>Drug expenditures</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-14.03" NO="3">
<NAME>Drug use</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-14.04" NO="4">
<NAME>Health Care Utilisitation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-14.01" NO="1">
<NAME>Drug prices</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2011-08-30 21:05:31 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2011-08-30 22:10:53 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-09-18 15:37:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Not relevant for ITS. Objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2014-09-18 15:37:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Not relevant for ITS. Objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" MODIFIED="2013-06-27 12:14:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" MODIFIED="2013-06-27 12:15:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2011-08-31 17:51:13 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2011-08-31 18:12:17 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" MODIFIED="2011-08-31 18:12:18 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" MODIFIED="2011-09-01 15:15:19 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2013-11-14 18:10:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2013-11-14 18:15:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done, outcomes are objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" MODIFIED="2013-11-14 20:36:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done, outcomes are objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" MODIFIED="2013-11-14 18:10:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2013-12-11 17:48:15 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2014-09-18 15:37:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Not discussed in the paper if pre-knowledge of intervention affected behaviour of patients, physicians and pharma companies before intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" MODIFIED="2014-09-18 15:37:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Not discussed in the paper if pre-knowledge of intervention affected behaviour of patients, physicians and pharma companies before intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" MODIFIED="2013-12-11 17:47:13 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" MODIFIED="2011-09-06 19:11:18 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" MODIFIED="2013-12-14 15:03:18 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-09-18 15:37:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2013-11-15 23:59:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" MODIFIED="2013-11-16 00:02:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" MODIFIED="2013-06-25 16:21:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2011-09-28 13:47:39 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" MODIFIED="2011-09-28 14:35:22 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-McManus-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" MODIFIED="2013-06-25 16:33:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" MODIFIED="2013-06-25 16:30:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" MODIFIED="2011-09-28 23:41:44 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Narine-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2011-09-29 00:32:00 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2014-09-18 15:38:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Puig-2007">
<DESCRIPTION>
<P>Quote: The data are in the form of a monthly time series from January 2001 to October 2004 (46 monthly periods) of quantity and volume of sales valued at regulated ex-factory prices (not including potential producer discounts to wholesale distribution firms or to pharmacies) at the level of each active ingredient for the six statins available in the Spanish market during that period, separated into Andalusia and the rest of Spain. An observation is equal to an active ingredient-month</P>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2014-09-18 15:38:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2011-10-03 18:28:09 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2014-09-18 15:38:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" MODIFIED="2014-09-18 15:38:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" MODIFIED="2014-09-18 15:38:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2011-10-03 19:25:06 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" MODIFIED="2011-10-03 19:25:13 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" MODIFIED="2013-12-14 15:05:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2013-12-01 14:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2013-10-08 17:55:31 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.03" MODIFIED="2014-09-18 15:38:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P>Not discussed in the paper if pre knowledge of intervention affected behaviour of patients, physicians and pharma companies before intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.04" MODIFIED="2013-12-11 16:41:48 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-10-03 19:14:41 +0200" MODIFIED_BY="Angela Acosta" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-10-03 19:14:41 +0200" MODIFIED_BY="Angela Acosta" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-10-03 19:14:41 +0200" MODIFIED_BY="Angela Acosta" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:41 +0200" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Were incomplete outcome data adequately addressed?</NAME>
<DESCRIPTION>
<P>Score &#8220;Yes&#8221; if missing outcome measures were unlikely to bias the results (e.g. the proportion of missing data was similar in the pre- and post-intervention periods or the proportion of missing data was less than the effect size i.e. unlikely to overturn the study result). Score &#8220;No&#8221; if missing outcome data was likely to bias the results. Score &#8220;Unclear&#8221; if not specified in the paper (Do not assume 100% follow up unless stated explicitly).</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-15.01" NO="1">
<NAME>Drug price</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-15.04" NO="4">
<NAME>Health Care Utilization</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-15.02" NO="2">
<NAME>Drug expenditure</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-15.03" NO="3">
<NAME>Drug use</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2011-08-30 21:14:45 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2011-08-30 22:11:48 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-08-30 04:41:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Complete data set</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" MODIFIED="2013-12-15 20:11:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Complete data set</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" MODIFIED="2013-06-27 12:15:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" MODIFIED="2013-06-27 12:12:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2011-08-31 17:51:13 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" MODIFIED="2011-08-31 18:16:06 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" MODIFIED="2011-08-31 18:16:08 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" MODIFIED="2013-12-14 14:28:22 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2013-11-14 18:10:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" MODIFIED="2013-11-14 18:15:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done, all relevant outcomes in the methods section are reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" MODIFIED="2013-11-14 20:34:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done, all relevant outcomes in the methods section are reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" MODIFIED="2013-11-14 18:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2013-12-11 17:48:15 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" MODIFIED="2013-12-11 17:51:54 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Register data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" MODIFIED="2013-12-11 17:52:00 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Register data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" MODIFIED="2013-12-11 17:48:15 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" MODIFIED="2011-09-06 19:11:25 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" MODIFIED="2013-12-14 15:11:07 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-09-18 15:37:57 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>It isn't clear which are the utilisation and expenditure outcomes, the article doesn't present it, authors did not show neither the data nor the time series constructed from these two measures<BR/>
<BR/>Monthly utilisation of and expenditures on drugs were determined, but it isn't clear if they are well addressed. Authors calculated cost savings for each policy by multiplying the change in price by total days supply. Authors measured utilisation using the number of days covered by each prescription&#8212;or days&#8217; supply&#8212;to control for prescription size<BR/>
<BR/>Even though drug expenditure and use aggregate data could be a limitation, it isn't an exclusion reason for this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" MODIFIED="2014-09-18 15:38:00 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>It isn't clear which are the utilisation and expenditure outcomes, the article doesn't present it, authors did not show neither the data nor the time series constructed from these two measures<BR/>
<BR/>Monthly utilisation of and expenditures on drugs were determined, but it isn't clear if they are well addressed. Authors calculated cost savings for each policy by multiplying the change in price by total days supply. Authors measured utilisation using the number of days covered by each prescription&#8212;or days&#8217; supply&#8212;to control for prescription size<BR/>
<BR/>Even though drug expenditure and use aggregate data could be a limitation, it isn't a exclusion reason for this study<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" MODIFIED="2013-11-16 00:03:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" MODIFIED="2013-06-25 16:21:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" MODIFIED="2011-09-28 13:48:04 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" MODIFIED="2014-09-18 15:38:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McManus-2001">
<DESCRIPTION>
<P>Comment: Probably done, this does only apply to the study cohort which was studied (prescription dispensed in the first week of April)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2013-12-15 20:14:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Complete data set</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" MODIFIED="2013-12-15 20:14:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Complete data set</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" MODIFIED="2013-12-15 20:14:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Complete data set</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" MODIFIED="2013-06-25 16:30:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" MODIFIED="2014-09-18 15:38:23 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Narine-2001">
<DESCRIPTION>
<P>Comment: Probably not done. There were changes in data set sample during study period, changes in the IMS data set´s sample population was done in June 1996, therefore trends after this time may not be directly comparable to those prior to June 1996</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2011-09-29 00:32:20 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" MODIFIED="2011-10-07 10:43:20 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Puig-2007">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" MODIFIED="2014-09-18 15:38:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2011-10-03 18:28:10 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" MODIFIED="2014-09-18 15:38:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" MODIFIED="2014-09-18 15:38:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" MODIFIED="2014-09-18 15:38:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" MODIFIED="2011-10-03 19:26:26 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" MODIFIED="2011-10-03 19:26:27 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" MODIFIED="2013-12-14 15:09:39 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2013-12-01 14:39:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.02" MODIFIED="2013-10-08 17:55:28 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.03" MODIFIED="2013-10-08 17:55:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P>National wide register data </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.04" MODIFIED="2013-12-11 16:42:03 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-16" LEVEL="GROUP" MODIFIED="2014-09-22 12:34:57 +0200" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Reliable primary outcome measure(s)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-16.03" NO="3">
<NAME>Drug use</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-16.02" NO="2">
<NAME>Drug expenditures</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-16.01" NO="1">
<NAME>Drug prices</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-16.04" NO="4">
<NAME>Health care utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2011-08-30 21:17:49 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2011-08-30 22:11:54 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-09-18 15:37:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>They used data from Farmastat, a database that includes information on sales value and volume for each package of drugs sold at the Norwegian pharmaceutical market. Values are in pharmacy purchase prices and volumes in defined daily doses (DDD) for the active substance according to the ATC-code system. They have information on all off-patent prescription drugs within the 40 largest ATC groups (in terms of sales volume). All drugs in our sample are on the government's reimbursement list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" MODIFIED="2014-09-18 15:37:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>They used data from Farmastat, a database that includes information on sales value and volume for each package of drugs sold at the Norwegian pharmaceutical market. Values are in pharmacy purchase prices and volumes in defined daily doses (DDD) for the active substance according to the ATC-code system. They have information on all off-patent prescription drugs within the 40 largest ATC groups (in terms of sales volume). All drugs in our sample are on the government's reimbursement list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" MODIFIED="2013-06-27 12:15:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" MODIFIED="2013-06-27 12:12:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2011-08-31 17:51:13 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" MODIFIED="2011-08-31 18:15:03 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" MODIFIED="2011-08-31 18:15:05 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2013-11-14 18:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" MODIFIED="2013-11-14 18:15:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" MODIFIED="2013-11-14 20:35:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" MODIFIED="2013-11-14 18:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2013-12-11 17:48:15 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" MODIFIED="2013-12-11 17:52:24 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Register data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" MODIFIED="2013-12-11 17:52:31 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Register data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" MODIFIED="2013-12-11 17:48:15 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" MODIFIED="2011-09-06 19:11:31 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" MODIFIED="2013-12-14 15:03:28 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2013-06-25 16:21:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" MODIFIED="2014-09-22 12:34:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Claims data for non-institutionalised dual eligibles age 65 yr and older covering fiscal years 2000&#8211;04 were drawn from Michigan&#8217;s Medicaid outpatient prescription drug fee-for-service program database. Reliability is not reported for outcome measures that are obtained by chart extraction or collected by an individual</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" MODIFIED="2014-09-22 12:34:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Claims data for non-institutionalised dual age 65 yr and older covering fiscal years 2000&#8211;04 were drawn from Michigan&#8217;s Medicaid outpatient prescription drug fee-for-service program database. Reliability is not reported for outcome measures that are obtained by chart extraction or collected by an individual</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" MODIFIED="2013-06-25 16:21:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" MODIFIED="2011-09-28 13:48:46 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" MODIFIED="2011-09-28 14:35:37 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-McManus-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2013-06-25 16:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Data were provided by the Catalan Health Service</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" MODIFIED="2013-06-25 16:34:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Data were provided by the Catalan Health Service</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" MODIFIED="2013-06-25 16:34:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Data were provided by the Catalan Health Service</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" MODIFIED="2013-06-25 16:30:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" MODIFIED="2011-09-28 23:52:09 +0200" MODIFIED_BY="Angela Acosta" RESULT="NO" STUDY_ID="STD-Narine-2001">
<DESCRIPTION>
<P>Comment: Probably not done. IMS data include pharmacist fees and/or distribution costs, thus cost increases may stem from either changes in pharmacist and/or distribution costs or changes in ingredient cost</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2011-09-29 00:32:35 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" MODIFIED="2011-10-07 10:44:11 +0200" MODIFIED_BY="Angela Acosta" RESULT="NO" STUDY_ID="STD-Puig-2007">
<DESCRIPTION>
<P>Quote: Public expenditure data on dispensed statins are proxied in this paper by overall volume of sales, including publicly financed but also out-of-pocket sales in order to evaluate public financing reforms, public procurement data should be used</P>
<P>Comment: Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" MODIFIED="2011-10-03 18:16:54 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2011-10-03 18:28:10 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" MODIFIED="2014-09-18 15:38:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" MODIFIED="2014-09-18 15:38:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" MODIFIED="2014-09-18 15:38:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" MODIFIED="2011-10-03 19:26:46 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" MODIFIED="2011-10-03 19:26:50 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" MODIFIED="2013-12-14 15:05:29 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2013-10-08 17:54:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.02" MODIFIED="2013-10-08 17:55:58 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.03" MODIFIED="2013-10-08 17:56:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P>National wide register data </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.04" MODIFIED="2013-10-08 17:56:14 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-10-03 19:14:41 +0200" MODIFIED_BY="Angela Acosta" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-25" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:42 +0200" MODIFIED_BY="[Empty name]" NO="25">
<NAME>Was the study adequately protected against contamination?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-25.01" NO="1">
<NAME>Health Care Utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" MODIFIED="2013-06-27 12:16:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" MODIFIED="2013-11-14 18:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" MODIFIED="2013-12-11 17:48:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" MODIFIED="2013-06-25 16:21:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" MODIFIED="2013-06-25 16:36:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" MODIFIED="2014-09-18 15:38:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" MODIFIED="2011-10-03 19:27:04 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-25.01" MODIFIED="2013-10-08 17:54:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-10-03 19:14:41 +0200" MODIFIED_BY="Angela Acosta" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-17" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:43 +0200" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Other risk of bias</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-17.01" NO="1">
<NAME>Drug prices</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-17.04" NO="4">
<NAME>Health care utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-17.02" NO="2">
<NAME>Drug expenditures</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-17.03" NO="3">
<NAME>Drug use</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2011-08-30 21:20:21 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-09-18 15:37:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION>
<P>Comment: Probably not done. Sample of 10 pharmacies, small &#8211; thus large confidence intervals, the point estimates may vary a lot. Do not know if sample is representative or not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2013-06-27 12:16:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>No evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" MODIFIED="2013-06-27 12:16:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>No evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" MODIFIED="2013-06-27 12:16:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" MODIFIED="2013-06-27 12:12:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2011-08-31 17:51:13 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" MODIFIED="2011-08-31 18:21:04 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" MODIFIED="2011-09-02 13:03:35 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" MODIFIED="2013-12-14 14:28:40 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2013-11-14 18:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" MODIFIED="2013-11-14 18:15:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Unlikely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" MODIFIED="2013-11-14 20:36:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Unlikely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" MODIFIED="2013-11-14 18:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2013-12-11 17:48:15 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" MODIFIED="2013-12-11 17:53:55 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Not discussed in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" MODIFIED="2013-12-11 17:53:57 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Not discussed in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" MODIFIED="2013-12-11 17:48:15 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" MODIFIED="2011-09-06 19:11:44 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" MODIFIED="2013-12-14 15:03:39 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-09-18 15:38:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>First, expenditures were not adjusted for the supplemental manufacturer rebates received by Michigan, because that is proprietary information, the estimated cost savings generated by Michigan&#8217;s policies may be understated, given that three of the four policies (preferred lists and both purchasing arrangements) have supplemental manufacturer rebates<BR/>
<BR/>Second, study findings might not be generalizable to other Medicaid programs with different beneficiary demographics and prescription drug use<BR/>
<BR/>Third, study did not include a control group. A limitation of the interrupted time series design is that we could not control for individual-level factors such as generic drug entry and brand-name drug patent expiration<BR/>
<BR/>Finally, it is unclear what role, if any, the sequencing of policy implementation or the mix of policies played in generating the calculated cost savings. In other words, we might not have arrived at the same conclusion if both the preferred lists and the joint pool had not preceded maximum pricing. Taking this into account, we only will include the impact measure for joint purchasing arrangement policy<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" MODIFIED="2014-09-18 15:38:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>First, expenditures were not adjusted for the supplemental manufacturer rebates received by Michigan, because that is proprietary information, the estimated cost savings generated by Michigan&#8217;s policies may be understated, given that three of the four policies (preferred lists and both purchasing arrangements) have supplemental manufacturer rebates. However, this approach is consistent with other studies that have evaluated state Medicaid spending.11<BR/>Second, study findings might not be generalizable to other Medicaid programs with different beneficiary demographics and prescription drug use.<BR/>Third, study did not include a control group. A limitation of the interrupted time-series design is that we could not control for individual-level factors such as generic drug entry and brand-name drug patent expiration<BR/>
<BR/>Finally, it is unclear what role, if any, the sequencing of policy implementation or the mix of policies played in generating the calculated cost savings. In other words, we might not have arrived at the same conclusion if both the preferred lists and the joint pool had not preceded maximum pricing. Taking this into account, we only will include the impact measure for joint purchasing arrangement policy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" MODIFIED="2013-06-25 16:21:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" MODIFIED="2013-06-25 16:21:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" MODIFIED="2011-09-28 13:49:00 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" MODIFIED="2011-09-28 14:37:16 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-McManus-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>No evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>No evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>No evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" MODIFIED="2013-06-25 16:30:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" MODIFIED="2011-09-28 23:53:12 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Narine-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2011-09-29 00:32:45 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" MODIFIED="2014-09-18 15:38:26 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Puig-2007">
<DESCRIPTION>
<P>Quote: Public expenditure data on dispensed statins are proxied in this paper by overall volume of sales, including publicly financed but also out-of-pocket sales in order to evaluate public financing reforms, public procurement data should be used. However, in the Spanish market, most dispensed prescription drugs are publicly financed, out-of-pocket prescription sales representing a very small market share. Furthermore, the public financing reforms established the reimbursement limits at the level of the consumer price, therefore volume of sales valued at consumer prices would be more appropriate for evaluating the impact of these reforms. Notwithstanding, in this case price regulation establishes consumer prices by adding proportional distribution margins to the regulated ex-factory price, so this ex-factory price presents a perfect correlation with consumer prices.</P>
<P>The impact of the interventions under evaluation on other health services and on health status is not considered in this paper</P>
<P>Comment: Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" MODIFIED="2011-10-03 18:17:14 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2011-10-03 18:28:12 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" MODIFIED="2014-09-18 15:38:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" MODIFIED="2014-09-18 15:38:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" MODIFIED="2011-10-03 18:28:12 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" MODIFIED="2011-10-03 19:29:23 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" MODIFIED="2011-10-03 19:29:28 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" MODIFIED="2011-10-03 19:29:34 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2013-10-08 17:54:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.02" MODIFIED="2013-10-08 17:58:57 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P>  </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.03" MODIFIED="2013-10-08 17:59:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> Not discussed in the paper </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.04" MODIFIED="2013-12-11 16:42:19 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-19" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:27 +0200" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Baseline adjustment analysis done (properly)?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-19.01" NO="1">
<NAME>Drug prices</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-19.04" NO="4">
<NAME>Health care utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-19.03" NO="3">
<NAME>Drug use</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-19.02" NO="2">
<NAME>Drug expenditures</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" MODIFIED="2011-08-30 21:23:43 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" MODIFIED="2014-09-18 15:37:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" MODIFIED="2013-06-27 12:16:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" MODIFIED="2013-06-27 12:16:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" MODIFIED="2013-06-27 12:16:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" MODIFIED="2013-06-27 12:12:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" MODIFIED="2011-08-31 17:51:13 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" MODIFIED="2011-08-31 18:25:29 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" MODIFIED="2011-08-31 18:25:34 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" MODIFIED="2011-09-02 13:16:39 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" MODIFIED="2013-11-14 18:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" MODIFIED="2014-09-18 15:37:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Quote: the authors extrapolated average reimbursement per day of NSAID therapy over the months before RP to estimate what expenditures would have been without the policies. These counterfactual predictions were compared with actual values to estimate the impact of the policies; the estimated impacts on reimbursement rates were multiplied by the postpolicy volume of NSAIDS dispensed, which appeared unaffected by the policies, to estimate expenditure changes. Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" MODIFIED="2014-09-18 15:37:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Quote: the authors extrapolated average reimbursement per day of NSAID therapy over the months before RP to estimate what expenditures would have been without the policies. These counterfactual predictions were compared with actual values to estimate the impact of the policies; the estimated impacts on reimbursement rates were multiplied by the postpolicy volume of NSAIDS dispensed, which appeared unaffected by the policies, to estimate expenditure changes. Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" MODIFIED="2013-11-14 18:10:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" MODIFIED="2013-12-11 17:48:19 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" MODIFIED="2013-12-11 17:56:17 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Data scanned and reanalysis done by reviewers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" MODIFIED="2013-12-11 17:56:26 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Data scanned and reanalysis done by reviewers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" MODIFIED="2013-12-11 17:48:19 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" MODIFIED="2011-09-06 19:12:22 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" MODIFIED="2011-09-06 19:04:10 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably not done </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" MODIFIED="2014-09-18 15:38:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Done, included in the ITS model</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" MODIFIED="2014-09-18 15:38:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Done, included in the ITS model</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" MODIFIED="2013-11-16 00:04:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" MODIFIED="2013-06-25 16:21:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" MODIFIED="2011-09-28 13:51:22 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" MODIFIED="2013-06-25 16:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" MODIFIED="2013-06-25 16:30:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" MODIFIED="2011-09-28 23:54:41 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Narine-2001">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" MODIFIED="2011-09-29 00:34:01 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" MODIFIED="2014-09-18 15:38:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Puig-2007">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" MODIFIED="2011-10-03 18:18:11 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" MODIFIED="2011-10-03 18:28:13 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" MODIFIED="2011-10-03 18:59:00 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" MODIFIED="2011-10-03 18:59:12 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" MODIFIED="2011-10-03 18:28:13 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" MODIFIED="2011-10-03 19:30:59 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" MODIFIED="2011-10-03 19:30:41 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" MODIFIED="2011-10-03 19:31:04 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" MODIFIED="2013-12-14 15:06:04 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.01" MODIFIED="2013-12-01 14:39:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.02" MODIFIED="2013-12-01 14:39:08 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.03" MODIFIED="2013-10-08 17:57:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-19.04" MODIFIED="2013-12-11 16:43:04 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-20" LEVEL="GROUP" MODIFIED="2014-09-18 15:38:27 +0200" MODIFIED_BY="[Empty name]" NO="20">
<NAME>Intention to treat analysis done (properly)?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-20.03" NO="3">
<NAME>Drug use</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-20.01" NO="1">
<NAME>Drug prices</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-20.04" NO="4">
<NAME>Health care utilisation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-20.02" NO="2">
<NAME>Drug expenditures</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" MODIFIED="2011-08-30 21:25:31 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION>
<P>Comment: Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" RESULT="UNKNOWN" STUDY_ID="STD-Aronsson-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" MODIFIED="2014-09-18 15:37:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" MODIFIED="2013-06-27 12:16:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" MODIFIED="2013-06-27 12:16:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" MODIFIED="2013-06-27 12:16:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" MODIFIED="2013-06-27 12:12:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brekke-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" MODIFIED="2011-08-31 17:51:17 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" MODIFIED="2011-08-31 18:26:31 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" MODIFIED="2011-08-31 18:26:36 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" MODIFIED="2011-09-02 13:20:35 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" MODIFIED="2013-11-14 18:10:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" MODIFIED="2013-11-14 20:37:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" MODIFIED="2013-11-14 20:37:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" MODIFIED="2013-11-14 18:10:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" MODIFIED="2013-12-11 17:48:19 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" MODIFIED="2013-12-11 17:56:42 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P> Not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" MODIFIED="2013-12-11 17:57:13 +0100" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION>
<P>Not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" MODIFIED="2013-12-11 17:48:20 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Grootendorst-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" MODIFIED="2011-09-06 19:12:31 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" MODIFIED="2013-12-14 15:04:27 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Hazlet-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" MODIFIED="2014-09-18 15:38:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" MODIFIED="2013-06-25 16:21:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P>Not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" MODIFIED="2013-11-16 00:04:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" MODIFIED="2013-06-25 16:21:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kibicho-2012">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" MODIFIED="2011-09-28 13:51:42 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" RESULT="UNKNOWN" STUDY_ID="STD-McManus-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" MODIFIED="2013-06-25 16:34:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" MODIFIED="2013-06-25 16:34:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" MODIFIED="2013-06-25 16:34:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION>
<P>Not relevant for ITS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" MODIFIED="2013-06-25 16:30:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno_x002d_Torres-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" MODIFIED="2011-09-28 23:55:06 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Narine-2001">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" RESULT="UNKNOWN" STUDY_ID="STD-Narine-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" MODIFIED="2011-09-29 00:34:59 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" RESULT="UNKNOWN" STUDY_ID="STD-Pavcnik-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" MODIFIED="2014-09-18 15:38:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Puig-2007">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" RESULT="UNKNOWN" STUDY_ID="STD-Puig-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" MODIFIED="2011-10-03 18:18:22 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" RESULT="UNKNOWN" STUDY_ID="STD-Sawyer-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" MODIFIED="2011-10-03 18:28:13 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" MODIFIED="2011-10-03 18:59:34 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" MODIFIED="2011-10-03 18:59:51 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION>
<P>Comment: Probably done, not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" MODIFIED="2011-10-03 18:28:15 +0200" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" MODIFIED="2011-10-03 19:31:47 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" MODIFIED="2011-10-03 19:31:56 +0200" MODIFIED_BY="Angela Acosta" RESULT="YES" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION>
<P>Comment: Not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" MODIFIED="2013-12-14 15:06:11 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Schneeweiss-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.01" MODIFIED="2013-12-01 14:39:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.02" MODIFIED="2013-12-01 14:42:59 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.03" MODIFIED="2013-12-01 14:42:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION>
<P>Comment: Not relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-20.04" MODIFIED="2013-12-11 16:43:20 +0100" MODIFIED_BY="Angela Acosta" RESULT="UNKNOWN" STUDY_ID="STD-Stargardt-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-09-18 16:16:21 +0200" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-09-18 15:39:05 +0200" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-12-30 21:00:51 +0100" MODIFIED_BY="Grade Profiler">Reference pricing policy compared to no reference pricing</TITLE>
<TABLE COLS="4" ROWS="12">
<TR>
<TD COLSPAN="4">
<P>
<B>Reference pricing policy compared to no reference pricing</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Population:</B> Patients with drug insurance<BR/>
<B>Settings: </B>Canada, US, Germany<BR/>
<B>Intervention:</B> Reference pricing<BR/>
<B>Comparison: </B>No reference pricing</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Impact</P>
<P>Median relative effect (range)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>No of studies</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
<P>
<B>Insurer's cumulative drug expenditures one year after the transition period</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Reference drugs + cost share drugs: </B>Median relative cumulative drug expenditures of -18% (range: from -36% to 3%)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2 studies<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Insurer's drug expenditures one year after the transition period</B>
<BR/>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Reference drugs + cost share drugs: </B>Median relative drug expenditures of -10% (range: from -53% to 4%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 studies<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
<P>
<B>Drug use one year after the transition period</B>
<BR/>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Reference drugs: </B>Median relative change in prescriptions of 15% (range: from -14% to 166%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 studies</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Cost share drugs: </B>Median relative change in prescriptions of -39% (range: from -87% to -17%)</P>
</TD>
<TD>
<P>3 studies</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Healthcare utilisation</B>
</P>
</TD>
<TD>
<P>No studies meeting the inclusion criteria were found</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Health outcomes</B>
</P>
</TD>
<TD>
<P>No studies meeting the inclusion criteria were found</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
</TD>
<TD>
<P>No studies meeting the inclusion criteria were found</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Reference drugs:</B> drugs that determine the reference price level. There is no cost share by the patients for these drugs, which are fully reimbursed. The expectation is that reference pricing will lead to an increase in use of these drugs.<BR/>
<B>Cost share drugs:</B> drugs in the same group as the reference drugs that cost more. Patients have to pay the difference between reference price drugs and the price of these drugs. The expectation is that reference pricing will lead to a decrease in use of these drugs.</P>
<P>
<B>Reference drugs + cost share drugs</B>: both the reference drugs and the cost share drugs. The expectation is that reference pricing will lead to little or no change in the overall use of these drugs.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>1. <LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK> was not considered for the median because this study reported the outcome different than the other two studies (mean monthly savings of total lovastatin and simvastatin sales).</P>
<P>2. We only included Pharmacare data from <LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-09-18 15:39:12 +0200" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2013-12-30 21:05:03 +0100" MODIFIED_BY="Grade Profiler">Index pricing compared to no index pricing</TITLE>
<TABLE COLS="4" ROWS="11">
<TR>
<TD COLSPAN="4">
<P>
<B>Index pricing compared to no index pricing</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Population:</B> Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin (allergy), enalapril (high blood pressure) and lisinopril (high blood pressure), simvastatin (high cholesterol) or amlodipin (high blood pressure)<BR/>
<B>Settings: </B>Norway<BR/>
<B>Intervention:</B> Index pricing<BR/>
<B>Comparison: </B>No index pricing</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>No of studies</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Drug use 6 months after policy start date</B>
<BR/>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Generic citalopram: 55% (95% CI 11 to 98%)</P>
<P>Brand citalopram: -43% (95% CI -67 to -18%)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 study</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Drug prices 6 months after policy start date</B>
</P>
</TD>
<TD>
<P>Generic drug prices: -5.3% (95% CI NA)</P>
<P>Brand drugs prices: -1.1% (95% CI NA)</P>
</TD>
<TD>
<P>1 study</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Drug expenditures</B>
</P>
</TD>
<TD>
<P>No studies meeting the inclusion criteria were found</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Healthcare utilisation</B>
</P>
</TD>
<TD>
<P>No studies meeting the inclusion criteria were found</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Health outcomes</B>
</P>
</TD>
<TD>
<P>No studies meeting the inclusion criteria were found</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
</TD>
<TD>
<P>No studies meeting the inclusion criteria were found</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>CI:</B> Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2014-09-18 15:39:14 +0200" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2011-10-14 12:14:21 +0200" MODIFIED_BY="Grade Profiler">Maximum prices compared to no maximum prices for drug expenditures</TITLE>
<TABLE COLS="4" ROWS="11">
<TR>
<TD COLSPAN="4">
<P>
<B>Maximum prices compared to no maximum prices for drug expenditures</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Population:</B> Patients taking statins<BR/>
<B>Settings: </B>Andalusia, Spain<BR/>
<B>Intervention:</B> Maximum prices<BR/>
<B>Comparison: </B>No maximum prices</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
<P/>
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<BR/>No of studies</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Drug expenditure one year after the transition period</B>
<BR/>
<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>21.4% (95% CI 19.0 to 23.7%) in volume of sales for total statins</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1 study</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Drug prices</B>
</P>
</TD>
<TD>
<P>No studies meeting the inclusion criteria were found</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Healthcare utilisation</B>
</P>
</TD>
<TD>
<P>No studies meeting the inclusion criteria were found</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Health outcomes</B>
</P>
</TD>
<TD>
<P>No studies meeting the inclusion criteria were found</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Drug use</B>
</P>
</TD>
<TD>
<P>No studies meeting the inclusion criteria were found</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
</TD>
<TD>
<P>No studies meeting the inclusion criteria were found</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>CI:</B> Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> High risk of bias due to the intervention not being independent of other changes.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2014-09-18 16:16:21 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2014-09-18 16:16:21 +0200" MODIFIED_BY="[Empty name]">Reference pricing versus no reference pricing: drug expenditures</TITLE>
<TABLE COLS="10" ROWS="13">
<TR>
<TH>
<P>STUDY ID</P>
</TH>
<TH>
<P>REFERENCE PRICE FOR</P>
</TH>
<TD>
<P>
<B>EFFECTS ON EXPENDITURES OF***</B>
</P>
</TD>
<TH>
<P>OUTCOME</P>
</TH>
<TH>
<P>ABSOLUTE CHANGE LEVEL, IMMEDIATE AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, IMMEDIATE AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, 1/2 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, 1 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, 2 YEARS AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>NOTES</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>*</P>
</TD>
<TD>
<P>ACE inhibitors</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>ACE inhibitors. Pharmacare expenditure per 100,000 senior citizens. Canadian dollar per month</P>
</TD>
<TD>
<P>18,203<BR/>(-1611 to 38,017)<BR/>
</P>
</TD>
<TD>
<P>5%<BR/>(0% to 10%)<BR/>
</P>
</TD>
<TD>
<P>5%<BR/>(-2% to 10%)</P>
</TD>
<TD>
<P>4%<BR/>(-3% to 10%)<BR/>
</P>
</TD>
<TD>
<P>1%<BR/>(-8% to 9%)<BR/>
</P>
</TD>
<TD>
<P>Price year not specified in study papers</P>
</TD>
</TR>
<TR>
<TD>
<P>CCBs</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>CCBs. Pharmacare expenditure per 100,000 senior citizens. Canadian dollar per month</P>
</TD>
<TD>
<P>-91,547<BR/>(-122,082 to -61,011)<BR/>
</P>
</TD>
<TD>
<P>-19%<BR/>(-26% to -13%)<BR/>
</P>
</TD>
<TD>
<P>-18%<BR/>(-30% to -5%)</P>
</TD>
<TD>
<P>-16%<BR/>(-36% to 5%)<BR/>
</P>
</TD>
<TD>
<P>-14%<BR/>(-51% to 23%)<BR/>
</P>
</TD>
<TD>
<P>Price year not specified in study papers</P>
</TD>
</TR>
<TR>
<TD>
<P>Nitrates</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>Nitrates. Pharmacare expenditures per 100,000 senior citizens. Canadian dollar per month</P>
</TD>
<TD>
<P>-66,473 (-72,620 to -60,326)</P>
</TD>
<TD>
<P>-50% (-55% to -46%)</P>
</TD>
<TD>
<P>-47% (-52% to -41%)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Price year not specified in study papers</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>
</P>
</TD>
<TD>
<P>NSAIDs (RP 1)</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>Average monthly expenditure per day of therapy dispensed (Canadian dollars 2004) for Pharmacare (Ph) and Patient (Pa)</P>
</TD>
<TD>
<P>Ph:-0.08 (-0.12 to -0.04)</P>
<P>Pa: 0.00 (-0.03 to 0.02)</P>
</TD>
<TD>
<P>Ph: -9.6%</P>
<P>(95% CI NA)</P>
<P>Pa: NA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Ph: -8.8% (95% CI NA)</P>
<P>Pa: 690% (95% CI NA)</P>
</TD>
<TD>
<P>Ph: -8.3% (95% CI NA)</P>
<P>Pa: 571% (95% CI NA)</P>
</TD>
<TD>
<P>Last estimated effect at 19 months</P>
</TD>
</TR>
<TR>
<TD>
<P>NSAIDs (RP 2)</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>Average monthly expenditure per day of therapy dispensed (Canadian dollars 2004) for Pharmacare (Ph) and Patient (Pa)</P>
</TD>
<TD>
<P>Ph:-0.31 (-0.36 to -0.27)</P>
<P>Pa: 0.07 (0.04 to 0.10)</P>
</TD>
<TD>
<P>Ph: -37% (95% CI NA)</P>
<P>Pa: 550% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Ph: -53% (95% CI NA)</P>
<P>Pa: 500% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>*</P>
</TD>
<TD>
<P>H2RAs</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>H2RAs. Pharmacare expenditures per 100000 senior citizens. Canadian dollar per month</P>
</TD>
<TD>
<P>-45,139<BR/>(-50,096 to -40,183)<BR/>
</P>
</TD>
<TD>
<P>-39%<BR/>(-44% to -35%)<BR/>
</P>
</TD>
<TD>
<P>-38%<BR/>(-44% to -31%)<BR/>
</P>
</TD>
<TD>
<P>-35%<BR/>(-45% to -25%)<BR/>
</P>
</TD>
<TD>
<P>-30%<BR/>(-48% to -12%)<BR/>
</P>
</TD>
<TD>
<P>Price year not specified in study papers</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>
</P>
</TD>
<TD>
<P>ACE inhibitors</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>All ACE inhibitors. Drug plan expenditures per DDD dispensed. CAD</P>
</TD>
<TD>
<P>-0.04 (-0.09 to 0.02)</P>
</TD>
<TD>
<P>-4% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-7% (95% CI NA)</P>
</TD>
<TD>
<P>-11% (95% CI NA)</P>
</TD>
<TD>
<P>Price specified in study papers</P>
</TD>
</TR>
<TR>
<TD>
<P>CCBs</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>All CCBs. Drug plan expenditures per DDD dispensed. CAD</P>
</TD>
<TD>
<P>-0.20</P>
<P>(-0.25 to -0.15)</P>
</TD>
<TD>
<P>-16% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-10% (95% CI NA)</P>
</TD>
<TD>
<P>-4% (95% CI NA)</P>
</TD>
<TD>
<P>Price year not specified in study papers</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK>
</P>
</TD>
<TD>
<P>52 dosage forms of 25 multisource chemical entities</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>Monthly Medicaid drug expenditures in Maryland. USD</P>
</TD>
<TD>
<P>-291276<BR/>(-478,458 to -104,094)<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.87 per month (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Price year not specified in study papers</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>
</P>
</TD>
<TD>
<P>The RP covered six chemical substances: Citalopram, Omeprazol, Cetirizin, Loratadin, Enalapril and Lisinopril . The system was later extended with two additional substances; simvastatin and amlodipin</P>
</TD>
<TD>
<P>Cost share drugs</P>
</TD>
<TD>
<P>Change in copayments NOK</P>
</TD>
<TD>
<P>Generic copayment -12.92 (95% CI NA)</P>
<P/>
<P>Brand-name copayment -6.37 (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Generic copayment -12.76% (95% CI NA)</P>
<P/>
<P>Brand-name copayment -14.82% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Results from reanalysis by reviewers.</P>
<P>**NA = Not available.</P>
<P>***<B>EFFECTS ON EXPENDITURES OF:</B>
</P>
<P>
<B>Reference drugs</B>, drugs that determine the reference price level. There is no cost share by the patients for these drugs, which are fully reimbursed. The expectation is that reference pricing will lead to an increase in use of these drugs.<BR/>
<B>Cost share drugs</B>, drugs in the same group as the reference drugs that cost more. Patients have to pay the difference between reference price drugs and the price of these drugs. The expectation is that reference pricing will lead to a decrease in use of these drugs.</P>
<P>
<B>Reference drugs + cost share drugs</B>, both the reference drugs and the cost share drugs. The expectation is that reference pricing will lead to little or no change in the overall use of these drugs.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-09-22 12:36:04 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-09-18 15:39:19 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Abbreviations</TITLE>
<TABLE COLS="2" ROWS="20">
<TR>
<TH>
<P>Abbreviations</P>
</TH>
<TH>
<P>Complete name</P>
</TH>
</TR>
<TR>
<TD>
<P>ACE</P>
</TD>
<TD>
<P>Angiotensin converting enzyme</P>
</TD>
</TR>
<TR>
<TD>
<P>ARIMA</P>
</TD>
<TD>
<P>Autoregressive integrated moving average</P>
</TD>
</TR>
<TR>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>Controlled before and after</P>
</TD>
</TR>
<TR>
<TD>
<P>CCB</P>
</TD>
<TD>
<P>Dihydropyridine channel blocker</P>
</TD>
</TR>
<TR>
<TD>
<P>CRM</P>
</TD>
<TD>
<P>Controlled repeated measures</P>
</TD>
</TR>
<TR>
<TD>
<P>EPOC</P>
</TD>
<TD>
<P>Effective Practice and Organisation of Care</P>
</TD>
</TR>
<TR>
<TD>
<P>H2RA</P>
</TD>
<TD>
<P>Histamine-2 receptor antagonist</P>
</TD>
</TR>
<TR>
<TD>
<P>INN</P>
</TD>
<TD>
<P>International non-proprietary name</P>
</TD>
</TR>
<TR>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>Interrupted time series</P>
</TD>
</TR>
<TR>
<TD>
<P>OECD</P>
</TD>
<TD>
<P>Organisation for Economic Co-operation and Development</P>
</TD>
</TR>
<TR>
<TD>
<P>PPI</P>
</TD>
<TD>
<P>Proton pump inhibitors</P>
</TD>
</TR>
<TR>
<TD>
<P>PPRS</P>
</TD>
<TD>
<P>Pharmaceutical Price Regulation Scheme</P>
</TD>
</TR>
<TR>
<TD>
<P>RCT</P>
</TD>
<TD>
<P>Randomised controlled trial</P>
</TD>
</TR>
<TR>
<TD>
<P>RM</P>
</TD>
<TD>
<P>Repeated measures</P>
</TD>
</TR>
<TR>
<TD>
<P>ROR</P>
</TD>
<TD>
<P>Rate of return</P>
</TD>
</TR>
<TR>
<TD>
<P>RP</P>
</TD>
<TD>
<P>Reference pricing</P>
</TD>
</TR>
<TR>
<TD>
<P>RR</P>
</TD>
<TD>
<P>Risk ratio (intervention vs control group)</P>
</TD>
</TR>
<TR>
<TD>
<P>RR (adj)</P>
</TD>
<TD>
<P>Risk ratio (adjusted for pre-intervention differences) = RR post-intervention/RR pre-intervention</P>
</TD>
</TR>
<TR>
<TD>
<P>WHO</P>
</TD>
<TD>
<P>World Health Organization</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-09-22 12:36:04 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-04-17 16:17:22 +0200" MODIFIED_BY="[Empty name]">Intervention description</TITLE>
<TABLE COLS="4" ROWS="23">
<TR>
<TH>
<P>STUDY ID / INTERVENTION PERIOD IN STUDY</P>
</TH>
<TH>
<P>DRUGS INCLUDED IN ANALYSIS</P>
</TH>
<TH>
<P>INTENSITY AND INCENTIVES</P>
</TH>
<TH>
<P>EXEMPTIONS</P>
</TH>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>POLICY: REFERENCE PRICING</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Aronsson-2001" TYPE="STUDY">Aronsson 2001</LINK>
</P>
<P>1993-1996</P>
</TD>
<TD>
<P>12 different brand drugs: cimetidine, furosemide, atenolol, pindolol, propranolol, indomethacin, naproxen, allopurinol, paracetamol/codeine, diazepam, clomipramine, timolol</P>
</TD>
<TD>
<P>Reference price: 10% above the price of the least expensive generic substitute</P>
</TD>
<TD>
<P>No information provided</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>
</P>
<P>2003</P>
</TD>
<TD>
<P>Drugs included in the analysis: brand-names and generics and pharmaceutical expenditures</P>
</TD>
<TD>
<P>Under a reference pricing (RP) system, firms are free to set drug prices, but patient copayment is based on a RP, that is set by a regulator.More specifically, if a consumer chooses a drug that is priced higher than the RP, she has to pay the full difference between the RP and the actual drug price. Usually, the RP is set at a level somewhere between the lowest and highest drug price in the market.</P>
</TD>
<TD>
<P>No information provided</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>
</P>
<P>For nitrates: October/November 1995 to May 1999 (March 1998 for some outcomes). For ACE inhibitors and CCBs: January 1997 to March 1998</P>
</TD>
<TD>
<P>Nitrates (used for stable angina) for long term prophylaxis, ACE inhibitors (used for hypertension, congestive heart failure and diabetic nephropathy) and dihydropyridine CCBs (used for hypertension and stable angina)</P>
</TD>
<TD>
<P>Reference price: Nitrates: Price of lowest priced regular-release ISDN. ACE inhibitors and dihydropyridine CCBs: A fixed cost per 30 day supply. Incentives for physicians to prescribe lower dosages to not exceed monthly cap. Costs for the least-expensive captopril, quinapril, and ramipril preparations available in pharmacies were covered. For other ACE inhibitors (enalapril, lisinopril, fosinopril, cilazapril, benazepril) patients were required to pay the difference, ranging from 2 to 62 Canadian Dollars per monthly supply. Reference prices in Canadian Dollar per 30 day supply were about 11 for H2RAs, 31 for dCCBs, 4 for nitrates and 27 for ACE inhibitors. Price year not reported.</P>
</TD>
<TD>
<P>Special authority exemptions*: Nitrates, ACE inhibitors, CCBs. Therapeutic trial exemptions**: ACE inhibitors, CCBs. Automatic exemptions: Users of asthma or diabetes drugs: ACE inhibitors, CCBs. Residents of long term facilities: Nitrates. Prescriptions dispensed by specific specialists: CCBs, Nitrates. Some transdermal nitroglycerin patches were exempted from the reference pricing from January 1996 and March 1996. Suffciently low doses (not exceeding reference price for 30 day supply) were exempted from the reference pricing: ACE inhibitors, CCBS, nitrates (after September 1, 1998).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>
</P>
<P>Pharmacare introduced two different forms of RP to the NSAIDs, Type 1 in April 1994 and Type 2 in November 1995</P>
<P/>
</TD>
<TD>
<P>Drug class NSAIDs</P>
</TD>
<TD>
<P>Under the policy, the less costly 'unrestricted' NSAIDs, enteric-coated acetylsalicylic acid (ASA) (650 mg), ibuprofen, and naproxen remained fully reimbursed (at an average rate of about $0.23 daily). Pharmacare also began to reimburse acetaminophen (500 mg). The decision to provide full reimbursement for acetaminophen, ASA, ibuprofen, and naproxen was consistent with earlier recommendations by an independent academic research group, the BC Therapeutics Initiative, that these drugs be used as first line therapy for osteoarthritis (Therapeutics Initiative 1995).</P>
</TD>
<TD>
<P>Patients intolerant of unrestricted NSAIDS or with specific diagnoses (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, collagen vascular disease, or gout) were eligible for exemption from the policy. Exemption for a &#8216;&#8216;second line restricted&#8217;&#8217; NSAID (nabumetone, piroxicam, tenoxicam, tiaprofenic acid, to- lmetin, sulindac, ketorolac, or diclofenac potassium) required failure on a first line restricted NSAID.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>
</P>
<P>Jan 1994 to December 2000</P>
</TD>
<TD>
<P>ACE inhibitors and CCBs</P>
</TD>
<TD>
<P>Reference pricing (RP) limits drug plan reimbursement of interchangeable medicines to a reference price, which is typically equal to the price of the lowest-cost interchangeable drug.</P>
</TD>
<TD>
<P>Under the RP policy, Pharmacare reimbursement of the ACE inhibitors enalapril, lisinopril, fosinopril, cilazapril, and benazepril was limited to $27 per month; the lower-cost ACE inhibitors, captopril, quinapril, and ramipril remained fully reimbursed. Reimbursement of the dihydropyridine CCBs nifedipine, nicardipine and amlodipine was limited to $31 per month; felodipine remained fully reimbursed. Also, reimbursement of the sustained release forms of the CCBs diltiazem and verapamil was limited to the price of regular release versions of the equivalent dosage sizes of the same drugs. Beneficiaries who required a higher-cost anti- hypertensive for medical reasons could be exempted from RP upon written petition by the physician.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK> October 1995 to</P>
<P>March 1996</P>
</TD>
<TD>
<P>Histamine2 receptor antagonists</P>
</TD>
<TD>
<P>Reference prices per 30 day supply were about 11 Canadian dollars for H2RAs (See <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>), lowest priced H2RA available. Special authority restrictions for reimbursement of PPIs, made H2RAs more attractive.</P>
</TD>
<TD>
<P>Special authority exemptions*. Exemptions for low doses</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>
</P>
<P>2003</P>
</TD>
<TD>
<P>1. Antihypertensive drugs</P>
<P>2. Antihyperlipidemic drugs</P>
<P>3. Generic drugs</P>
<P>4. Brand-name drugs</P>
</TD>
<TD>
<P>The maximum allowable cost is a ceiling price set for generic and multisource brands that are chemically equivalent and have the same active ingredients (generic substitutes). Maximum allowable cost is similar to reference pricing used in Canada, which extends the concept of drug interchangeability to include chemically related<BR/>active ingredients that are pharmacologically equivalent (therapeutic substitutes).Instituting maximum allowable cost is the only policy designed to directly reduce the cost of generic drugs by limiting the amount that Medicaid can reimburse pharmacies.</P>
</TD>
<TD>
<P>No information provided</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>
</P>
<P>October 1995 to May 1999</P>
</TD>
<TD>
<P>Histamine2 receptor antagonists</P>
</TD>
<TD>
<P>See <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>
</P>
</TD>
<TD>
<P>See <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-McManus-2001" TYPE="STUDY">McManus 2001</LINK> June 1997 to December 1997</P>
</TD>
<TD>
<P>Ranitidine</P>
</TD>
<TD>
<P>The policy operated where there was more than one brand of a drug available through the Pharmaceutical Benefit Scheme and where the brands where therapeutically interchangeable. Generic substitution allowed. Premium on original brand Ranitidine 150 mg and 300 mg: $0,71 in May 1997. Price year not reported.</P>
</TD>
<TD>
<P>No information provided</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>
</P>
<P>December 2000</P>
<P/>
</TD>
<TD>
<P>This system was applied to products with the same active ingredient, pharmaceutical form, dosage and number of units for which there was at least one generic</P>
</TD>
<TD>
<P>For each group, a reference price was calculated as the weighted average selling price of the cheapest drug accounting for at least 20% of the market. This system established the maximum price that could be reimbursed by the NHS for any version of the same drug.</P>
</TD>
<TD>
<P>No information provided</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK>
</P>
<P>October 1995 to November 1996</P>
</TD>
<TD>
<P>Histamine2 receptor antagonists</P>
</TD>
<TD>
<P>See <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>
</P>
</TD>
<TD>
<P>See <LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pavcnik-2002" TYPE="STUDY">Pavcnik 2002</LINK>
</P>
<P>Oral antidiabetics: The first batch of reference pricing: 1989 to 1996 The second batch of reference pricing: 1994 to 1996 Anti-ulcer drugs 1992 to 1996</P>
</TD>
<TD>
<P>Oral antidiabetics and anti-ulcer drugs</P>
</TD>
<TD>
<P>No information provided</P>
</TD>
<TD>
<P>No information provided</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>
</P>
<P>January 2001 to October 2004</P>
</TD>
<TD>
<P>Oral HMG-CoA reductase inhibitors (statins): atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin and cerivastatin</P>
</TD>
<TD>
<P>Reference pricing (RP) is a reimbursement policy that sets a maximum allowable cost that will be covered,RP systems can be grouped into different levels according to drug interchangeability. In September 2001 the Andalusian Public Health Service (henceforth APHS) introduced a new pharmaceutical procurement mechanism based on a more &#8220;intensive&#8221; RP system, including maximum prices.</P>
<P/>
<P>The previous situation was characterized by the absence of incentives to prescribe lower-cost drugs with the same active ingredient, and by the absence of incentives for brand firms to lower prices even in the presence of lower-priced generics.<BR/>
<BR/>Seasonal fluctuations were controlled by including a term for August in the regression model. Seasonal variation is observed in the monthly periods resulting in a significant decrease during summer holidays (August).</P>
</TD>
<TD>
<P>No information provided</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK>
</P>
<P>September 1976 to October 1979</P>
</TD>
<TD>
<P>52 dosage forms of 25 multisource chemical entities, including ampicillin, chlordiazepoxide HCL(Librium), penicillin VK, propoxyphene HCL (Darvon) and tetracykline</P>
</TD>
<TD>
<P>State of Maryland used Maximum Allowable Costs - Estimated Acquisition Costs (MAC-EAC) procedures to reimburse community pharmacists for outpatient drugs dispensed to Medicaid patients. Maryland pharmacies billed Medicaid their usual and customary charges to the general public. Medicaid officials then determined the allowable cost for each claim by comparing billed charges against the appropriate MAC and/or EAC limits. Pharmacies were reimbursed the lowest established level (+ the flat dispensing fee).</P>
</TD>
<TD>
<P>No information provided</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK> January 1997 - April 1998 (for the outcome drug use)</P>
</TD>
<TD>
<P>ACE inhibitors</P>
</TD>
<TD>
<P>See <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>
</P>
</TD>
<TD>
<P>See <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK> January 1997 to April 1998</P>
</TD>
<TD>
<P>CCBs</P>
</TD>
<TD>
<P>See <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>
</P>
</TD>
<TD>
<P>See <LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>
</P>
<P>January 2003 to December 2006</P>
</TD>
<TD>
<P>Atorvastatin and other statins</P>
</TD>
<TD>
<P>Reference pricing has been the subject of great debate since its introduction in Germany in 1989, the inclusion of statins was on 1 January 2005.</P>
<P/>
<P>Atorvastatin was classified as a &#8216;&#8216;me-too&#8217;&#8217; drug and grouped with other statins, including generics. Additional co-payments due to reference pricing for atorvastatin ranged from &#8364; 18.17 per package (30 mg/30 units) to &#8364; 109.00 per package (80 mg/100 units). As a result, pre- policy users of atorvastatin had to decide whether to switch to another statin to avoid additional co-payments or to pay the difference between the price of atorvastatin and its reference pricing.</P>
<P/>
</TD>
<TD>
<P/>
<P>In contrast to reference pricing in British Columbia, the German reference pricing system does not allow requests for exemption on a case-by-case basis, nor does it allow specific subgroups of patients to be excluded from the scheme</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>POLICY: INDEX PRICING</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>
</P>
<P>1998-2003</P>
</TD>
<TD>
<P>Six groups of active substances: cetirizin (treatment of allergy), citalopram (antidepressant), enalapril (antihypertensive), lisinopril (antidepressant), loratadin (treatment of allergy) and omeprazol (treatment of gastro-intestinal disorders)</P>
</TD>
<TD>
<P>The levels of index prices relative to the prices of substitute drugs were not reported by the authors.</P>
</TD>
<TD>
<P>When prescribing physician proscribes substitution of a generic in pharmacies</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>POLICY: MAXIMUM PRICES</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>
</P>
<P>2004</P>
</TD>
<TD>
<P>Oral HMG-CoA reductase inhibitors (statins): atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin and cerivastatin</P>
</TD>
<TD>
<P>In September 2001 the Andalusian Public Health Service (henceforth APHS) introduced a new pharmaceutical procurement mechanism based on a more &#8220;intensive&#8221; RP system, including maximum prices. In the APHS the reference price level is set at the level of the higher price of the two lowest-priced products for each active ingredient with the same package size and dose strength. This system only works when and if physicians prescribe the active ingredient of the product. The pharmacies agreed with the regional government to dispense the lowest-priced product for each active ingredient, independently of its generic status. In addition, economic incentives were introduced for physicians to prescribe using the non-commercial name of the active ingredient.</P>
</TD>
<TD>
<P>No information reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Pharmacare may give special authority exemptions, based on therapeutic reasons provided by the physician in an application. Special authority exemptions were valid indefinitely for ACE inhibitors, CCBs and nitrates (after January 21, 1997) users. See Grootendorst 2002.</P>
<P>** The physicians may apply for therapeutic trial exemptions in cases of intolerance or treatment failure or if the patient is frail. See Grootendorst 2002.</P>
<P>*** In British Columbia Pharmacare covers all prescription drug costs for seniors with a dispensing deductible fee of CAD 200. Others can obtain similar coverage, but must pay a monthly.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2014-09-18 15:39:37 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE>Factors that could modify the effects of reference drug pricing</TITLE>
<TABLE COLS="3" ROWS="7">
<TR>
<TH>
<P>FACTOR</P>
</TH>
<TH>
<P>CONDITION</P>
</TH>
<TH>
<P>POTENTIAL EFFECTS OF CONDITIONS NOT FULFILLED</P>
</TH>
</TR>
<TR>
<TD>
<P>Equivalence of drugs</P>
</TD>
<TD>
<P>The drugs in the reference drug group should be therapeutically similar. If they are not, the patients may have to pay more to get the most effective drug - or they may choose less effective drugs</P>
</TD>
<TD>
<P>Drug use: Less shift towards cheaper drugs<BR/>Health: Decrease<BR/>Healthcare utilisation: Increase<BR/>Patient drug expenditures: Increased<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Incentives</P>
</TD>
<TD>
<P>Adequate incentives for patients, physicians, pharmacists and pharmaceutical companies to comply with the reference price system</P>
</TD>
<TD>
<P>Drug use: Less shift towards cheaper drugs<BR/>Drug expenditures: Less savings<BR/>Drug prices: Less reductions<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Exemptions</P>
</TD>
<TD>
<P>Reasonable mechanisms for exemptions for patients that need such for medical reasons. Too limited exemptions could lead to higher co-payments of the most effective drug and to prescribing of less effective drugs by physicians. Too generous exemptions could reduce the savings, by not shifting the drug use towards cheaper drugs</P>
</TD>
<TD>
<P>Drug use: Less shift towards cheaper drugs<BR/>Health: Decrease<BR/>Healthcare utilisation: Increase<BR/>Patient drug expenditures: Increased<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Availability of drugs</P>
</TD>
<TD>
<P>The reference drugs and other cheap drug choices of the reference groups should be available. If not, more expensive drugs would be used</P>
</TD>
<TD>
<P>Drug expenditures: Less savings<BR/>Drug prices: Less reductions<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Price levels</P>
</TD>
<TD>
<P>To achieve savings there should be significant price differences between the drugs in a reference group before the reference price system is introduced, with relatively high prices on the drugs most used</P>
</TD>
<TD>
<P>Drug expenditures: Less savings<BR/>Drug prices: Less reductions<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Electronic information systems</P>
</TD>
<TD>
<P>The administration costs, like time use for identifying, prescribing and dispensing the reference drugs and for handling exemption cases should be as low as possible. An electronic processing system would be useful and potentially time saving</P>
</TD>
<TD>
<P>Drug use: Less shift towards cheaper drugs<BR/>Drug expenditures: Less savings<BR/>Drug prices: Less reductions<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2014-09-18 15:40:15 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2014-04-17 20:06:51 +0200" MODIFIED_BY="[Empty name]">Reference pricing versus no reference pricing: Cumulative drug expenditures</TITLE>
<TABLE COLS="10" ROWS="9">
<TR>
<TH>
<P>STUDY ID</P>
</TH>
<TH>
<P>POLICY: REFERENCE PRICE FOR</P>
</TH>
<TD>
<P>
<B>EFFECTS ON CUMULATIVE EXPENDITURES OF****</B>
</P>
</TD>
<TH>
<P>OUTCOME</P>
</TH>
<TH>
<P>ABSOLUTE CUMULATIVE DRUG EXPENDITURES, 1/2 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CUMULATIVE DRUG EXPENDITURES, 1/2 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>ABSOLUTE CUMULATIVE DRUG EXPENDITURES, 1 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CUMULATIVE DRUG EXPENDITURES, 1 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>ABSOLUTE CUMULATIVE DRUG EXPENDITURES, 2 YEARS AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CUMULATIVE DRUG EXPENDITURES, 2 YEARS AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>*</P>
</TD>
<TD>
<P>ACE inhibitors</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>ACE inhibitors. Pharmacare expenditure per 100,000 senior citizens. Canadian dollar per month</P>
</TD>
<TD>
<P>68554<BR/>(17,064 to 154,173)</P>
</TD>
<TD>
<P>3%<BR/>(1% to 7%)</P>
</TD>
<TD>
<P>144,630<BR/>(18,603 to 270,657)</P>
</TD>
<TD>
<P>3%<BR/>(0% to 6%)</P>
</TD>
<TD>
<P>153,191<BR/>(35,666 to 342,047)</P>
</TD>
<TD>
<P>2%<BR/>(0% to 4%)</P>
</TD>
</TR>
<TR>
<TD>
<P>CCBs</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>CCBs. Pharmacare expenditure per 100,000 senior citizens. Canadian dollar per month</P>
</TD>
<TD>
<P>-511,506<BR/>(-687,351 to -335,661)</P>
</TD>
<TD>
<P>-18%<BR/>(-25% to -12%)</P>
</TD>
<TD>
<P>-1,002,907<BR/>(-1,308,322 to -697,481)</P>
</TD>
<TD>
<P>-18%<BR/>(-24% to -13%)</P>
</TD>
<TD>
<P>-1,786,163<BR/>(-2,381,513 to -1,190,812)</P>
</TD>
<TD>
<P>-16%<BR/>(-22% to -11%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Nitrates</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>Nitrates. Pharmacare expenditures per 100,000 senior citizens. Canadian dollar per month</P>
</TD>
<TD>
<P>-390,230 (-422,501 to -357,958)</P>
</TD>
<TD>
<P>-48%</P>
<P>(-52% to -44%)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>*</P>
</TD>
<TD>
<P>H2RAs</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>H2RAs. Pharmacare expenditures per 100,000 senior citizens. Canadian dollar per month</P>
</TD>
<TD>
<P>-261,347<BR/>(-292,070 to -230,623)</P>
</TD>
<TD>
<P>-38%<BR/>(-43% to -34%)</P>
</TD>
<TD>
<P>-482,978<BR/>(-529,961 to -435,995)</P>
</TD>
<TD>
<P>-36%<BR/>(-40% to -33%)</P>
</TD>
<TD>
<P>-882,353<BR/>(-957,349 to -807,356)</P>
</TD>
<TD>
<P>-34%<BR/>(-37% to -31%)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>
</P>
<P/>
</TD>
<TD>
<P>lovastatin</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P/>
<P/>
<P>Mean monthly savings of total lovastatin sales (%)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P/>
<P/>
<P/>
<P/>
<P/>
<P>Not reported</P>
<P/>
<P/>
<P/>
<P/>
</TD>
<TD>
<P>10 months after intervention attributed to the RP revision applied (January 2004 &#8211; October 2004):</P>
<P>Rest of Spain</P>
<P>-16.3% (&#8722;23.4 to &#8722;9.1)</P>
<P>Andalusia -11.5% (-3.5% to -19.5%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Simvastatin</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>Mean monthly savings of total simvastatin sales (%)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>After intervention attributed to the initial application of RP to lovastatin (May 2002 &#8211; April 2003):</P>
<P/>
<P>Rest of Spain:</P>
<P>16.7% (13.0% to 20.4%) of total lovastatin sales representing only 1.1% (0.9% to 1.3%) of total statins sales</P>
<P>Andalusia: 23.7% (18.3% to 29.0%) representing only 1.3% (0.4% to 1.0%) of total statins sales</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>10 months after intervention attributed to the RP revision applied (January 2004 &#8211; October 2004):</P>
<P>Rest of Spain</P>
<P>-51.8% (-48.9% to -54.6%)</P>
<P>Andalusia: -29.7% (-26.8% to -32.6%),</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>
</P>
</TD>
<TD>
<P>1. Antihypertensive drugs</P>
<P>2. Antihyperlipidaemic drugs</P>
<P>3. Generic drugs</P>
<P>4. Brand-name drugs</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs***</P>
</TD>
<TD>
<P>Total cumulative drug expenditures (USD)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1: $18,562<BR/>(-$93 to $37,217)<BR/>2: $15,322<BR/>(-$30,452 to<BR/>$61,096)<BR/>3: -$35,448<BR/>(-$50,470 to -$20,425)<BR/>4: $69,331<BR/>($21,553 to<BR/>$117,109)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>
</P>
</TD>
<TD>
<P>All pharmaceuticals financed by the public sector in Catalonia</P>
</TD>
<TD>
<P/>
<P>Total market</P>
</TD>
<TD>
<P>Saving per insured person</P>
</TD>
<TD>
<P>EUR -4.06 (95% CI NA)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-1.54% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Results from reanalysis by reviewers. Negative values represent cost savings and positive values are cost increases.</P>
<P>**NA = Not available.</P>
<P>***Reference drugs (generic drugs) + cost share drugs (brand names).</P>
<P>****<B>EFFECTS ON CUMULATIVE EXPENDITURES OF:</B>
</P>
<P>
<B>Reference drugs</B>,<B>:</B> drugs that determine the reference price level. There is no cost share by the patients for these drugs, which are fully reimbursed. The expectation is that reference pricing will lead to an increase in use of these drugs.<BR/>
<B>Cost share drugs</B>, drugs in the same group as the reference drugs that cost more. Patients have to pay the difference between reference price drugs and the price of these drugs. The expectation is that reference pricing will lead to a decrease in use of these drugs.</P>
<P>
<B>Reference drugs + cost share drugs</B>, both the reference drugs and the cost share drugs. The expectation is that reference pricing will lead to little or no change in the overall use of these drugs.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2014-09-18 16:01:25 +0200" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2014-09-18 16:01:25 +0200" MODIFIED_BY="[Empty name]">Reference pricing versus no reference pricing: drug expenditures</TITLE>
<TABLE COLS="10" ROWS="13">
<TR>
<TH>
<P>STUDY ID</P>
</TH>
<TH>
<P>REFERENCE PRICE FOR</P>
</TH>
<TD>
<P>
<B>EFFECTS ON EXPENDITURES OF***</B>
</P>
</TD>
<TH>
<P>OUTCOME</P>
</TH>
<TH>
<P>ABSOLUTE CHANGE LEVEL, IMMEDIATE AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, IMMEDIATE AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, 1/2 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, 1 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, 2 YEARS AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>NOTES</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>*</P>
</TD>
<TD>
<P>ACE inhibitors</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>ACE inhibitors. Pharmacare expenditure per 100,000 senior citizens. Canadian dollar per month</P>
</TD>
<TD>
<P>18,203<BR/>(-1611 to 38,017)<BR/>
</P>
</TD>
<TD>
<P>5%<BR/>(0% to 10%)<BR/>
</P>
</TD>
<TD>
<P>5%<BR/>(-2% to 10%)</P>
</TD>
<TD>
<P>4%<BR/>(-3% to 10%)<BR/>
</P>
</TD>
<TD>
<P>1%<BR/>(-8% to 9%)<BR/>
</P>
</TD>
<TD>
<P>Price year not specified in study papers</P>
</TD>
</TR>
<TR>
<TD>
<P>CCBs</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>CCBs. Pharmacare expenditure per 100,000 senior citizens. Canadian dollar per month</P>
</TD>
<TD>
<P>-91,547<BR/>(-122,082 to -61,011)<BR/>
</P>
</TD>
<TD>
<P>-19%<BR/>(-26% to -13%)<BR/>
</P>
</TD>
<TD>
<P>-18%<BR/>(-30% to -5%)</P>
</TD>
<TD>
<P>-16%<BR/>(-36% to 5%)<BR/>
</P>
</TD>
<TD>
<P>-14%<BR/>(-51% to 23%)<BR/>
</P>
</TD>
<TD>
<P>Price year not specified in study papers</P>
</TD>
</TR>
<TR>
<TD>
<P>Nitrates</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>Nitrates. Pharmacare expenditures per 100,000 senior citizens. Canadian dollar per month</P>
</TD>
<TD>
<P>-66,473 (-72,620 to -60,326)</P>
</TD>
<TD>
<P>-50% (-55% to -46%)</P>
</TD>
<TD>
<P>-47% (-52% to -41%)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Price year not specified in study papers</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>
</P>
</TD>
<TD>
<P>NSAIDs (RP 1)</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>Average monthly expenditure per day of therapy dispensed (Canadian dollars 2004) for Pharmacare (Ph) and Patient (Pa)</P>
</TD>
<TD>
<P>Ph:-0.08 (-0.12 to -0.04)</P>
<P>Pa: 0.00 (-0.03 to 0.02)</P>
</TD>
<TD>
<P>Ph: -9.6%</P>
<P>(95% CI NA)</P>
<P>Pa: NA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Ph: -8.8% (95% CI NA)</P>
<P>Pa: 690% (95% CI NA)</P>
</TD>
<TD>
<P>Ph: -8.3% (95% CI NA)</P>
<P>Pa: 571% (95% CI NA)</P>
</TD>
<TD>
<P>Last estimated effect at 19 months</P>
</TD>
</TR>
<TR>
<TD>
<P>NSAIDs (RP 2)</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>Average monthly expenditure per day of therapy dispensed (Canadian dollars 2004) for Pharmacare (Ph) and Patient (Pa)</P>
</TD>
<TD>
<P>Ph:-0.31 (-0.36 to -0.27)</P>
<P>Pa: 0.07 (0.04 to 0.10)</P>
</TD>
<TD>
<P>Ph: -37% (95% CI NA)</P>
<P>Pa: 550% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Ph: -53% (95% CI NA)</P>
<P>Pa: 500% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Marshall-2002" TYPE="STUDY">Marshall 2002</LINK>*</P>
</TD>
<TD>
<P>H2RAs</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>H2RAs. Pharmacare expenditures per 100000 senior citizens. Canadian dollar per month</P>
</TD>
<TD>
<P>-45,139<BR/>(-50,096 to -40,183)<BR/>
</P>
</TD>
<TD>
<P>-39%<BR/>(-44% to -35%)<BR/>
</P>
</TD>
<TD>
<P>-38%<BR/>(-44% to -31%)<BR/>
</P>
</TD>
<TD>
<P>-35%<BR/>(-45% to -25%)<BR/>
</P>
</TD>
<TD>
<P>-30%<BR/>(-48% to -12%)<BR/>
</P>
</TD>
<TD>
<P>Price year not specified in study papers</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>
</P>
</TD>
<TD>
<P>ACE inhibitors</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>All ACE inhibitors. Drug plan expenditures per DDD dispensed. CAD</P>
</TD>
<TD>
<P>-0.04 (-0.09 to 0.02)</P>
</TD>
<TD>
<P>-4% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-7% (95% CI NA)</P>
</TD>
<TD>
<P>-11% (95% CI NA)</P>
</TD>
<TD>
<P>Price specified in study papers</P>
</TD>
</TR>
<TR>
<TD>
<P>CCBs</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>All CCBs. Drug plan expenditures per DDD dispensed. CAD</P>
</TD>
<TD>
<P>-0.20</P>
<P>(-0.25 to -0.15)</P>
</TD>
<TD>
<P>-16% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-10% (95% CI NA)</P>
</TD>
<TD>
<P>-4% (95% CI NA)</P>
</TD>
<TD>
<P>Price year not specified in study papers</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sawyer-1983" TYPE="STUDY">Sawyer 1983</LINK>
</P>
</TD>
<TD>
<P>52 dosage forms of 25 multisource chemical entities</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>Monthly Medicaid drug expenditures in Maryland. USD</P>
</TD>
<TD>
<P>-291276<BR/>(-478,458 to -104,094)<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.87 per month (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Price year not specified in study papers</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>
</P>
</TD>
<TD>
<P>The RP covered six chemical substances: Citalopram, Omeprazol, Cetirizin, Loratadin, Enalapril and Lisinopril . The system was later extended with two additional substances; simvastatin and amlodipin</P>
</TD>
<TD>
<P>Cost share drugs</P>
</TD>
<TD>
<P>Change in copayments NOK</P>
</TD>
<TD>
<P>Generic copayment -12.92 (95% CI NA)</P>
<P/>
<P>Brand-name copayment -6.37 (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Generic copayment -12.76% (95% CI NA)</P>
<P/>
<P>Brand-name copayment -14.82% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Results from reanalysis by reviewers.</P>
<P>**NA = Not available.</P>
<P>***<B>EFFECTS ON EXPENDITURES OF:</B>
</P>
<P>
<B>Reference drugs</B>, drugs that determine the reference price level. There is no cost share by the patients for these drugs, which are fully reimbursed. The expectation is that reference pricing will lead to an increase in use of these drugs.<BR/>
<B>Cost share drugs</B>, drugs in the same group as the reference drugs that cost more. Patients have to pay the difference between reference price drugs and the price of these drugs. The expectation is that reference pricing will lead to a decrease in use of these drugs.</P>
<P>
<B>Reference drugs + cost share drugs</B>, both the reference drugs and the cost share drugs. The expectation is that reference pricing will lead to little or no change in the overall use of these drugs.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2014-09-18 16:00:32 +0200" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2014-09-18 16:00:32 +0200" MODIFIED_BY="[Empty name]">Reference pricing versus no reference pricing: drug use</TITLE>
<TABLE COLS="9" ROWS="32">
<TR>
<TH>
<P>STUDY ID</P>
</TH>
<TH>
<P>POLICY: REFERENCE PRICE FOR</P>
</TH>
<TD>
<P>
<B>EFFECTS ON USE OF******</B>
</P>
</TD>
<TH>
<P>OUTCOME</P>
</TH>
<TH>
<P>ABSOLUTE CHANGE IN LEVEL, IMMEDIATE AFTER TRANSMISSION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, IMMEDIATE AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, 1/2 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, 1 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>NOTES</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Grootendorst-2002" TYPE="STUDY">Grootendorst 2002</LINK>*</P>
</TD>
<TD>
<P>Nitrates</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>Reference standard nitrate prescriptions. Monthly number dispensed per 100,000 senior citizens</P>
</TD>
<TD>
<P>378 (353 to 404)</P>
</TD>
<TD>
<P>196% (183% to 209%)</P>
</TD>
<TD>
<P>163% (147% to 179%)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>
</P>
</TD>
<TD>
<P>NSAIDs (RP 1)*****</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>NSAIDs: Days therapy dispensed per 1000 seniors</P>
</TD>
<TD>
<P>-140.36 (-412.06 to 131.35)</P>
</TD>
<TD>
<P/>
<P>-6.2% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-13.5% (95% CI NA)</P>
</TD>
<TD>
<P>-17% at 19 months (95% CI NA)</P>
</TD>
</TR>
<TR>
<TD>
<P>NSAIDs (RP 2)*****</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>NSAIDs: Days therapy dispensed per 1000 seniors</P>
</TD>
<TD>
<P>-78.62 (-351.25 to 194.00)</P>
</TD>
<TD>
<P>-4% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>8.6% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Acetaminophen/Codeine (RP 1)</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>Days therapy dispensed per 1000 seniors</P>
</TD>
<TD>
<P>-32.26 (-137.18 to 72.66)</P>
</TD>
<TD>
<P/>
<P>-4% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-9.9% (95% CI NA)</P>
</TD>
<TD>
<P>-12% at 19 months</P>
<P>(95% CI NA)</P>
</TD>
</TR>
<TR>
<TD>
<P>Acetaminophen/Codeine (RP 2)</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>Days therapy dispensed per 1000 seniors</P>
</TD>
<TD>
<P>50.50 (-56.06 to 157.06)</P>
</TD>
<TD>
<P>7% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>20.7% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>
</P>
</TD>
<TD>
<P>ACE inhibitors</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>Days therapy dispensed per 1000 seniors</P>
</TD>
<TD>
<P>59 (-12 to 129)</P>
</TD>
<TD>
<P>43% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>166% (95% CI NA)</P>
</TD>
<TD>
<P>900% at two years (95% CI NA)</P>
</TD>
</TR>
<TR>
<TD>
<P>CCBs</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>Days therapy dispensed per 1000 seniors</P>
</TD>
<TD>
<P>29 (26 to 32)</P>
</TD>
<TD>
<P>40% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>50% (95% CI NA)</P>
</TD>
<TD>
<P>62% at two years (95% CI NA)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-McManus-2001" TYPE="STUDY">McManus 2001</LINK>*</P>
</TD>
<TD>
<P>Ranitidine</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>Days therapy dispensed per 1000 seniors</P>
</TD>
<TD>
<P>23,763 (18,503 to 29,022)</P>
</TD>
<TD>
<P>160% (124% to 195%)</P>
</TD>
<TD>
<P>137% (87% to 186%)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Ranitidine</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>Monthly ranitidine total prescriptions dispensed (GW, i.e. brand)</P>
</TD>
<TD>
<P>-50,977 (-87,278 to -14,676)</P>
</TD>
<TD>
<P>-19% (-32%, -5%)</P>
</TD>
<TD>
<P>-35% (-61% to -9%)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Narine-2001" TYPE="STUDY">Narine 2001</LINK>*</P>
</TD>
<TD>
<P>H2RAs</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>Cimetidine prescriptions reimbursed. Monthly total number</P>
</TD>
<TD>
<P>19,237 (17,944 to 20,530)</P>
</TD>
<TD>
<P>249% (232% to 265%)</P>
</TD>
<TD>
<P>251% (225% to 276%)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>H2RAs</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>H2 antagonist prescription reimbursed. Monthly total number</P>
</TD>
<TD>
<P>5206 (2975 to 7438)</P>
</TD>
<TD>
<P>13% (8%, 19%)</P>
</TD>
<TD>
<P>19% (11% to 28%)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hazlet-2002" TYPE="STUDY">Hazlet 2002</LINK>
</P>
</TD>
<TD>
<P>H2RAs</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>Mean monthly utilisation per DDD</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>no significant difference in slope pre- versus post-intervention (P=0.08)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>**</P>
</TD>
<TD>
<P>ACE inhibitors</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>Reference ACE inhibitors. Number of median monthly doses dispensed per 10,000 senior residents</P>
</TD>
<TD>
<P>275 (95% CI NA)</P>
</TD>
<TD>
<P>79% (95% CI NA)</P>
</TD>
<TD>
<P>87% (95% CI NA)</P>
</TD>
<TD>
<P>94% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>**</P>
</TD>
<TD>
<P>CCBs</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>Reference CCBs. Number of median monthly doses dispensed per 10,000 senior residents</P>
</TD>
<TD>
<P>87 (95% CI NA)</P>
</TD>
<TD>
<P>max 60% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>
</P>
</TD>
<TD>
<P>Statins. However price for atorvastatin higher than reference price</P>
</TD>
<TD>
<P>Reference drugs</P>
</TD>
<TD>
<P>Other statins than atorvastatin. Number of prescriptions</P>
</TD>
<TD>
<P>8425 (2721, 14129)</P>
</TD>
<TD>
<P>21.9% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>9% (95% CI NA)</P>
</TD>
<TD>
<P>0% at 2 years (95% CI NA)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>
</P>
</TD>
<TD>
<P>ACE inhibitors</P>
</TD>
<TD>
<P>Cost share drugs</P>
</TD>
<TD>
<P>Partly reimbursed ACE inhibitors. Defined daily doses dispensed per 100 seniors</P>
</TD>
<TD>
<P>-116 (-124 to -107)</P>
</TD>
<TD>
<P>-28% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-34% (95% CI NA)</P>
</TD>
<TD>
<P>-39% at two years (95% CI NA)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>
</P>
</TD>
<TD>
<P>CCBs</P>
</TD>
<TD>
<P>Cost share drugs</P>
</TD>
<TD>
<P>Partly reimbursed CCBs. Defined daily doses dispensed per 100 seniors</P>
</TD>
<TD>
<P>-65 (-77 to -53)</P>
</TD>
<TD>
<P>-17% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-17% (95% CI NA)</P>
</TD>
<TD>
<P>-18% at two years (95% CI NA)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>**</P>
</TD>
<TD>
<P>ACE inhibitors</P>
</TD>
<TD>
<P>Cost share drugs</P>
</TD>
<TD>
<P>Cost sharing ACE inhibitors. Number of median monthly doses dispensed per 10,000 senior residents.</P>
</TD>
<TD>
<P>-705 (95% CI NA)</P>
</TD>
<TD>
<P>-38 % (95% CI NA)</P>
</TD>
<TD>
<P>-41 % (95% CI NA)</P>
</TD>
<TD>
<P>-43 % (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>
</P>
</TD>
<TD>
<P>CCBs</P>
</TD>
<TD>
<P>Cost share drugs</P>
</TD>
<TD>
<P>Cost sharing CCBs. Number of median monthly doses dispensed per 10000 senior residents</P>
</TD>
<TD>
<P>-343 (95% CI NA)</P>
</TD>
<TD>
<P>-38 % (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>
</P>
</TD>
<TD>
<P>Statins (more expensive than RP atorvastatin)</P>
</TD>
<TD>
<P>Cost share drugs</P>
</TD>
<TD>
<P>Atorvastatin. Number of prescriptions</P>
</TD>
<TD>
<P>-14,788 (-16,694 to -12,882)</P>
</TD>
<TD>
<P>-81.2% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-87% (95% CI NA)</P>
</TD>
<TD>
<P>-90% at 2 years (95% CI NA)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stargardt-2010" TYPE="STUDY">Stargardt 2010</LINK>
</P>
</TD>
<TD>
<P>Statins. However price for atorvastatin higher than reference price</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>Total no of prescriptions</P>
</TD>
<TD>
<P>-7037 (-14,803 to 729)</P>
</TD>
<TD>
<P>-10.5% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-20% (95% CI NA)</P>
</TD>
<TD>
<P>-28% (95% CI NA)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Moreno_x002d_Torres-2011" TYPE="STUDY">Moreno-Torres 2011</LINK>
</P>
</TD>
<TD>
<P>All active ingredients</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>Prescription per capita</P>
<P>(Data from Fig. 1)</P>
</TD>
<TD>
<P>No changes</P>
</TD>
<TD>
<P>No changes</P>
</TD>
<TD>
<P>No changes</P>
</TD>
<TD>
<P>No changes</P>
</TD>
<TD>
<P>No changes from 1995 to 2006</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schneeweiss-2002" TYPE="STUDY">Schneeweiss 2002</LINK>**</P>
</TD>
<TD>
<P>ACE inhibitors</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>All ACE inhibitors. Number of median monthly doses dispensed per 10,000 senior residents</P>
</TD>
<TD>
<P>-225 (95% CI NA)</P>
</TD>
<TD>
<P>-11% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schneeweiss-2003" TYPE="STUDY">Schneeweiss 2003</LINK>**</P>
</TD>
<TD>
<P>CCBs</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>All CCBs. Number of median monthly doses dispensed per 10,000 senior residents</P>
</TD>
<TD>
<P>-80 (95% CI NA)</P>
</TD>
<TD>
<P>-9% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Grootendorst-2006" TYPE="STUDY">Grootendorst 2006</LINK>
</P>
</TD>
<TD>
<P>ACE inhibitors</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>All ACE inhibitors. Defined daily doses dispensed per 100 seniors</P>
</TD>
<TD>
<P>-65 (-158 to 29)</P>
</TD>
<TD>
<P>-12% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>8% (95% CI NA)</P>
</TD>
<TD>
<P>30% at 2 years (95% CI NA)</P>
</TD>
</TR>
<TR>
<TD>
<P>CCBs</P>
</TD>
<TD>
<P>Reference drugs + cost share drugs</P>
</TD>
<TD>
<P>All CCBs. Defined daily doses dispensed per 100 seniors</P>
</TD>
<TD>
<P>-34 (-49 to -20)</P>
</TD>
<TD>
<P>-8% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-7% (95% CI NA)</P>
</TD>
<TD>
<P>-6% at 2 years (95% CI NA)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Grootendorst-2005" TYPE="STUDY">Grootendorst 2005</LINK>
</P>
</TD>
<TD>
<P>Opiates (RP 1)*****</P>
</TD>
<TD>
<P>Other drugs</P>
</TD>
<TD>
<P>Days therapy dispensed per 1000 seniors</P>
</TD>
<TD>
<P>79.30 (-95.10 to 253.71)</P>
</TD>
<TD>
<P/>
<P>22% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-3% (95% CI NA)</P>
</TD>
<TD>
<P>-18% at 19 months</P>
<P>(95% CI NA)</P>
</TD>
</TR>
<TR>
<TD>
<P>Opiates (RP 2)*****</P>
</TD>
<TD>
<P>Other drugs</P>
</TD>
<TD>
<P>Days therapy dispensed per 1000 seniors</P>
</TD>
<TD>
<P>118.13 (-56.53 to 292.78)</P>
</TD>
<TD>
<P>40% (95% CI NA)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>106% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Results from reanalysis by reviewers.</P>
<P>** Calculated by reviewers based on figures provided in the text of the study.</P>
<P>***NA = Not available.</P>
<P>****Type 1 RP&#8212;only chemically equivalent drugs (i.e., branded and &#8216;&#8216;generic&#8217;&#8217; versions of the same drug) are considered interchangeable. Under Type 2 RP, all drugs from the same therapeutic class are considered interchangeable.</P>
<P>***** Pharmacare savings are attenuated if physicians substitute relatively costly opiate analgesics, which were not targeted by Type 2 RP, for the NSAIDs that were.</P>
<P>******<B>EFFECTS ON USE OF:</B>
</P>
<P>
<B>Reference drugs</B>, drugs that determine the reference price level. There is no cost share by the patients for these drugs, which are fully reimbursed. The expectation is that reference pricing will lead to an increase in use of these drugs.<BR/>
<B>Cost share drugs</B>, drugs in the same group as the reference drugs that cost more. Patients have to pay the difference between reference price drugs and the price of these drugs. The expectation is that reference pricing will lead to a decrease in use of these drugs.</P>
<P>
<B>Reference drugs + cost share drugs</B>, both the reference drugs and the cost share drugs. The expectation is that reference pricing will lead to little or no change in the overall use of these drugs.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2014-09-18 16:04:48 +0200" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2014-09-18 16:04:48 +0200" MODIFIED_BY="[Empty name]">Reference pricing versus no reference pricing: drug prices and patients' out-of-pocket payments</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TH>
<P>STUDY ID</P>
</TH>
<TH>
<P>POLICY: REFERENCE PRICING FOR</P>
</TH>
<TH>
<P>OUTCOME</P>
</TH>
<TH>
<P>LEVEL, LONG RUN (OVER THE 12 MONTHS OR LONGER POST PERIOD) (95% CI)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Aronsson-2001" TYPE="STUDY">Aronsson 2001</LINK>
</P>
</TD>
<TD>
<P>12 different brand drugs: cimetidine, furosemide, atenolol, pindolol, propranolol, indomethacin, naproxen, allopurinol, paracetamol/codeine, diazepam, clomipramine, timolol</P>
</TD>
<TD>
<P>Change in prices/Swedish krona (SEK)</P>
</TD>
<TD>
<P>The reference price system tends to decrease the price of the original relative to the price of the generics. Estirnation results for Equatíons from -0.466 to -0.476*</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brekke-2011" TYPE="STUDY">Brekke 2011</LINK>
</P>
</TD>
<TD>
<P>The RP covered six chemical substances: citalopram, omeprazol, cetirizin, loratadin, enalapril and lisinopril. The system was later extended with two additional substances; simvastatin and amlodipin</P>
</TD>
<TD>
<P>Change in prices (DDD, NOK)</P>
</TD>
<TD>
<P>Copayments price decreased 13% for generic drugs and 23% for brand-name drugs</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kibicho-2012" TYPE="STUDY">Kibicho 2012</LINK>
</P>
</TD>
<TD>
<P>1. Antihypertensive drugs</P>
<P>2. Antihyperlipidaemic drugs</P>
<P>3. Generic drugs</P>
<P>4. Brand-name drugs</P>
</TD>
<TD>
<P>Marginal effect in prices of each policy, controlling for level and trend effects in the other three policy periods (USD)</P>
</TD>
<TD>
<P>1: $0.06 ($0, $0.12)</P>
<P>2: $0.37 ($0.09, $0.64)</P>
<P>3: -$0.13 (-$0.20, -$0.06)</P>
<P>4: $0.17 (-$0.03, $0.38)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pavcnik-2002" TYPE="STUDY">Pavcnik 2002</LINK>
</P>
</TD>
<TD>
<P>Reference pricing on oral antidiabetics (i.e. glibenclamide) and antiulcerants (in particular, H2 antagonists)</P>
</TD>
<TD>
<P>Price of average daily dose (1990 Deutsche marks)</P>
</TD>
<TD>
<P>Depending on the therapeutic group and specification, the estimates of average price reductions due to changes in insurance reimbursement range from 10% for generic drugs to 26% for brand drugs.#</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Long post periods: 1993 to 1996</P>
<P>#Long post periods: 1989 to 1996 for antidiabetics and 1993 to 1996 for antiulcerants</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2014-09-18 16:15:44 +0200" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2014-09-18 16:15:44 +0200" MODIFIED_BY="[Empty name]">Index pricing versus no index pricing: drug use</TITLE>
<TABLE COLS="6" ROWS="5">
<TR>
<TH>
<P>STUDY ID</P>
</TH>
<TH>
<P>POLICY: INDEX PRICING FOR</P>
</TH>
<TH>
<P>OUTCOME</P>
</TH>
<TH>
<P>ABSOLUTE CHANGE IN LEVEL, IMMEDIATE AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, IMMEDIATE AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, 1/2 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>GENERIC DRUGS</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>*</P>
</TD>
<TD>
<P>Citalopram</P>
</TD>
<TD>
<P>Monthly DDDs sold</P>
</TD>
<TD>
<P>437,368<BR/>(247,454 to 627,282)<BR/>
</P>
</TD>
<TD>
<P>114% (64% to 164%)</P>
</TD>
<TD>
<P>55%<BR/>(11% to 98%)<BR/>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>BRAND DRUGS</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>*</P>
</TD>
<TD>
<P>Citalopram</P>
</TD>
<TD>
<P>Monthly DDDs sold</P>
</TD>
<TD>
<P>-599,489<BR/>(-982,279 to -216,699)<BR/>
</P>
</TD>
<TD>
<P>-29%<BR/>(-48% to -11%)<BR/>
</P>
</TD>
<TD>
<P>-43%<BR/>(-67% to -18%)<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Results from reanalysis by reviewers</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" MODIFIED="2014-09-18 16:15:18 +0200" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2014-09-18 16:15:18 +0200" MODIFIED_BY="[Empty name]">Index pricing versus no index pricing: copayments and drug prices</TITLE>
<TABLE COLS="6" ROWS="4">
<TR>
<TH>
<P>STUDY ID</P>
</TH>
<TH>
<P>INDEX PRICING FOR</P>
</TH>
<TH>
<P>OUTCOME</P>
</TH>
<TH>
<P>IMMEDIATE CHANGE AFTER POLICY START DATE (95% CI)</P>
</TH>
<TH>
<P>CHANGE 6 MONTHS AFTER POLICY START DATE</P>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<LINK REF="STD-Brekke-2003" TYPE="STUDY">Brekke 2003</LINK>
</P>
</TD>
<TD ROWSPAN="3">
<P>The RP covered six chemical substances: citalopram, omeprazol, cetirizin, loratadin, enalapril and lisinopril. The system was later extended with two additional substances; simvastatin and amlodipin</P>
</TD>
<TD>
<P>Change in copayments NOK</P>
</TD>
<TD>
<P>Generic copayment -12.9% (95% CI NA)</P>
<P/>
<P>Brand-name copayment -6.4% (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Generic copayment -12.8% (95% CI NA)</P>
<P/>
<P>Brand-name Copayment -14.8% (95% CI NA)</P>
</TD>
</TR>
<TR>
<TD>
<P>Generic drug prices</P>
</TD>
<TD>
<P>-4.0 % (-5.14%, -2.90%)<BR/>
</P>
</TD>
<TD>
<P>-5.30 % (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Brand drugs prices</P>
</TD>
<TD>
<P>-0.8 % (95% CI NA)</P>
</TD>
<TD>
<P>-1.1 % (95% CI NA)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*NA = Not available</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-10" MODIFIED="2014-09-18 16:05:14 +0200" MODIFIED_BY="[Empty name]" NO="10">
<TITLE MODIFIED="2014-09-18 16:05:14 +0200" MODIFIED_BY="[Empty name]">Maximum prices versus no maximum prices: drug expenditures</TITLE>
<TABLE COLS="9" ROWS="3">
<TR>
<TH>
<P>STUDY ID</P>
</TH>
<TH>
<P>MAXIMUM PRICE FOR</P>
</TH>
<TH>
<P>OUTCOME</P>
</TH>
<TH>
<P>ABSOLUTE CHANGE LEVEL, IMMEDIATE AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, IMMEDIATE AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, 1/2 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, 1 YEAR AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>RELATIVE CHANGE IN LEVEL, 2 YEARS AFTER TRANSITION PERIOD (95% CI)</P>
</TH>
<TH>
<P>NOTES</P>
</TH>
</TR>
<TR>
<TD COLSPAN="9">
<P>
<B>DRUG CLASS, TOTAL</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Puig-2007" TYPE="STUDY">Puig 2007</LINK>
</P>
</TD>
<TD>
<P>Statins</P>
</TD>
<TD>
<P>Mean monthly change</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>21.4% (19.0 to 23.7) increase of volume in sales for all statins in Andalusia</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Also reported the impact after one year of maximum consumer prices plus proportion of off-patent statin prescriptions (MCP plus PI)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2014-09-22 12:34:58 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-09-18 15:42:04 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
<P>* Out of 125 full-text reports excluded in the update, 49 did not meet study design criteria, 64 did not meet intervention criteria, 3 did not meet outcome criteria, 2 were duplicated and 4 for other reasons.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAIhCAYAAABkNDy8AAA0cElEQVR42u2df4RV2///L0mSJJKM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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-09-22 12:34:58 +0200" MODIFIED_BY="[Empty name]" NO="2" NOTES="&lt;p&gt;With less pixels it's impossible to read the text&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2013-12-30 10:37:00 +0100&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;Unit of analysis errors affect the confidence intervals and are NOT a risk of bias (for the point estimate)&lt;/span&gt;&lt;span modified=&quot;2013-12-30 10:38:00 +0100&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;.&lt;/span&gt;&lt;span modified=&quot;2013-12-30 10:43:00 +0100&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt; &lt;/span&gt;&lt;span class=&quot;inserted&quot; modified=&quot;2013-12-30 10:43:05 +0100&quot; modified_by=&quot;[Empty name]&quot;&gt;As (correctly) summarised in the Methods section, Unit of analysis error is NOT a risk of bias criterion and should not be included in the Risk of bias tables.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2013-12-30 10:47:00 +0100&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;Why is &amp;quot;Were baseline outcome measurements similar?&amp;quot; only reported for 8 studies?&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-09-22 12:34:58 +0200" NOTES_MODIFIED_BY="[Empty name]" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABkcAAASSCAIAAACE266EAACAAElEQVR42uzdP499R1bu8Z+EhAgc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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-09-22 12:34:58 +0200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA38AAAUaCAMAAABigDpuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-09-22 10:17:09 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-09-22 10:17:09 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-09-22 10:14:06 +0200" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-22 10:17:09 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>1. CENTRAL, Cochrane Library</B>
</P>
<TABLE COLS="1" ROWS="42">
<TR>
<TD VALIGN="TOP">
<P>#1 MeSH descriptor: [Drug Costs] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#2 MeSH descriptor: [Economics, Pharmaceutical] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#3 MeSH descriptor: [Fees, Pharmaceutical] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#4 MeSH descriptor: [Prescription Fees] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#5 MeSH descriptor: [Pharmaceutical Preparations] explode all trees and with qualifiers: [Economics - EC]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#6 MeSH descriptor: [Drug Prescriptions] this term only and with qualifiers: [Economics - EC]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#7 MeSH descriptor: [Drug Substitution] this term only and with qualifiers: [Economics - EC]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#8 #1 or #2 or #3 or #4 or #5 or #6 or #7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#9 MeSH descriptor: [Pharmaceutical Preparations] explode all trees</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#10 MeSH descriptor: [Drug Prescriptions] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#11 MeSH descriptor: [Drug Substitution] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#12 #9 or #10 or #11</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#13 MeSH descriptor: [Economics] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#14 MeSH descriptor: [Health Expenditures] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#15 MeSH descriptor: [Costs and Cost Analysis] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#16 MeSH descriptor: [Health Care Costs] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#17 MeSH descriptor: [Cost Control] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#18 MeSH descriptor: [Cost Savings] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#19 MeSH descriptor: [Commerce] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#20 MeSH descriptor: [Rate Setting and Review] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#21 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#22 MeSH descriptor: [Policy] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#23 MeSH descriptor: [Health Policy] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#24 MeSH descriptor: [Health Care Reform] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#25 MeSH descriptor: [National Health Programs] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#26 MeSH descriptor: [Policy Making] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#27 MeSH descriptor: [Government Regulation] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#28 MeSH descriptor: [Legislation, Drug] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#29 MeSH descriptor: [Politics] this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#30 (policy or policies or politics or plan or plans or planning or program* or regulat* or legislat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#31 #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#32 (reference or index or "volume based" or reimburs* or "best available") near/3 (price or prices or pricing) near/3 (drug or drugs or pharmaceutic* or medicines or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#33 (max* or minim* or reimburs* or ceiling or fixed) near/3 (price or prices or pricing or cost or costs) near/3 (drug or drugs or pharmaceutic* or medicines or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#34 (price or prices) near/3 (control or controls or caps or negotiat* or compar* or cut or cuts or freez*) near/3 (drug or drugs or pharmaceutic* or medicines or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#35 ("price volume" or "cost plus") near/3 (drug or drugs or pharmaceutic* or medicines or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#36 (profit near/3 regulat* or profit near/3 limit*) near/3 (drug or drugs or pharmaceutic* or medicines or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#37 (procure* or purchas* or rebate or acquisition or econom* or financ* or sale or sales) near/3 (policy or policies or intervention*) near/3 (drug or drugs or pharmaceutic* or medicines or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#38 #32 or #33 or #34 or #35 or #36 or #37</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#39 (drug or drugs or pharmaceutic* or medicines or medicat*) near/6 (cost or costs or fee or fees or expenditure* or expense* or price or prices or pricing or spending* or purchas* or procure* or acquisition or sale or sales) near/6 (policy or policies or intervention* or politics or plan or plans or planning or program* or regulat* or legislat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#40 #8 and #31</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#41 #12 and #21 and #31</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#42 #38 or #39 or #40 or #41</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>2. MEDLINE In-Process &amp; Other Non-Indexed Citations and MEDLINE, Ovid<BR/>
</B>
</P>
<TABLE COLS="3" ROWS="65">
<TR>
<TD VALIGN="TOP">
<P>
<B>#</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Searches</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Results</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>Drug Costs/</P>
</TD>
<TD VALIGN="TOP">
<P>11364</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>Economics, Pharmaceutical/</P>
</TD>
<TD VALIGN="TOP">
<P>2379</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>Fees, Pharmaceutical/</P>
</TD>
<TD VALIGN="TOP">
<P>1105</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>Prescription Fee/</P>
</TD>
<TD VALIGN="TOP">
<P>939</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>exp Pharmaceutical Preparations/ec [Economics]</P>
</TD>
<TD VALIGN="TOP">
<P>4131</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>Drug Prescriptions/ec [Economics]</P>
</TD>
<TD VALIGN="TOP">
<P>2562</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>Drug Substitution/ec [Economics]</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>or/1-7</P>
</TD>
<TD VALIGN="TOP">
<P>18829</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>exp Pharmaceutical Preparations/</P>
</TD>
<TD VALIGN="TOP">
<P>587714</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>Drug Prescriptions/</P>
</TD>
<TD VALIGN="TOP">
<P>20886</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>Drug Substitution/</P>
</TD>
<TD VALIGN="TOP">
<P>487</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>or/9-11</P>
</TD>
<TD VALIGN="TOP">
<P>606182</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>Economics/</P>
</TD>
<TD VALIGN="TOP">
<P>26629</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>Health Expenditures/</P>
</TD>
<TD VALIGN="TOP">
<P>12736</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>"Costs and Cost Analysis"/</P>
</TD>
<TD VALIGN="TOP">
<P>40253</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>Health Care Costs/</P>
</TD>
<TD VALIGN="TOP">
<P>24066</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>Cost Control/</P>
</TD>
<TD VALIGN="TOP">
<P>19418</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>Cost Savings/</P>
</TD>
<TD VALIGN="TOP">
<P>7866</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>Commerce/</P>
</TD>
<TD VALIGN="TOP">
<P>16300</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>"Rate Setting and Review"/</P>
</TD>
<TD VALIGN="TOP">
<P>2438</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>or/13-20</P>
</TD>
<TD VALIGN="TOP">
<P>138351</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>Policy/</P>
</TD>
<TD VALIGN="TOP">
<P>457</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>Health Policy/</P>
</TD>
<TD VALIGN="TOP">
<P>47001</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>Health Care Reform/</P>
</TD>
<TD VALIGN="TOP">
<P>26362</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>National Health Programs/</P>
</TD>
<TD VALIGN="TOP">
<P>23941</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>Policy Making/</P>
</TD>
<TD VALIGN="TOP">
<P>11218</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>Government Regulation/</P>
</TD>
<TD VALIGN="TOP">
<P>16371</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>Legislation, Drug/</P>
</TD>
<TD VALIGN="TOP">
<P>8329</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>29</P>
</TD>
<TD VALIGN="TOP">
<P>Politics/</P>
</TD>
<TD VALIGN="TOP">
<P>38756</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>(policy or policies or politics or plan or plans or planning or program* or regulat* or legislat*).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>1890437</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>or/22-30</P>
</TD>
<TD VALIGN="TOP">
<P>1987077</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P>((reference or index or volume based or reimburs* or best available) adj3 (price or prices or pricing) adj3 (drug or drugs or pharmaceutic* or medicines or medicat*)).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>141</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>((max* or minim* or reimburs* or ceiling or fixed) adj3 (price or prices or pricing or cost or costs) adj3 (drug or drugs or pharmaceutic* or medicines or medicat*)).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>219</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>((price or prices) adj3 (control or controls or caps or negotiat* or compar* or cut or cuts or freez*) adj3 (drug or drugs or pharmaceutic* or medicines or medicat*)).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>156</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>((price volume or cost plus) adj3 (drug or drugs or pharmaceutic* or medicines or medicat*)).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>(profit adj3 (regulat* or limit*) adj3 (drug or drugs or pharmaceutic* or medicines or medicat*)).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>37</P>
</TD>
<TD VALIGN="TOP">
<P>((procure* or purchas* or rebate or acquisition or econom* or financ* or sale?) adj3 (policy or policies or intervention?) adj3 (drug or drugs or pharmaceutic* or medicines or medicat*)).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>57</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>38</P>
</TD>
<TD VALIGN="TOP">
<P>or/32-37</P>
</TD>
<TD VALIGN="TOP">
<P>493</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>((drug or drugs or pharmaceutic* or medicines or medicat*) adj6 (cost or costs or fee or fees or expenditure? or expense? or price or prices or pricing or spending? or purchas* or procure* or acquisition or sale?) adj6 (policy or policies or intervention? or politics or plan or plans or planning or program* or regulat* or legislat*)).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>1491</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>8 and 31</P>
</TD>
<TD VALIGN="TOP">
<P>5191</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>41</P>
</TD>
<TD VALIGN="TOP">
<P>12 and 21 and 31</P>
</TD>
<TD VALIGN="TOP">
<P>1508</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>42</P>
</TD>
<TD VALIGN="TOP">
<P>38 or 39 or 40 or 41</P>
</TD>
<TD VALIGN="TOP">
<P>6931</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>randomized controlled trial.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>340079</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>controlled clinical trial.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>85448</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>multicenter study.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>151515</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>(randomis* or randomiz* or randomly).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>487333</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>groups.ab.</P>
</TD>
<TD VALIGN="TOP">
<P>1210865</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>48</P>
</TD>
<TD VALIGN="TOP">
<P>(trial or multicenter or multi center or multicentre or multi centre).ti.</P>
</TD>
<TD VALIGN="TOP">
<P>128649</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>49</P>
</TD>
<TD VALIGN="TOP">
<P>(intervention* or controlled or control group or compare or compared or (before adj5 after) or (pre adj5 post) or pretest or pre test or posttest or post test or quasiexperiment* or quasi experiment* or evaluat* or effect? or impact? or time series or time point? or repeated measur*).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>6850206</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>or/43-49</P>
</TD>
<TD VALIGN="TOP">
<P>7373617</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>51</P>
</TD>
<TD VALIGN="TOP">
<P>exp Animals/</P>
</TD>
<TD VALIGN="TOP">
<P>16427399</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P>Humans/</P>
</TD>
<TD VALIGN="TOP">
<P>12629645</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>53</P>
</TD>
<TD VALIGN="TOP">
<P>51 not (51 and 52)</P>
</TD>
<TD VALIGN="TOP">
<P>3797754</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>54</P>
</TD>
<TD VALIGN="TOP">
<P>comment.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>521909</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>55</P>
</TD>
<TD VALIGN="TOP">
<P>editorial.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>319891</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>cochrane database of systematic reviews.jn.</P>
</TD>
<TD VALIGN="TOP">
<P>9224</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>comment on.cm.</P>
</TD>
<TD VALIGN="TOP">
<P>521908</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>58</P>
</TD>
<TD VALIGN="TOP">
<P>review.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>1748075</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>review.ti.</P>
</TD>
<TD VALIGN="TOP">
<P>227088</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>60</P>
</TD>
<TD VALIGN="TOP">
<P>or/53-59</P>
</TD>
<TD VALIGN="TOP">
<P>6198639</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>50 not 60</P>
</TD>
<TD VALIGN="TOP">
<P>5001053</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P>42 and 61</P>
</TD>
<TD VALIGN="TOP">
<P>2934</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>201012*.ed. or 2011*.ed,yr. or 2012*.ed,yr.</P>
</TD>
<TD VALIGN="TOP">
<P>2315721</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>64</P>
</TD>
<TD VALIGN="TOP">
<P>62 and 63</P>
</TD>
<TD VALIGN="TOP">
<P>481</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>3. EconLit, ProQuest </B>
</P>
<P>
<B>4. PAIS International, ProQuest</B>
</P>
<P>
<B>5. World Wide Political Science Abstracts, ProQuest</B>
</P>
<P>ALL("drug" or "drugs" or pharmaceutic* or "medicines" or medicament*) AND ALL(regulat* or requirement* or restrict* or monitor* or control* or "legislation" or "law" or "laws" or "act" or "acts" or "policy" or "policies" or "politics" or reform* or "system" or "systems" or "plan" or "plans" or "planning" or program* or strateg*) NEAR/3 ALL("price" or "prices" or "pricing" or purchas* or procure* or "sale" or "sales") AND ALL("randomised" or "randomized" or "randomly" or "trial" or "intervention" or "interventions" or "controlled" or "control group" or "control groups" or "before and after" or "pre and post" or "pretest" or "pre test" or "posttest" or "post test" or quasiexperiment* or "quasi experiment" or "quasi experiments" or "quasi experimental" or evaluat* or "effect" or "effects" or impact or "impacts" or "time series" or "time point" or "time points" or "repeated measure" or "repeated measures" or "repeated measurement" or "repeated measurements") NOT ALL("narcotic" or &#8220;narcotics&#8221; or "crime" or "crimes" or "war" or "wars" or terror* or weapon* or "drug abuse" or "illicit drug" or "illicit drugs" or "drug trafficking")</P>
<SUBSECTION>
<HEADING LEVEL="3">6. INRUD Bibliography </HEADING>
<P>Search field: All Non-Indexed Text Fields</P>
<P>{price} or {pricing} or {purchas} or {procure}</P>
<P>AND</P>
<P>{regulat} or {requirement} or {restrict} or {monitor} or {control} or {legislation} or {law} or {act} or {policy} or {policies} or {politics} or {reform} or {system} or {plan} or {program} or {strateg}</P>
<P>AND</P>
<P>{randomis} or {randomiz} or {randomly} or {intervention} or {control group} or {compar} or {before and after} or {pretest} or {posttest} or {pre test} or {post test} or {quasiexperiment} or {quasi experiment} or {evaluat} or {effect} or {impact} or {time series} or {time point} or {repeated measur}</P>
<P>
<B>7. Embase, Ovid</B>
</P>
<TABLE COLS="1" ROWS="41">
<TR>
<TD VALIGN="TOP">
<P>1. (regulat$ or requirement? or restrict$ or monitor$ or control$).tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2. (legislation? or law? or act? or policy or policies or politics or reform$ or system? or plan$ or program$ or strateg$).tw. or Drug Legislation/ or Policy/ or Health Care Policy/ or Politics/ or Drug Program/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3. (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$).tw. or exp Pharmaceutics/ or exp Drug/ or Prescription/ or "Drug Use"/ or Drug Utilization/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4. *Cost Control/ and 3 and 2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5. ((control$ or containment or curtailment or reduc$ or save or saving) adj3 cost?).tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6. ((cost? or expenditure? or expense?) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7. 5 and 6 and 2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8. ((control$ or reduc$ or cut$ or regulat$ or negotiat$ or fix$) adj3 (price? or pricing)).tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9. ((price? or pricing) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10. 8 and 9 and 2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>11. (reference$ adj3 (price? or pricing)).tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12. (index$ adj3 (price? or pricing)).tw. and 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>13. ((maxim$ or minim$) adj3 (cost? or price? or pricing)).tw. and 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14. (cost? effect$ adj3 (price? or pricing)).tw. and 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15. (reimburs$ adj1 contract?).tw. and 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>16. (*Drug Cost/ or *Pharmacoeconomics/) and (1 or 2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>17. *Hospital Purchasing/ and 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>18. (purchas$ adj3 (group? or join$ or hospital? or shared)).tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>19. ((group? or join$ or hospital? or shared) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>20. 18 and 19 and 2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>21. (procurement$ adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw. and 2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>22. (acquisition cost? adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw. and 2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>23. (rebate? adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw. and 2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>24. (generic adj3 (price? or pricing or substitut$)).tw. and 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>25. ((price? or pricing) adj3 (policy or policies or regulat$ or negotiat$)).tw. and 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>26. (rate? adj1 return).tw. and 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>27. (profit$ adj3 regulat$).tw. and 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>28. 4 or 7 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>29. Randomized Controlled Trial/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>30. (randomised or randomized).tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>31. experiment$.tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>32. (time adj series).tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>33. (pre test or pretest or (posttest or post test)).tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>34. evaluat$.tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>35. Comparative Study/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>36. or/29-35</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>37. 28 and 36</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>38. Nonhuman/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>39. 37 not 38</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>40. medlinex00ae.cr.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>41. 39 not 40</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>8. NHSEED, Cochrane Library</B>
</P>
<TABLE COLS="2" ROWS="56">
<TR>
<TD VALIGN="TOP">
<P>#1</P>
</TD>
<TD VALIGN="TOP">
<P>(regulat* or requirement* or restrict* or monitor* or control*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#2</P>
</TD>
<TD VALIGN="TOP">
<P>(legislation* or law or laws or act or acts or policy or policies or politics or reform* or system or systems or plan or plans or program* or strateg*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#3</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Policy Making, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#4</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Legislation, Drug, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#5</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Public Policy, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#6</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Health Policy, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#7</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Politics, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#8</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Health Care Reform, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#9</P>
</TD>
<TD VALIGN="TOP">
<P>(#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#10</P>
</TD>
<TD VALIGN="TOP">
<P>(drug or drugs or pharmaceutic* or medicines or medicament* or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#11</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Pharmaceutical Preparations explode all trees</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#12</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Drug Prescriptions explode all trees</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#13</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Drug Utilization, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#14</P>
</TD>
<TD VALIGN="TOP">
<P>(#10 OR #11 OR #12 OR #13)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#15</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Cost Control, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#16</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Cost Savings, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#17</P>
</TD>
<TD VALIGN="TOP">
<P>(#15 OR #16)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#18</P>
</TD>
<TD VALIGN="TOP">
<P>(#17 AND #9 AND #14)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#19</P>
</TD>
<TD VALIGN="TOP">
<P>(control* or containment or curtailment or reduc* or save or saving) NEAR/3 (cost or costs):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#20</P>
</TD>
<TD VALIGN="TOP">
<P>(cost or costs or expenditure* or expense*) NEAR/3 (drug or drugs or pharmaceutic* or medicines or medicament* or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#21</P>
</TD>
<TD VALIGN="TOP">
<P>(#19 AND #20 AND #9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#22</P>
</TD>
<TD VALIGN="TOP">
<P>(control* or reduc* or cut* or regulat* or negotiat* or fix*) NEAR/3 (price* or pricing):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#23</P>
</TD>
<TD VALIGN="TOP">
<P>(price* or pricing) NEAR/3 (drug or drugs or pharmaceutic* or medicines or medicament* or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#24</P>
</TD>
<TD VALIGN="TOP">
<P>(#22 AND #23 AND #9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#25</P>
</TD>
<TD VALIGN="TOP">
<P>reference* NEAR/3 (price* or pricing):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#26</P>
</TD>
<TD VALIGN="TOP">
<P>index* NEAR/3 (price* or pricing):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#27</P>
</TD>
<TD VALIGN="TOP">
<P>(#26 AND #14)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#28</P>
</TD>
<TD VALIGN="TOP">
<P>(maxim* or minim*) NEAR/3 (cost or costs or price* or pricing):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#29</P>
</TD>
<TD VALIGN="TOP">
<P>(#28 AND #14)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#30</P>
</TD>
<TD VALIGN="TOP">
<P>(cost or costs) NEAR/4 (price* or pricing):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#31</P>
</TD>
<TD VALIGN="TOP">
<P>(#30 AND #14)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#32</P>
</TD>
<TD VALIGN="TOP">
<P>(reimburs* NEAR/1 contract*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#33</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Drug Costs, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#34</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Economics, Pharmaceutical, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#35</P>
</TD>
<TD VALIGN="TOP">
<P>(#33 OR #34)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#36</P>
</TD>
<TD VALIGN="TOP">
<P>(#1 OR #9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#37</P>
</TD>
<TD VALIGN="TOP">
<P>(#35 AND #36)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#38</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Purchasing, Hospital, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#39</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor Group Purchasing, this term only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#40</P>
</TD>
<TD VALIGN="TOP">
<P>(#38 OR #39)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#41</P>
</TD>
<TD VALIGN="TOP">
<P>(#40 AND #14)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#42</P>
</TD>
<TD VALIGN="TOP">
<P>purchas* NEAR/3 (group* or join* or hospital* or shared):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#43</P>
</TD>
<TD VALIGN="TOP">
<P>(group* or join* or hospital* or shared) NEAR/3 (drug or drugs or pharmaceutic* or medicines or medicament* or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#44</P>
</TD>
<TD VALIGN="TOP">
<P>(#42 AND #43 AND #9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#45</P>
</TD>
<TD VALIGN="TOP">
<P>procurement* NEAR/3 (drug or drugs or pharmaceutic* or medicines or medicament* or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#46</P>
</TD>
<TD VALIGN="TOP">
<P>(acquisition NEXT cost*) NEAR/3 (drug or drugs or pharmaceutic* or medicines or medicament* or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#47</P>
</TD>
<TD VALIGN="TOP">
<P>(#46 AND #9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#48</P>
</TD>
<TD VALIGN="TOP">
<P>rebate* NEAR/3 (drug or drugs or pharmaceutic* or medicines or medicament* or medicat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#49</P>
</TD>
<TD VALIGN="TOP">
<P>generic NEAR/3 (price* or pricing or substitut*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#50</P>
</TD>
<TD VALIGN="TOP">
<P>(#49 AND #14)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#51</P>
</TD>
<TD VALIGN="TOP">
<P>(price* or pricing) NEAR/3 (policy or policies or regulat* or negotiat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#52</P>
</TD>
<TD VALIGN="TOP">
<P>(#51 AND #14)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#53</P>
</TD>
<TD VALIGN="TOP">
<P>(rate* NEAR/1 return):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#54</P>
</TD>
<TD VALIGN="TOP">
<P>(#53 AND #14)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#55</P>
</TD>
<TD VALIGN="TOP">
<P>(profit* NEAR/3 regulat*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#56</P>
</TD>
<TD VALIGN="TOP">
<P>(#18 OR #21 OR #24 OR #25 OR #27 OR #29 OR #31 OR #32 OR #37 OR #41 OR #44 OR #45 OR #47 OR #48 OR #50 OR #52 OR #54 OR #55)</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>9. LILACS, VHL (IAH search interface)</B>
</P>
<P>(cost or costs or expend$ or expens$ or price or prices or pricing or purchas$ or costo or costos or gasto$ or gasta$ or precio or precios or compra$ or adquisicion$ or custo or custos or preco or precos or aquisicao$ or despesa or adquisicao) and (drug or drugs or pharmaceutic$ or medicin$ or medicament$ or farmaceutic$ or droga or remedio) and (regulat$ or requirement$ or restrict$ or monitor$ or contro$ or legislat$ or law or laws or policy or policies or reform$ or system$ or program$ or regulacion or requisito$ or politica$ or sistema$ or seguimiento or regulacao$ or condicao$ or seguimento or acompanhamento or exigencia) and (randomi$ or randomly or azar or acaso or aleat$ or control$ or intervention$ or intervencion$ or intervencao or intervencoes or evaluat$ or evaluar or evaluacion or avaliar or impact$) [Words]</P>
<P>
<B>10. International Political Science Abstracts (IPSA) </B>
</P>
<P/>
<TABLE COLS="3" ROWS="5">
<TR>
<TD>
<P>S5</P>
</TD>
<TD>
<P>S1 and S2 and S3 and S4</P>
</TD>
<TD>
<P>55</P>
</TD>
</TR>
<TR>
<TD>
<P>S4</P>
</TD>
<TD>
<P>TX (random* or intervention* or control* or compar* or evaluat* or "time series" or pretest or posttest or "pre test" or "post test" or impact* or chang* or effect* or experiment*)</P>
</TD>
<TD>
<P>117558</P>
</TD>
</TR>
<TR>
<TD>
<P>S3</P>
</TD>
<TD>
<P>TX (regulat* or requirement* or restrict* or monitor* or control* or legislation or law or laws or act or acts or policy or policies or politics or reform* or system or systems or plan* or program* or strateg*)</P>
</TD>
<TD>
<P>189060</P>
</TD>
</TR>
<TR>
<TD>
<P>S2</P>
</TD>
<TD>
<P>TX (cost or costs or price* or pricing or expenditure* or expense* or procurement* or reimburs* or purchas* or rebate* or profit*)</P>
</TD>
<TD>
<P>14426</P>
</TD>
</TR>
<TR>
<TD>
<P>S1</P>
</TD>
<TD>
<P>TX (drug or drugs or pharmaceutic* or medicines or medicament*)</P>
</TD>
<TD>
<P>774</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>11. OpenSIGLE (now called OpenGrey)</B>
</P>
<P>
<I>Keywords:</I> drug or drugs or pharmaceutical or pharmaceuticals or medicaments or medicines</P>
<P>AND</P>
<P>
<I>Keywords: </I>price or prices or pricing or purchase or purchased or purchasing or procurement</P>
<P>
<B>12. WHOLIS, WHO </B>
</P>
<P>
<I>Search field: &#8216;Words or phrase&#8217;</I>
</P>
<P>drug or drugs or pharmaceutic$ or medicament$ or medicines</P>
<P>AND</P>
<P>cost or costs or price$ or pricing or expenditure$ or expense$ or procurement$ or reimburs$ or purchas$ or rebate$ or profit$</P>
<P>AND</P>
<P>regulat$ or requirement$ or restrict$ or monitor$ or control$ or legislation$ or law or laws or act or acts or policy or policies or politics or reform$ or system or systems or plan or plans or planning or program$ or strateg$</P>
<P>AND</P>
<P>random$ or intervention$ or control$ or compar$ or evaluat$ or impact$ or chang$ or effect$ or experiment$</P>
<P>
<B>13. World Bank </B>(Documents &amp; Reports)</P>
<P>
<I>Advanced Search - All Documents </I>
</P>
<P>
<I>In Title (Any words): </I>drug drugs pharmaceutical pharmaceuticals medicaments medicines</P>
<P>
<B>14. Jolis</B>
</P>
<P>
<I>Search fields: &#8216;Keywords Anywhere&#8217;</I>
</P>
<P>
<I>Search done in two separate stages</I>
</P>
<P>1.</P>
<P>keywords anywhere "pric$ or cost$ or purchas$ or procur$ or profit$" AND keywords anywhere "drug or drugs or pharmaceutic$ or medicament$ or medicines or prescrip$ or prescrib$"</P>
<P>2.</P>
<P>keywords anywhere "rate$" AND keywords anywhere "return" AND keywords anywhere "drug or drugs or pharmaceutic$ or medicament$ or medicines or prescrip$ or prescrib$"</P>
<P>
<B>15. Global Jolis</B>
</P>
<P>
<I>Search field: &#8216;Words or Phrase&#8217;</I>
</P>
<P>
<I>Search done in two separate stages</I>
</P>
<P>1.</P>
<P>words or phrase "pric$ or cost$ or purchas$ or procur$ or profit$" AND words or phrase "drug or drugs or pharmaceutic$ or medicament$ or medicines or prescrip$ or prescrib$"</P>
<P>2.</P>
<P>words or phrase "rate$&#8221; AND words or phrase &#8220;return&#8221; AND words or phrase "drug or drugs or pharmaceutic$ or medicament$ or medicines or prescrip$ or prescrib$".</P>
<P>
<B>16. OECD</B>
</P>
<P>
<I>Searched: Publications &amp; Documents limited to OECD Publications only</I>
</P>
<P>drug or drugs or pharmaceutical or pharmaceuticals or medicaments or medicines or prescription or prescriptions or prescribe or prescribing</P>
<P>
<B>17. OECD iLibrary </B>(formerly called SourceOECD)</P>
<P>
<I>Advanced search</I>
</P>
<P>
<I>Option 1</I>: drug or drugs or pharmaceutical or pharmaceuticals or medicaments or medicines, in <I>Title and Abstract</I>
</P>
<P>AND</P>
<P>
<I>Option2</I>: price or prices or pricing or purchase or purchased or purchasing or procurement, in <I>Title and Abstract</I>
</P>
<P>
<B>18. World Bank iLibrary</B>
</P>
<P>
<I>Search fields: &#8216;Title&#8217; or &#8216;Abstract&#8217; or &#8216;Keywords&#8217;</I>
</P>
<P>drug or drugs or pharmaceutical or pharmaceuticals or pharmaceutic or pharmaceutics or medicament or medicaments or medicines or prescription or prescriptions or prescribe or prescribed or prescribing</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;18 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;380 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;26797 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;26797 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;27935 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;92 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;26417 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;362 full-text articles excluded, reasons*&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_38330998020910453246101013122633_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="38330998020910453246101013122633"><ADDRESS><DEPARTMENT>Facultad de Medicina, Facultad de Farmacia y Bioquímica</DEPARTMENT><ORGANISATION>Universidad de Buenos Aires</ORGANISATION><CITY>Buenos Aires</CITY><COUNTRY CODE="AR">Argentina</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>